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This dissertation considers a number of interlinked concepts, propositions and relations, and puts 
forward a set of design theses, to support the role of informatics in the overall goal of 
knowledge-based, information-driven, integrated, patient-centred, collaborative healthcare and 
research. This rather ambitious scope may be delimited by exclusion: the work is not concerned 
explicitly with genomics or bioinformatics, but it does encompass certain aspects of trans-
lational medicine and personalized healthcare, which I take to be subsumed in some sense 
under “knowledge-based” and “information-driven”. Although I do not exclude public health 
informatics, my exposure extends only to surveillance of infectious diseases, patient 
engagement, and the effectiveness of screening programmes. I do take ethical, legal, social and 
economic issues (ELSE) to be included, at least to the extent that I aim at an infrastructure that 
encompasses these issues and aims to incorporate them in technical designs in an effort to meet 
ethicists’, lawyers’, policy makers’, and economists’ concerns halfway. To a first approx-
imation, the aim has been to integrate two strands of work over the last decade or more: the 
informatics of medical records on one hand and the distributed computational infrastructures 
for healthcare and biomedical research on the other. 
The papers assembled in this dissertation span a period of rapid growth in biomedical inform-
atics (BMIi). Their unifying theme was not declared programmatically at the beginning of this 
period, but rather developed, along with individual pieces of work, as my engagement – and that 
of my students – with BMI became more focused and penetrated deeper into the issues. 
Nevertheless, I believe I have learned something from each project I have been involved in and 
have brought this cumulative experience to bear on the central theme of my present work. My 
thematic vision is of a scientifically literate and engaged community whose members – citizens, 
patients, caregivers, advocates – are sufficiently interested in medical progress and in their own 
health to take ownership of their medical records, to subscribe to a research service that informs 
them about progress and about current studies that may interest them, and so take responsibility 
for their own and the health of those close to them. This entails many things: agreements on 
what constitutes legitimate data sharing and when such sharing may be permitted or required by 
the patient as owner of the data. It calls for a means of recognizing the intellectual contribution, 
and in some healthcare economies, the economic interest of a physician who generates that 
record. Ethically, it requires a consenting policy that allows patients to control who may 
approach them for participation in a study, whether as a subject, as a co-investigator, as a patient 
advocate, or as a lay advisor. Educationally, it requires willingness on the part of physician-
researchers and scientists to disseminate what they have discovered and what they have learned 
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This is a collection of loosely interrelated papers published over a period of ten years or so, 
submitted in partial fulfilment of the requirements of the degree of Doctor of Philosophy by 
publication (DPhil). This section provides a listing of the main papers included with a brief 
rationale for its inclusion. Some related additional subsidiary papers are also listed in the 
bibliography but are not included in the submission in the interests of conciseness. The main 
body of the dissertation offers what may reasonably be described as a rational reconstruction of 
the intellectual process that led to the particular sequence of papers. 
 
 




Main papers form the substance of the submission; 
subsidiary papers are discussed relatively briefly 
and are used to flesh out aspects of the work or 
additional contributions that are related to the 
main claim.  
 
This overview is based on two peer reviewed 
workshop contributions, the first to a panel on The 
Many Meanings of Precision Medicine at the AMIA 
Joint Summits in Translational Science 2016, and 
the second to the fourth Middlesex University 
Workshop on ICT in Healthcare – Legal, Ethical 
and Social Challenges also in March 2016. 
 
 







In the first phase of MammoGrid, the interpretation 
of clinicians’ and clinical researchers’ requirements 
and translation of the languages of doctors and 
technologists to each other was central to my role in 
the project.  
Contribution I contributed sections corresponding 
to the data model and to user modelling and 
reviewed the paper as a whole. 








Contribution I provided the first complete draft of 
this paper ab initio. Professor Brady read and 
improved the description of the Standard 
Mammogram Form. Dr. Warren brought the 
language into line with standard radiological usage. 
I reviewed all changes before publication.  
(Note that the lead author was required by the 





Chapters and Corresponding Papers Comments / Author’s Contribution 
 






This retrospective paper reflects on (a) the 
applicability of software engineering techniques in 
the specification and implementation of a 
healthgrid project (MammoGrid) and shows that 
use-case modelling is a suitable vehicle for 
representing medical requirements and for 
communicating effectively with the clinical 
community; and on (b) the practical advantages 
and limitations of applying the Grid to real-life 
clinical applications and presents the con- sequent 
lessons learned, especially in terms of demands on 
the level of commitment needed from collaborating 
radiologists and the degree of standardization and 
stability of the underlying software. 
Contribution Seeking a convenient means for 
communication between clinician researchers and 
software engineers, I led the adoption of UML use 
case diagrams as a structured means of 
representing interactions between radiologists and 
the MammoGrid infrastructure. This led to my 
principal contribution to this paper in the precise 
specification of user requirements and the 










I led the EuroPGDcode project on behalf of the 
European Society for Human Reproduction and 
Embryology (ESHRE). Although funded by the 
Executive Agency for Health and Consumers, so 
not directly a “healthgrid” application, the purpose 
of the project was to demonstrate the possibility of 
codifying and automating the collection of 
Preimplantation Genetic Diagnosis (PGD) data 
across Europe in such a way as to support research. 
Although the project did not succeed in unifying 
the process across Europe, it led to a highly 
productive collaboration with the relevant British 
researchers. 
Contribution This paper was jointly written by the 
three authors, each of whom made their 
contribution from a different point of view. I 
conceived the project in this form, bringing 
together my PGD work with that of Mark Olive’s 
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Following a number of successful and well-received 
European projects exploiting health grids, the 
HealthGrid Association was formed and 
incorporated in France by the leading investigators 
in the area. Vincent Breton at CNRS, France, Kevin 
Dean at Cisco, UK, and Tony Solomonides, UWE, 
Bristol, were invited by HealthGrid to solicit 
contributions, including their own, and to edit and 
publish a peer reviewed white paper that would 
describe both the early achievements and the 
potential of grid technologies in healthcare.  
Contribution Whilst the majority of grid research 
was preoccupied with data grids (rapid storage of 
large volumes) and computational grids (virtual 
parallel machines), I particularly identified and 
discussed the potential of healthgrids to support 
collaboration in the spirit of the e-Science 






After the HealthGrid White Paper, HealthGrid was 
granted an EU FP6 project, SHARE, with the 
explicit brief to establish healthgrids a the 
infrastructure of choice for biomedical research, 
and subsequently for healthcare, in Europe. The 
envisaged system of healthgrids would be able to 
serve as a web-like backbone for the sharing of 
research objects (data and metadata, workflows, 
collaboration, results, analyses, etc.) and when 
proved mature and secure through research, to be 
further deployed in the delivery of healthcare. 
Contribution This paper presents a methodological 
review of the challenges and opportunities facing 
the SHARE collaboration. The paper provides an 
account of the multi-phase process through which 
the ultimate road map was developed. Vincent 
Breton devised the earliest deployment plan while I 
supplied the methodological framework; Blanquer 
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MedInfo 2007 provided a unique opportunity to 
address a very broad international conference and to 
expose the “HealthGrid” philosophy in its historical 
context, as it transitioned from the white paper to 
the SHARE Roadmap 1. 
Contribution I was the lead author and presenter. 
Once again, in this paper authors are listed by 




Vincent Breton, Nicolas Jacq and Yannick
Legré (IN2P3, CNRS, Clermont-Ferrand, France &
HealthGrid, EU)
Ignacio Blanquer and Vicente Hernandez
(Universidad Politécnica de Valencia, Spain)
Isabelle Andoulsi and Jean Herveg
(Universitaires Notre-Dame de la Paix, Belgium)
Celine Van Doosselaere and Petra Wilson
(European Health Management Association, EU)
Alexander Dobrev, Karl Stroetmann and Veli
Stroetmann (Empirica GmbH, Germany)
SHARE: A European Healthgrid Roadmap in
Handbook of Research on Computational
Grid Technologies for Life Sciences,
Biomedicine, and Healthcare (Mario
Cannataro, Ed). Chapter 1, pp. 1–27. IGI-
Global, Hershey, PA. 2009.
This publication is a distillation of the full roadmap 
and other final reports (on technology, on ethical 
and legal issues, on case studies, etc.) 
A preliminary version of this was the subject of a 
two-day workshop review by more than twenty 
invited experts. Once approved and accepted by the 
EU, it was published as a glossy report by the 
European Commission under the title SHARE the 
journey: A European Healthgrid Roadmap. 
Subsequently, the paper underwent further peer 
review and finally appeared in Cannataro’s 
handbook.  
Contribution This paper was primarily authored by 
Tony Solomonides with assistance from two 
graduate students, Rahmouni and Olive. The 
authors are listed by institution with the senior 
author from each institution listed last. 
From the abstract in the Handbook:  
The principal goal of this chapter is to elucidate the 
future requirements of healthgrids if they are to 
become the infrastructure of choice for biomedical 
research and healthcare. These requirements take 
many forms, technical, organizational and 
economic, with initiatives required in the domains 
of ethical and legal regulation. Thus, particular 
objectives of the chapter are to explore and analyse 
each of these domains to a sufficient depth to be 
able to make sense of the overall picture. 
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3—Phase II – HealthGrid White Paper and SHARE Road Map (continued) 
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Contribution Sole authorship. The ideas in this 
paper are a reflection of the author’s views and 
thought alone. 






From the abstract to the paper: 
To capture complete medical records without 
compromising patient privacy and confidentiality, 
the network created policies and mechanisms for 
patient consultation, central IRB approval, de- 
identification, de-duplication, and integration of 
patient data by study cohort, randomization and 
sampling, re- identification for consent by providers 
and patients, and communication with patients to 
elicit patient-reported outcomes through validated 
instruments. The paper describes these policies and 
mechanisms and discusses two case studies to prove 
the feasibility and effectiveness of the network. 
Contribution This paper was written by Tony 
Solomonides to define how the hashing approach to 
the de-identification of patient data would work in 
practice. 
^< K'-.$'8"#$%$&$'()*+<*E@"*T"-1('()
;-7'"(7*'(*7@"*T"-1('()*F"-%7@*I<#7"9M[,*)0'/$":DE=7*)54$&00('\ This submission is a short version of a longer paper under development on the role of “expert” patients in a learning health system. 
Contribution Sole authorship. The ideas in this 





























AES 170217 DPhil final.docx* * LL*
F! G>',>1'0%
The papers assembled in this dissertation span a decade and a half of work in biomedical 
informatics (BMI). Their unifying theme was not declared programmatically at the beginning of 
this period, but rather developed, along with individual pieces of work, as my engagement – and 
that of my students – with BMI became more focused and penetrated deeper into the issues. 
Nevertheless, I believe I have learned something from each project I have been involved in and 
have brought this cumulative experience to bear on the central theme of my present work. It may 
be helpful to begin from this before recapitulating the experience that led there. My thematic 
vision is of a scientifically literate and engaged community whose members – citizens, patients, 
caregivers, advocates – are sufficiently interested in medical progress and in their own health to 
take ownership of their medical records, to subscribe to a research service that informs them 
about progress and about current studies that may interest them, and so take responsibility for 
their own and the health of those close to them. This entails many things: agreements on what 
constitutes legitimate data sharing and when such sharing may be permitted or required by the 
patient as owner of the data. It calls for a means of recognizing the intellectual contribution, and 
in some healthcare economies, the economic interest of a physician who generates that record. 
Ethically, it requires a consenting policy that allows patients to control who may approach them 
for participation in a study, be it as a subject, as a co-investigator, as a patient advocate or as a 
lay advisor. Educationally, it requires willingness on the part of physician-researchers and 
scientists to disseminate what they have discovered and what they have learned in terms that are 
comprehensible to the interested lay participant but do not speak down to her. 
FYF! Q'41E,+41#H%
Central to this view is a triangle of reciprocal relationships between patients and their 









At each of the three vertices is an archetype. Each is the focal representative of a category of 
roles or actors. A “patient” stands also for individuals who are well and wish to preserve their 
health; for parents and caregivers; for patient advocates and other support groups. A “physician” 
is at the apex of a phalanx of fellow professionals, including pathologists, radiologists, nurses, 
technicians, dieticians, social workers, psychologists, and so on. A “researcher” may be a wet-
lab scientist, a pharmacologist, a bioinformatician, a statistician – the possibilities are even more 
numerous. Behind each of these archetypes is a source of funds: an employer (or savings) for the 





company for the researcher. Associated with each vertex is a characteristic cost: the cost of 
being ill or of looking after someone who is ill; the cost of running a medical office or hospital 
system; the cost of providing medical or nursing care; the cost of a research lab. Overlaying the 
entire scheme, the inevitable frictional costs of a market-based healthcare economy and the cost 
of public health. These constitute the healthcare economy.  
Each of the three archetypes at the vertices both depends on the other two and provides 
something essential to them. The interdependence of physician and patient is perhaps obvious. 
Their relationship can be parsed in each direction: the physician provides care for the patient and 
adds to her experience as she delivers care. The physician takes responsibility for the patient’s 
wellbeing and the patient repays the physician with trust and loyalty, helping to maintain the 
stability of her practice. Historically, it has been said that physicians used to do things to patients 
(the object model of the patient), then moved on to do things for patients (the consumer model 
of the patient), and now finally are coming to do things with patients (the collaborative model of 
healthcare). This development is mirrored in certain demographic segments where there is 
demand for a more active engagement in health maintenance (witness the growth of exercise and 
yoga cultures, and the “quantified self” movement) and in information seeking on the Internet to 
support or supplement, and even to question, medical authority. 
The relationship between researcher and physician may be read as “translational” – the problems 
of physicians are at the heart of projects that researchers tackle; the knowledge that researchers 
establish is translated into medical or operational improvements in care.  The time scale over 
which this relationship manifests itself is longer and the very relationship itself is less readily 
identified. Healthcare providers’ typical focus is on providing care for patients as efficiently and 
effectively as possible, with just enough attention to maintenance of records, especially 
electronic records, to ensure continuity of care. These records often require considerable 
treatment before they can be used for research; for example, if they are in free text, either chart 
review by another expert or reliable natural language processing would have to be performed to 
extract discrete data that can be mined or correlated with other outcomes data towards 
discovery. Discrete data entry renders data more useable for research, but providers often find 
discrete entry systems, with their succession of menus, limited choices and cascades of screens, 
both more time consuming and more restrictive than free text. Thus, unless a physician has some 
investment in a research project, the value of their work to the researcher is at best highly 
mediated and at worst of no use at all. Conversely, the results of research, published often in 
recondite articles in a highly diverse specialist literature, cannot be translated immediately into 
care decisions. Typically, it filters through to physicians in “journal club”iii, or decision support 
aids (cf. [3], [4]), or commissioned articles in professional (as opposed to learned) journals and 
newsletters.  
The third relationship, that between patient and researcher, is less sharply defined, not least 
because it has traditionally been mediated by a healthcare provider and also because it is rapidly 
evolving in the face of larger changes. As the principles of evidence-based medicine have been 
widely adopted and translated into practice, the financial cost and the slow nature of traditional 
methods of knowledge creation, notably clinical trials, have underscored a need for effective 
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alternatives. Evidence creation – perhaps discovery would be a better term – now relies 
increasingly on comparative effectiveness research (CER) based on observational data from 
electronic health records (EHR) generated by physicians and other providers in the course of the 
delivery of care. Much of this can be done through analysis of de-identified data, bypassing the 
need for consent by appeal to an institutional review board (IRB) for an exemption. A 
complementary trend has seen increasing activism on the part of patients and patient advocacy 
groups, both to assert the need for more emphasis on patient-centred outcomes research (PCOR) 
and a willingness to engage in the formulation of research questions, programmes and proposals. 
Consequently, a need has arisen for consultative structures that allow patient communities 
(broadly conceived, as above) to engage, propose and approve research projects, fulfilling in an 
indirect way the informative requirement of the consent process without necessarily reverting to 
the—sometimes prohibitively difficult—old processes of obtaining consent. The entire 
enterprise of the Patient-Centered Outcomes Research Institute (PCORI) in the United States is 
dedicated to promoting, funding and disseminating this approach [5]. 
FYJ! G;7#"4/'7%#+%#3'%,'"/1Z"#1+)%+.%,'41E,+4"/%,'/"#1+)731E7%
I have posited the “triangle of reciprocity” above as an aspirational goal; each pairwise 
relationship provides opportunities, but is equally fraught with challenges. In this section, I shall 
attempt to navigate these more or less in the order physician—patient—researcher—physician, 
but it will be clear that they are mutually implicated and impinge on each other, so that it is 
necessary to keep the triangle in view throughout. 
FYJYF! Q'/"#1+)731E%")(%G0)',731E%
I have already noted the transition from “doing things to patients”, through “doing things for 
patients”, to “doing things with patients”, respectively viewing the patient as the passive 
recipient of treatment, as the active customer, and now increasingly as the principal stakeholder 
and quasi-expert in her or his own health. In the latter, current view, predicated to some extent 
on limited resources, patients have significant responsibilities — as well as rights — in the 
maintenance of their own health. Arising out of these responsibilities is the patient’s right to 
know what the medical records say about him or her. In this dissertation, one thread discusses 
how these concerns may be addressed from a technological point of view. 
An inevitable issue in healthcare informatics is the question of ownership: Who is the owner and 
who should have custody of a patient’s medical records? This has been inherited from the era of 
paper records, when the tension was more between providers and payers than between patients 
and physicians. For example, in the NHS, ownership is now explicitly attributed to the custodian 
organization in [6] [7]; in an extreme case a dispute between the relevant government 
department and a practice that has lost records through flooding may hinge on the distinction 
between ownership of the physical medium on which patient data were recorded and the data 
itselfiv. In the US, the project Health Information and the Law maintains an online map [8] of 
the United States with links to state legislation concerning ownership of patients’ records. 
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In the era of EHRs, the questions multiply: Who may access those records in the course of 
healthcare delivery to the patient, under what circumstances and how? When, if at all, may those 
records be accessed for other purposes, such as public health, quality improvement, and 
research? When is the data subject’s consent necessary for such “secondary” use of patient data? 
Granted patient consent, what are the privacy and confidentiality implications of any sharing or 
secondary use of personal medical records? This issue has been further politicized in the United 
States as the Trump administration has moved quickly to suspend all regulatory actions of the 
Obama administration, including the updated “Common Rule” [9]. 
Discussion of this issue in depth requires a monograph in itself. While the patient’s record 
primarily holds (more accurately: represents) information concerning the patient’s health status, 
it also incorporates some of the physician’s intellectual work, and it includes billing data that 
may legitimately be claimed for the payer. If the patient links data from a health-related social or 
quasi-social site, such as HealthHeritage [10] or WiserCare [11], or from a wearable device 
through the manufacturer’s linked web services, the picture becomes even more confused. Does 
advice or a risk score from one of these sites belong to the patient, the physician, or the 
originator? It is clear that to take proper account of this, a highly ramified data structure would 
be necessary, and one that would only be obtainable if it can be recorded automatically. No one, 
not the physician, not the patient, nor any administration could otherwise justify the investment 
in time. 
It has been shown that the problem is tractable, if still somewhat expensive to implement, in the 
case of privacy constraints based on data provenance and a formal understanding of the 
regulatory framework. A series of joint papers [12] authored by my student, Hanene Rahmouni, 
addressed some formal aspects of these issues in a particularly elegant manner, by representing 
the legal framework in a declarative logic and translating them into actionable deontic logic at 
the operational level. 
FYJYJ! %5(')#1.14"#1+)%")(%<+)7')#%
In many, possibly most, cases, the researcher requires access to the patient primarily to test a 
therapy or other intervention. Less frequently, access is needed to survey the patient about a 
recent illness or procedure to determine, respectively, its sequelae or effectiveness. An 
increasing volume of research, however, involves—at least initially—only observational data 
recorded in the process of health care provision. A significant research industry has built up 
around this activity. Identifying the right patients to study requires accurate “phenotyping”, i.e. 
the specification of a set of criteria in the medical record that identify precisely those patients of 
interest. The eMerge network’s Phenotype Knowledgebase [13] holds a collection of rigorously 
tested phenotype algorithms. More widely, the large number of PCORnet Phase I demonstration 
projects have generated interest and awareness of the phenotyping problem in the research 
community. Once the basic population of interest has been identified, a number of alternatives 
for research are available: a random sample may be drawn and matched controls identified by 
means of another algorithm applied to the same EHR. Or matched samples from different health 
systems where different approaches are employed may be compared prospectively for effective-
ness. A major advance in the PCORnet approach to research is the emphasis on patient 
engagement and participation in research project formulation. This leads to a fresh set of 
requirements which have refocused the question, not so much on ownership, as in the navigation 
!"#"$"%&'()*+,-&#*
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of permissions to access. This is not a new area of research; for example, the Manchester 
group’s FARSITE architecture has addressed this issue in the British context. [14] However, the 
need in the case of PCOR is broader: the scheme for such research involves the patient (and 
caregiver, advocate, etc.) as an active contributor in the design of the research project, from 
proposal, through question formulation, determination of primary and secondary goals, 
hypothesis formation, target population and recruitment process, to the collection, analysis and 
interpretation of results. There is an implied transition from subjecthood through what may be 
described as “co-design” to full “co-production”. Ainsworth and Buchan (and co-discussants) 
[15] have very recently extended and deepened the argument for “combining” health data uses
towards health system learning (i.e. the necessary prerequisite for a learning health system) in a
way that complements the argument made here for the learning stakeholder in the learning
health system. I remain agnostic as to the right verb for this convergence: “combined” conveys
the right sense of economy—non-redundancy—but I also want to reflect the diversity of
viewpoints. I freely confess that a paragraph here will not suffice to do justice to their work; a
natural next step in my research would be to seek to marry their insights with the concept of the
learning stakeholder.
Consent to participate in research is a deceptively complex concept. The strict legal requirement 
in most settings is informed consent for a specific study. The first qualifier, “informed”, entails 
an explanation to the potential research subject, in relatively plain terms, of what the study 
entails, what its goals are, and what risks it may impose, as well as to assert the freedom to 
withdraw at any time. On the specificity restriction, an extension of the study, or even a 
variation of the protocol, requires the researcher to return to the patient for further consent, and 
that may yet need to be approved, and so mediated, by a healthcare provider. Once consented 
and enrolled, the patient—study-subject—has only one principal sanction available, to withdraw 
from a study. It is possible to envisage a different form of mediated (mediated) relationship in 
which the patient consents to be involved in research, to offer to participate in studies and to be 
kept informed of progress, especially when publications are available. The practice, adopted 
already by some journals, of publishing a “patient’s summary” of research findings would make 
this even more potent as a means of engaging the patient fully. There are several issues to be 
addressed, including the immature researcher’s tendency to aim for immodest goals and the 
problem of research subjects over-identifying with the researchers’ desire to see their project 
succeed. I am currently working with a member of the African American community on the 
“South Side” of Chicago and a colleague at the University of Denver to formulate an education 
programme termed “Boot Camp Translation” in research methods for patients. [16, 17]. The 
concept of taking the patient-subject into the researchers’ confidence and allowing her to make a 
meaningful intervention in a research programme may therefore best be broken into phases and 
forums where, through formal roles and formal settings, roles may be differentiated and 
unbiased engagement be made possible. A clear prerequisite for this is education that explains 
and justifies the means of goal setting, the “methodology”—a difficult notion about which 
experts disagree as much as any lay discussants—by which results will be obtained, and the 
interpretation of results into action. In the discussion of the goals and aims of PCORI [5], clear 
criticism has been voiced of research that leads to non-actionable results and even outcomes that 
may be good from a population health point of view but of less value to the individual patient. 
This is not to agree with this view, but to highlight the need for the broader scene-setting 




Human interaction and education are necessary, but not sufficient. There is a need for the 
relationship to be smoothly mediated between patient, physician and researcher. If, perhaps 
when, patient-managed electronic records are more widely adopted, it may be possible to 
transcend the questions of custody, ownership and control. The issues already discussed in terms 
of ownership are echoed here in a different form: must the physician share every hunch, every 
concern, with the patient? Conversely, must the physician write nothing in the record that may 
offend the patient? Will the patient’s right to correct his record mean removal of anything he 
does not like—e.g. “morbid obesity” in his problem list? (cf. the “fat acceptance movement” 
[18])v. Imaginative solutions are no doubt possible for many such problems: e.g. non-prejudicial 
private notes by the physician to herself may remain private, but may none the less be subject to 
scrutiny by the quality assurance process in the institution. The patient may object to 
unwarranted entries, but “morbid obesity” is a technically defined term; he has the choice to 
move to another doctor, if he can find one who would not consider his BMI to be a problem. 
Experiments in sharing information with patients have so far proved promising. For example, 
six years since its inception, the Open Notes initiative has made health records available to over 
12 million patients at 46 medical centres against considerable initial scepticism from the medical 
community [19, 20]. 
Notwithstanding, many problems remain. The banking system is occasionally used as an 
analogue of what may be implemented in an Electronic Health Bank. In October 1997, Dr. Bill 
Dodd, a Scottish GP, gave an interview to the British Journal of Healthcare Computing and 
Information Management in which he set out his proposal for a health banking system in three 
organizations: a Health Information Bank and a Health Information Academy, both non-profit, 
and a “commercially oriented Health Information Corporation”. [21] The proposal envisaged 
competition, so that the patient would have a choice of banks, much as he does in the financial 
sector. The idea lay dormant in the UK but had been apparently independently conceived and 
had begun to be developed in parallel by Marion Ball and others at IBM in the US [22]. Denis 
Protti, of the University of Victoria, Canada, invited to advise the ill-fated English National 
Programme for IT (NPfIT), revived Dr. Dodd’s proposal, first in an internal publication for 
Connecting for Health (CFH) and subsequently, in 2008, in the Canadian journal Electronic 
Healthcare [23]. It is not clear whether this idea transmuted into the subsequent proposal for 
Care.Data—which would have supported a different kind of data banking—but Professor 
Protti’s enthusiasm for Dr. Dodd’s idea is clear. 
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The idea of a health bank has since been taken up more widely, with several prominent 
academics championing the cause in the present decade. Prominent among these are Dr. Amnon 
Shabo (Shvo) at Haifa who made this a central plank of his keynote address at MedInfo 2015 as 
well as in a series of high profile publications [24]. Dr. Patricia Flatley Brennan, also used the 
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platform of a keynote at MedInfo 2015 to extend her eloquent argument [25, 26] for personal 
health records (PHRs) into a broad vision. In these presentations, as in the most recent papers, 
the question of research is broached, albeit somewhat obliquely. [27–31]. First, research is 
called for on how PHRs are used; this is a step towards evidence-based policy and would indeed 
provide some essential background knowledge to optimize the use of such records. The 
attribution of responsibility and costs goes hand in hand with the assertion of rights: how—and 
what part of—the physician’s record of an encounter become part of the PHR? How much of the 
patient’s PHR must be revealed to a provider? I have already discussed issues of ownership and 
custody, intellectual property and ethical disclosure. There is potential for the PHR to be used by 
provider organizations to market additional services to patients when it is clear that they are 
receiving such services elsewhere. Where must the line be drawn—a line that may in any case 
be deeply embedded in a “black box” technology? 
The generation of knowledge from medical records created in the course of healthcare delivery 
has been advocated by researchers for some time, but took a definite form and gained impetus 
from the Institute of Medicine’s (as the National Academy of Medicine then was) embrace of 
the concept of the Learning Health System (LHS) [32]. In a series of publications, different 
aspects of such a system were analysed and debated, ultimately culminating in the formation of 
a non-profit organization, the Learning Health Community.  
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The LHS approach to knowledge creation contrasts sharply with the traditional understanding of 
(randomized control) clinical trials.  Yet as far back as 1967, Schwartz and Lelouch introduced a 
distinction between explanatory and pragmatic trials to deal with the “real world” dimensions 
that must be taken into consideration in making comparisons: 
… Suppose, for example, we require to compare two analgesics and assume first that the 
two are chemically very alike, differing only in a single radical. The biologist may then be 
interested to know whether the drugs differ in their effects when they are administered on 
an equimolecular basis. This is the explanatory approach.  
On the other hand, assume that the two substances are chemically quite unrelated. Each 
will presumably have an optimal level of administration, having regard to its side- effects, 
and the problem of interest is now to compare the two drugs administered at these optimal 
levels. This is the pragmatic approach. [33] 
A discussion of causality per se is beyond the scope of this dissertation, but it is noted here that 
a plausible explanatory process (e.g. metabolic) is a requirement in assessing whether 
correlation is indicative of causation. The article [33] was reprinted in 2009 and given fresh 
impetus to work to support appropriate clinical trial design [30], including the creation of a tool 
PRECIS-2 [34] to help trial designers in their task. number of limitations: recruitment may be 
constrained by ethical permissions, so that the subjects may be less sick than the real population 
to be treated; recruitment may also be limited by the location of experienced investigators 
willing to recruit, resulting in small sample sizes and in lack of adequate diversity. 
Notwithstanding, they are also rather expensive to conduct. Observational studies relinquish 
some elements of control in the interest of addressing some of these issues: data may be 
collected from a much larger population “in the wild”—with all issues of compliance and 
monitoring that raises—yet with representative diversity and distribution of health status. 
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Observational studies may also be the only method possible when randomization is either 
impossible or would be unethical. Examples include surgery [35] and the current PCORnet 
Obesity Observational Study: Short- and Long-term Effects of Antibiotics on Childhood Growth 
[36] in which I am currently involved. The challenge in this study, as in many similar ones, lies 
in adequate control for confounders in the population to be studied. The population of interest is 
all children in the data warehouses of participating institutions (no cluster randomization is 
implied here) and the endpoints are weight at 5 and 10 years old, with data concerning antibiotic 
exposure in the first two years of life, reason for this, comorbidities (e.g. asthma with possible 
use of corticosteroids), and available demographics and social indicators.  
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A recent discussion paper from the National Academy of Medicine [27] discusses studies such 
as this in terms of the knowledge to be derived from “best care”. Although a major focus of the 
article is PCORI activity, there is little emphasis on patient engagement; rather progress is 
anticipated from top-down pressure from executive suites: 
As described above, within the current health context, the two activities of clinical 
operations and research operate in largely separate environments with different (and at 
times competing) players, funding streams, incentives, and priorities. The authors believe 
that research can move more quickly once research interests are aligned with operations. 
Likewise, operations will be more evidence based and thus the quality of care improved 
once operations stakeholders are engaged in the development of research priorities and 
their needs and strategies are reflected in the research agenda.  
To build these relationships requires that health executives promote the benefits of 
integration, including ideas related to seamless integration of research and practice, and 
that they create structures, funds flow, and processes, and allocate time and resources, to 
those collaborations.  
This is, perhaps, a pragmatic response to the issues that PCORI now confronts. How to persuade 
senior executives that its projects—and more importantly, its defining mission—are worth 
preserving? How will PCORnet “keep the lights on” after PCORI’s “sunset” in 2019? Concerns 
about what kinds of projects the Institute should be engaged in were expressed early on. [37] 
The idea of patient engagement in research was still novel when PCORI was established. One of 
its creative moves in this direction has been the funding of Patient-Powered Research Networks 
(PPRNs) alongside the Clinical Data Research Networks (CDRNs), which were cast in a more 
traditional mould and resembled the academic collaborations set up under the Clinical and 
Translational Science Awards (CTSA) programme. Returning to the issue of health banking, it 
is now evident that neither major players in the social media space (Microsoft, Google) nor 
governments are yet trusted by patients with their data, witness the failure of HealthVault, 
GoogleHealth and, in the UK, Care.Data. Patient-run organizations may finally prove to be the 
catalyst that makes this happen. Apart from faith-based organizations (in the US, at least), 
patient-run organizations appear more likely to be trusted than any current alternative. Health 
banks built around a particular condition common to their members would have the additional 
advantage of singular focus, the ability to tap into relevant research, and to keep their members 
engaged. However, they are unlikely to scale up to a viable size and would be vulnerable to the 
fatal attraction of financial support from commercial entities. 
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Having reviewed the obstacles, I turn to the potential of informatics in its broadest sense, 
encompassing both the abstract qualities, contexts and nuances of information and the 
technologies that can be used to manage it—from acquisition through representation, 
transformation, analysis, précis and dissemination, as well as from protection, through secure 
storage, encryption, censorship, to aggregation and obfuscation as means of preserving privacy 
and confidentiality. Informatics is fraught with the same questions, or mirrors of them, that we 
have already encountered, but as a young and optimistic discipline appears to offer more hope of 
solutions. The counter-danger lies in the tendency to settle on a “technical fix”, i.e. a purported 
solution that appears to solve the problem but does not address the underlying issue. 
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Medical records have long been an issue of concern: historically, in virtually all national health 
systems, they have been held in independently maintained, unconnected filing systems, both 
paper and electronic (“silos”). As the priorities of healthcare practice have changed, electronic 
patient records (EPR) have been increasingly adopted, giving rise to a number of questions:  
Should a health system maintain a single integrated record for each patient? If the claim that 
modern medicine is holistic is sustained, an assertion of the “obvious” value of an integrated 
record appears to follow immediately. However, this is readily countered by the observation that 
each healthcare professional needs to know only that part of the EPR that is relevant to their 
specialty (a restriction termed patient confidentiality) as well as by fears about unauthorized 
access to the entire record by others (posing a threat to patient privacy —even to the extent of 
identity theft— and, in some systems, compromising their ability to get health insurance 
coverage). Notwithstanding these valid concerns, there is considerable evidence that integrated 
patient records support better healthcare, so that the effort necessary to address them is amply 
justified. It will be argued that appropriate annotation of the EPR can address these challenges 
when coupled with adequate security of access to the systems [12]. 
May computed data be included in the EPR alongside observed data? Electronic records make it 
possible not only to record symptoms, signs and observations, but also to analyse patterns that 
may be suggestive of other possibilities. For example, a series of readings of high blood 
pressure, taken independently at different locations and on different occasions, may suggest that 
the patient should be screened for hypertension and an appropriate alert be entered into the 
system. This may be controversial for a number of reasons and may pit the physician’s 
professional responsibilities against the patient’s values concerning his or her own health. 
A further paradox arises in conditions, such as cancer, where a suitably curated patient registry 
is mandatory, considerable information about a patient’s status (e.g. staging information) may 
not be imported back into the record unless a physician reviews it anew, since it would become 
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actionable the moment it is (re-)instituted in the record. This information therefore remains 
siloed, despite the best intentions of the institution. 
What kind of access to her or his EPR should a patient have? Even today, in most settings this is 
a controversial question, but by and large governments have mandated, or at least adopted 
measures to encourage, the sharing of the EPR with the patient. In such settings, even if initially 
access to the record is “read only”, it will be necessary to allow patients to comment on and, 
indeed, sometimes to correct their record. Moreover, technically, there are many occasions and 
ways in which the patient’s record may be shared with the patient: online as a means of review 
and reflection, concurrently with the physician perhaps on a second screen during a consultation 
visit, as a means of health and wellbeing maintenance when using “apps” to interface 
monitoring or fitness devices such as blood glucose meters, pedometers, or gym equipment. 
The principle of “shared decision making”—doing things with the patient—also sometimes 
paints the electronic record as a jointly maintained chronicle of the patient’s health status, but 
poor design of interfaces has limited ways in which patients and providers can work together 
around the record. It is not difficult to imagine a dual screen, so that the patient and physician 












Fig 1: The data manifold Data is characterized not only by its values, but also by what is loosely termed its 
“metadata”, which can be analysed into metadata proper, provenance data, paradata, security data and various 
computed summaries, etc. 
 
In relation to the second and third questions above, I argue that it is necessary to differentiate 
data in the EPR according to its source and method of derivation (provenance), its form 
(metadata), its reliability (paradata), and other relevant characteristics. It will be argued that this 
enrichment of the data can be exploited to manage its use and reuse. (See Fig. 1, The Data 
Manifold.) 
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A number of European projects addressed technical and workflow issues arising from the use of 
mixed patient and imaging data. In the MammoGrid project, requirements were identified 
through a common graphical language that enabled physicians and developers to agree on a 
common specification, which was then gradually realised through successive refinements. While 
in MammoGrid the ostensible purpose was support for European collaboration in healthcare 
across borders, in Health-e-Child, the focus was research. Although this problem was tackled 
systematically at a later stage, in the Health-e-Child project ad hoc protocols had to be devised 
that satisfied clinicians, researchers and ethicists, proving that data were being shared with due 
regard to the project’s regulatory framework (for research protection), with due consents (for 
patient protection) and without disrupting the clinical process. 
A more demanding project in the field of electronic patient records was EuroPGDcode, 
concerning collaboration between European assisted reproduction clinics in tracking outcomes 
from pre-implantation genetic diagnosis (PGD). Although the data was ultimately pooled for 
statistical purposes, the complexity of assisted parenthood resulted in each pregnancy having a 
large and variable number of distinct fields to be tracked. With a view to accurately tracking the 
health of children born following PGD, it was necessary to track multi-parented children, whose 
siblings might well be differently multi-parented, with the possibility that there might not even 
be a one-to-one relationship between fertilized oocytes, implanted embryos and live births. 
In work undertaken in my last position at NorthShore University HealthSystem, I led a team that 
sought to address several of these issues against the limitations of the underlying EHR. This has 
been done through Structured Clinical Documentation Systems (SCDS), a means of recording 
discrete data from patient-physician encounters in a way that allows both the capture of precise 
data in compliance with the principle of “one source of truth”, and stores that data discretely, 
rather than embedded in a text note, so that it can be analysed at a later stage. 
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While personal patient records are primarily of value in the care of the individual, aggregated 
records may provide valuable information for public health, for quality improvement, and for 
research into particular conditions, comorbidities, treatments, and other questions of evidence in 
the quest for science-driven, evidence-based practice. I may use the term electronic health 
record (EHR) to refer to the aggregation of EPRs. Further questions arise from such 
aggregation: 
What are the legitimate (secondary) uses of EHR? A better form of this question is: What 
legitimizes secondary uses of EHR? In this form, the question can be analysed further.  
—Have the patients whose records have been aggregated in the EHR consented to its secondary 
use? The patient’s consent is often required to be “informed”, i.e. given in the light of full 
disclosure of the purpose of the proposed secondary use, so that – in principle – the patient may 
object even on the grounds of ideological difference from the implicit or explicit goals of any 
research or policy analysis based on data that includes his or her own.  
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—Does the EHR hold de-identified data? Anonymized (i.e. irreversibly de-identified) or 
pseudonymized (reversible under closely controlled conditions), and to what standard? It has 
often been asserted that de-identified data may be reused without further permission from the 
patient. However, there is a significant body of work showing that intelligent fusion of the data 
with public sources (such as the census or electoral rolls) may be exploited to re-identify the 
record, at least with a given degree of certainty. [38] 
In conjunction with the PhD work of my former student Hanene Rahmouni, I have shown that 
suitable annotation of the data with privacy-related metadata can be used to manage data 
exchanges. The argument will be extended to the management of the data more generally, 
including such issues as control of storage allocation and duplication in distributed platforms 
such as grids and clouds. 
This requirement bridges across from work funded by the EU and conducted in the UK to 
current work funded by PCORI and developed in Chicago. Both cases touch on data and 
information and connect to the technology and to policy making. 
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Chapter 1 has provided some of the history and motivation for the work that has been 
assembled in this dissertation. As already confessed, there was no grand programme at the outset 
which I set out to realize. Rather, beginning with a technical background and a growing interest 
in biomedical informatics, at least after my very first engagement in the mid-80’s, I have taken 
such opportunities as have arisen to deepen and to broaden my involvement. Throughout the late 
1980’s and the 1990’s, I was engaged in small-scale individual projects, some of very 
considerable interest in their own right, but without much connection to the professional world 
of BMI. This changed in the early 2000’s, when the opportunity to work in highly connected 
projects arose. The next three chapters trace this evolution through its stages, roughly, the 
European healthgrid technology projects, then the European healthgrid policy projects, and last 
the largely American Learning Health System period which continues to this day. 
Chapter 2 takes up the story of MammoGrid, a project that originated in deep and deeply 
informed technology. Considerable expertise was brought to bear on the problem of standard-
ization of mammography, the provision of remote annotation services, and the facilitation of 
tele-consultation with fellow radiologists. What my team from UWE, working at and through 
CERN, brought to the project was knowledge and experience of complex databases, while I 
personally happened also to be conversant with the biomedical field. MammoGrid was by all 
accounts a great success and was followed in spirit and in technology by a number of other 
projects, notably Health-e-Child and neuGRID, each extending the scope and reach of earlier 
projects either in the complexity of diseases covered or of services offered. 
Chapter 3 takes up the next phase of development. The European Commission’s e-Health Unit, 
led by the highly energetic T(2%OB#25'(*D(2#67*g2."59('*39&'*0(8-%"#"36*2)*m0-(*&%g92O)0958059(*"g*8-"&8(n*g"9*4&"$('&82#*2::#&820&"%)7*2%'*46*(l0(%)&"%*4&"$('&82#*9()(298-<*C-(6*0-(9(g"9(*(%8"5923('*0-(*g"9$20&"%*"g*2%*2))"8&20&"%7*D(2#0-f9&'7*&%8"9:"920('*&%*@92%8(*&%*=JJM7*2%'*0-(%*&%.&0('*D(2#0-f9&'*0"*'921*5:*2*:9"392$$20&8*m1-&0(*:2:(9n<*
!"#"$"%&'()*+,-&#*












































AES 170217 DPhil final.docx* * =R*
J! A3"7'%5%[%&"66+K,1(%=%2'"/#3L'L<31/(M%NB,+AK!4+('%
JYF! K,1(%<+6EB#1):%")(%2'"/#3%
The concept of grid computing was motivated by a variety of unmet technical requirements in 
distributed computing and by a sense of opportunity in the world of “big science”. It coalesced 
in the late 1990’s from various strands of technical research, empirical analysis of network and 
computing capacities, and developments in research policy. By the turn of the century, the need 
was abundantly evident in the physical sciences. Both particle physics and astronomy were on 
the point of launching experiments that would generate very large volumes of data at an 
unprecedented rate. Conventional architectures would not be able to sustain performance, nor 
provide the effective capacity necessary for storage. Meanwhile physics simulations in 
preparation for the experiments were already demanding increased performance for 
experimental studies. Meanwhile, with the advent of genomics, by the mid-1990s the field of 
bioinformatics had shifted focus from the study of information processes in biological systems 
to the narrower sense of analysis of the genome and thence the process of translation of DNA to 
protein and beyond—the eponymous “proteome” and thereafter the “metabolome”. The number 
and complexity of comparisons required for search, matching and alignment in genomic 
sequencing and in the discovery of specific genes also demanded an order of magnitude increase 
in the computational power available to researchers. Once the extension to life sciences had 
been realised, possible applications to medicine and healthcare were a likely next step. 
Technically, it had long been observed that the unused compute cycles in idle workstations 
represented what one informatician described as “the inverse tragedy of the commons” [39]. 
High performance computing (HPC) applications were perennially short of processing 
infrastructure, while workstations on researchers and other employees’ desks were sitting idle, 
not only when they were not being used, but even when carrying out ordinary processing tasks. 
Myron Livni’s Condor project [40] and David Anderson’s SETI@home [41] demonstrated the 
possibility of harnessing spare cycles either for local ad hoc distributed computing or for wide-
area Internet-based computing. Ian Foster, Carl Kesselman and Steven Tuecke [42,  43] pulled 
these ideas together into a coherent narrative that introduced the concept of “virtual 
organizations”, thus tying the social (and potentially, the economic) organization of big science 
into the design of the technical infrastructure. Virtual organizations (VOs) were to be loosely 
affiliated groups of institutions, researchers and projects that might come together perhaps only 
for a short time to address a specific issue, but they could equally be, or become, longer term 
collaborations. Foster and Kesselman edited a seminal collection of foundational papers [44] 
that became in effect the de facto definition of, a potent manifesto, and a blueprint for a grid. 
There was a marked difference in approach to, and even uses of, grid computing between 
scientific communities and continents, partly reflecting attitudes to funding. In the UK, scientists 
benefited both from the EU’s pronounced trend towards large multinational collaborations and 
from the UK’s own tightly controlled and targeted e-Science programme. On becoming Director 
General of the Research Councils in 1998, Dr. John Taylor launched the e-Science programme 
as the flagship of his tenure in this commanding position. He argued persuasively that scientists 
perform the “role of middleware” as they manually transport (or worse, re-key) data from one 
laboratory apparatus to another or collaborate by patching data and software into emails in order 
to exchange ideas. The UK e-Science programme would use appropriately designed infra-
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structure for the missing middleware, to support machine-to-machine interoperability and 
scientist-to-scientist collaboration. 
The medical field in which the idea of collaboration made immediate sense was Radiology. 
Images are stored in large files, there is often a need for second opinion or to distribute work 
where radiologists may be less busy (or provide a 24/7 service for a fee), and the users already 
have significant exposure to technology. It was indeed in Radiology that one of the most 
interesting and ambitious early grid projects was conceived.  
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MammoGrid, and its sister project eDiamond, were the brainchild of Professor Michael Brady at 
the University of Oxford, the former in collaboration with Professor Roberto Amendolia on 
secondment to CERN from the University of Sassari in Italy [45]. eDiamond was funded by the 
UK e-Science programme and—largely because of external industrial interest—was kept very 
much apart from MammoGrid, the only exceptions being two comparative publications. 
MammoGrid was proposed and funded more in keeping with the spirit of open science 
supported by EU Framework programmes, although here too there were some commercial 
interests to be protected. The goal of MammoGrid was to demonstrate remote synchronous and 
asynchronous collaboration between breast cancer screening clinics, including provision of a 
validation service, a second opinion service, standardization and automatic annotation of 
mammograms. 
Responsibilities among the different partners in the collaboration were distributed as follows: 
Clinical (Addenbrooke's and Udine) to specify, use and evaluate the system; Informatics 
(CERN, Division of Technology Transfer and UWE, Bristol) to capture requirements, design 
data structures, determine workflows, and implement the grid infrastructure; Medical 
Technologies (Oxford Medical Vision Laboratory, Mirada Solutions and University of Pisa) to 
deploy and adapt their respective mammogram standardization and annotation services. 
In the first phase, my contribution focused on capturing requirements through use cases. The 
language and diagrams of UML use cases, with suitable explanation and interpretation to begin 
with, proved a remarkably smooth intermediate language between physicians and software 





My interest grew in the Standard Mammogram Form (SMF™) [46] that had been devised by 
Ralph Highnam as part of his Oxford DPhil and then spun off into a company, Mirada Solutions. 
I undertook a Master’s course in Radiology and wrote an exposition of the method as one of two 
final assignments. The other assignment, an extended essay on MammoGrid, provided the first 
draft of the paper that eventually was published as: 
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A further paper presents a retrospective review of the MammoGrid project from a largely 
technical point of view. This reflective piece was published after the project had effectively been 
completed. I made a significant contribution to this paper, especially in the discussion of the 
workflow, in particular on the mediation through use-case models of the interaction between 
physicians and technologists and the interpretation of radiologists’ needs to capture an adequate 
set of user requirements. 
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Other publications about MammoGrid provide additional information and are mentioned here as 
subsidiary papers. These include a. the earliest announcement of the project in a publication (at 
MIE 2003), explaining the novelty and design of the project. I made a significant contribution to 
this paper and presented it at the conference. 
The second subsidiary paper, b., is a companion clinical paper to B. above. It proved the 
epidemiological value of an infrastructure like MammoGrid’s by demonstrating that breast 
density was a risk factor in its own right, not just as an impediment to good imaging. My 
contribution to this paper was of an editorial nature, making sure that the concepts and language 











Closing the loop from MammoGrid back to the work on grids that made it possible, the grid 
infrastructure for the project was directly borrowed from one of the particle experiments at 
CERN. Here, grid computing was under active development in anticipation of the voluminous 
data that would flow from the Large Hadron Collider (LHC) and the computational power that 
would be necessary even to triage the data into potentially useful or not. In the event, Mammo-
Grid used AliEn, the resource broker devised for the Alice experiment [74] as the basis for the 
necessary grid infrastructure. 
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The healthgrid projects that followed MammoGrid proved more significant in having added to 
the evidence that the approach could work than in breaking new ground. As additional support 
for the concept of the grid as a collaboration medium for a certain kind of biomedical project, 
they provided some of the concrete examples necessary to justify a systematic policy and 
strategy project, thus paving the way to the SHARE project which is the subject of the next 
chapter. 
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Health-e-Child was an attempt to take the lessons of MammoGrid and scale them up to three 
otherwise unrelated paediatric conditions, each requiring a different mode of imaging, to four 
European centres of excellence in these conditions, and to collaboration with an industrial giant 
in Siemens. The three conditions were brain tumours (gliomas), cardiac malformations (right 
ventricular overload cardiomyopathy), and juvenile idiopathic arthritis. The twin goals of the 
project were to provide knowledge for decision-making and to support clinical studies. In terms 
of clinical science, the cardiac study proved highly productive, giving rise to further projects. In 
decision support, I was involved in a simple approach to bring ontologies to bear on the 
interpretation of patient data and to present information to the physician in the course of 
decision-making. I worked with my Research Fellow, Tamás Hauer, on the introduction of 
ontologies and semantic reasoning, mainly to characterize tumours by location and type and 
visualize their prevalence. This resulted in a rudimentary system that was reported in two minor 
publications, one of which is appended as a subsidiary paper: 
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The greatest sophistication in imaging-related healthgrid projects came with neuGRID [75]. Its 
goal, in the words of its website, was “to become the ‘Google for Brain Imaging’, i.e. providing 
a virtual imaging laboratory that can be accessed by any scientist with a PC and web browser. 
This new environment will allow researchers in the field of Alzheimer’s disease answer 
complex neuroscientific questions.” My engagement with neuGRID focused more on its 
implications for healthgrid policy development and was reflected more in the work on the 
SHARE project. 
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EuroPGDcode was a very different kind of project. It was funded by the European Agency for 
Health and Consumers, so that it was by definition a project to deliver a particular innovation for 
real use, not just as a demonstrator project. The nominal goal of the project was to bring about 
some order in the terminologies and codes that were in use in the field of pre-implantation 
genetic diagnosis (PGD) in assisted reproduction. However, in reality, it focused much more on 
the collection of data and the design of the associated data structures to facilitate faithful 
representation of complex information. 
The European Society for Human Reproduction and Embryology (ESHRE), through its PGD 
Consortium, has collected statistics on the use of PGD from clinics in Europe and worldwide for 
nearly two decades. Their initial goal, as stated in [47], was to “undertake the first systematic 
and long-term study of the efficacy and clinical outcome of PGD.” The field is controversial, not 
only because of ethical objections to “designer babies”—hardly justified in the case of PGD—
but also because of methodological uncertainties. PGD requires DNA from the embryo; in 
traditional, early PGD, this required harvesting a cell at the four-cell stage of embryo 
development. Subsequent work has enabled polar body biopsy and ultimately free circulating 
DNA in blood to be used. Ethical objections are more frequently raised against pre-implantation 
genetic screening (PGS) and confuse the issue. PGD is targeted at genes that the parents are 
known to carry, and so is aimed at ruling out specific serious, usually fatal, conditions. PGS, on 
the other hand, entails a broad sweep across a number of serious genetic conditions in the 
absence of any particular reason to suspect that they may be present. It is in this context that 
ESHRE’s PGD Consortium has collected evidence of PGD over the years. The initial proposal 
did not envisage either data collection or a healthgrid application, but on harmonizing termino-
logies. In the face of the partners’ pragmatic needs, it was reoriented to easing the collection 
process. Resources did not allow a true healthgrid to be deployed, but an internet-based 
collection service was established. The most interesting part of this project lay in the extreme 
complexity of the data to be collected.  
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The first wave of “healthgrid” projects included MammoGrid. By the time the second wave of 
such projects was funded, including Health-e-Child, the European Commission, which had 
always encouraged collaboration between projects, went a step further and recommended the 
formation of an association to support and promote projects with the common theme of using 
some variety of grid computing as the infrastructure on which the work would be done, where 
the results would be stored and shared, and through which collaboration might proceed. Critical 
to these ambitions were the subscription model of participation and the concept of “virtual 
organizations” (VOs). As noted in Chapter 2, grid computing consolidated certain ideas about 
resource sharing and exploitation of surplus or redundant capacity in scientific networks. The 
subscription model meant that a node wishing to benefit from the vast resources it would gain 
access to, had, in return, to allow its own spare capacity to be used by other nodes on the 
network. The model was successful precisely because need was not constant at any node. 
However, in the medical world, certain features of this “sharing” could be problematic: data 
might be moved for processing, if not for storage, to locations outside the strict boundaries 
dictated by their source regulatory framework. When there was sufficient local processing 
power, one proposed solution to this was to move the algorithm to the data, rather than the data 
to the algorithm. So long as we were dealing with academic demonstrator software, this was not 
a problem, but as soon as the necessary software required commercial licensing, this “solution” 
was no longer viable. 
A better solution lay in a recursive or nested structure of (VOs of) VOs with appropriate 
regulatory frameworks at each level. I bracket the nested structure in this way to signify that 
there is always a bottom layer: this might be a VO of a hospital system under the authority of a 
single trust (in the UK) or “covered entity” (in the US), which can hold data with the highest 
regulatory privileges. Next might be a national or state-level super-VO integrating many local 
VOs; this would be subject to national or state legislation. Then at the supranational or federal 
level, a hyper-VO of super-VOs would operate under the most restrictive regulatory regime. 
With the idea of market economics being introduced into the healthcare space, it was also 
apparent that the grid could potentially provide a “marketplace” for competition between certain 
services. This was discussed explicitly in MammoGrid, where, e.g., different image annotation 
services might compete. This was still more evident in NeuGRID, where different data sets, 
services, image processing algorithms, and so on, could be available to choose from in the same 
ambient grid. Implicit in all this lay the question whether the ultimate goal was a single 
Healthgrid, like the (capitalized) Internet, or a multitude of healthgrids, each with a limited 
scope, but possibly able to interact with others and so still form ad hoc VOs. The former 
appeared the more elegant solution, albeit fraught with regulatory issues, the latter the more 
pragmatic and realizable option, especially as it allowed for regulatory frameworks to be 
reconciled as VOs are formed “bottom-up”. 
These ideas—more accurately, debates—were in the air at the second conference on healthgrids 
(in 2004 at Clermont-Ferrand) where the incorporation in France of a new association, to be 
designated HealthGrid, was decided upon and its first set of officers elected. Vincent Breton at 
the CNRS, France, took a leading role and suggested the formation of a working group to 
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establish the vision and mission, goals and prospects of the new association. A preliminary 
paper by Breton, Solomonides and McClatchey was published in the same year [48] and this led 
to the formation of an editorial group comprised of Breton, Kevin Dean (then of Cisco) and 
Solomonides which was tasked to bring together a larger definitive and more comprehensively 
representative work. The result of this was the HealthGrid White Paper [49]. 
An equivalent debate did take place in the United States, fuelled in part by massive funding for 
high profile projects such as The Cancer Biomedical Informatics Grid (caBIG) [50]. This project 
was finally judged to have been at best a partial success [51], but discussion of bottom-up grid 
development of a similar scope to that of the HealthGrid White Paper did take place; for 
example, the 2008 proposals for health information sharing in Utah [52] bear a marked 
resemblance to ideas from HealthGrid. 
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The HealthGrid White Paper [49] was remarkable in its day for three reasons: its timing was 
fortuitous, its fundamental assumptions had been tested in earlier proposals and were generally 
accepted, and its scope was almost comprehensive.  
At its meeting in Lisbon in March 2000, the European Council had included the mandate, as part 
of its economic agenda for Europe, 
To develop an intelligent environment that enables ubiquitous management of citizens' 
health status, and to assist health professionals in coping with some major challenges, 
risk management and the integration into clinical practice of advances in health 
knowledge. 
Strategic thinking among HealthGrid members, overoptimistic though it proved to be, was 
remarkably convergent with this EU goal. Although by November 2004 the report by Wim 
Kok’s Review [53] had noted a failure to work effectively towards the goals of the Lisbon 
Agenda, the EU Commission was pressing ahead with programmes to promote economic 
growth. With increasing integration in mind, and mobility among the goals, a move towards 
infrastructures that would allow seamless healthcare delivery and progress in biomedical 
research was perceived to be an important goal. Commission officers who had encouraged the 
formation of the association HealthGrid in the first place, were equally encouraging of the 
development of a White Paper to flesh out the vision with rationale, principles and, above all, 
examples. 
A clear principle was high connectivity. In a remarkable departure from traditional thinking, this 
was also linked to the idea of linking concepts and models from different levels of biosocial 
organization, informatics practices, and pathologies. This was nicely captured in the 
BioInfoMed [54] hierarchy: 
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Fig 2: The BioInfoMed Schema Levels of biosocial organization, from the molecular through to the 
population, correspond, on one hand to subdisciplines of biomedical informatics and on the other to 
biomedical disciplines. Neither correspondence is precise, but suggests possible links.  
Credit: Adapted with permission from a presentation by Fernando Martin-Sanchez 
 
 
The implicit—and disruptive—notion here is that the connectedness that would be fostered by 
the grid would not only bring different disciplines together, breaking down traditional academic 
boundaries, but by the same underlying means also allow scientists working at these different 
levels to integrate their models, so that, for example, a molecular model of tumour development 
might be coupled with a tissue model to characterize tumour growth. It is possible to claim this 
diagram as the progenitor of what eventually became the concept of the Virtual Physiological 
Human. 
The breadth of applications was also considerable: sandwiched between explorations of the 
business case for the grid and its ethico-legal dimensions, are studies of imaging, computational 
models of human biology, pharmaceutical research and development, epidemiology, and 
genomics. This range was necessary to make the case that the grid could really become a 
“healthgrid”, the theme of the third HealthGrid Conference in whose proceedings the White 
Paper was published. 
Another theme emerges here also that will recur in this analysis of the healthgrid concept. Both 
as editor and especially as author I had focused on familiar applications, such as imaging and 
epidemiology, and on ethical issues of privacy and confidentiality. I had highlighted, in the 
context of MammoGrid, the potential of the grid to be a marketplace platform, where services 
might compete on quality, performance, and cost. However, I had neglected aspects of cost 
sharing and the contractual dimension that would prove necessary in the full commercial 
exploitation of the paradigm. As “grid” transmuted into “cloud”, these economic matters came 
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to the fore, so that it was possible for someone somewhat superficially to characterize cloud 
computing as “grid computing with a business model”. Did the cloud, as an economics-aware 
infrastructure, achieve the planned goals of HealthGrid more quickly than could ever have been 




The successes of early healthgrid projects and of the first HealthGrid conferences led to the 
White Paper. This was well received by the community, but could not be defended as a rigorous 
scientific study; the need for a thorough examination of the issues was to be addressed through a 
formal “Specific Support Action” in the language of the European Union, the SHARE project 
[55]. The project took the White Paper as its starting point and sought to determine the steps 
necessary to establish an integrated, effective healthgrid infrastructure. The methodology 
recognized “non-functional” business and ethical requirements and “functional” technical 
developments that would have to be accomplished before a healthgrid could be realized and 
deployed. The steps, which are described in this IJMI paper; an exposition closer to the time of 





The SHARE Collaboration presented numerous papers in the process of refining its proposed 
road map. Significant ones from the point of view of my contributions were: 
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which represents the first attempt at a complete road map, albeit lacking in detail, and a further 
publication, 
!"#"$"%&'()*+,-&#*




which sought to define the outline of a debate around the first road map. This debate took place 
at a succession of venues, including workshops at the annual meeting of the European Health 
Management Association, at a meeting of the EGEE collaboration and another at the Open Grid 
Forum, at CCGrid, and CBMS Conferences, and on numerous occasions as ad hoc seminars at 
various academic settings. The two articles d. and e. above are listed here as subsidiary papers. 
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There was no single path from the first road map to the ultimate product that was delivered some 
18 months later. One track led through technical requirements and the ways in which 
development and deployment could be phased so as to make up a realistic project plan for the 
delivery of a functioning infrastructure, including security aspects. A second track undertook an 
in-depth analysis of ethical, legal and social issues, including privacy and confidentiality, 
organizational changes in workflows and in knowledge flows, possible impacts on reporting and 
control structures, and issues of liability. In retrospect, its economic analysis, at least compared 
with the in-depth study of legal issues, was not very deep. Nevertheless, a third strand of work, 
through case studies, investigated the applicability of these ideas to innovative medicine, 
including drug discovery and development, to epidemiology and public health surveillance, to 
collaboration in the biosciences and coordination of tertiary care.  
These three elements—technology, regulatory considerations, and case studies—were developed 
independently and could not readily be integrated into a coherent road map. I led the integration 
effort from UWE with the assistance of Hanene Rahmouni and Mark Olive. The collaboration 
provided the crucible in which our ideas were tested until it was possible to make a first draft of 
the road map public to a group of about thirty experts, twenty or so of whom were invited to a 
day-long meeting in Brussels to critically evaluate its proposals. The road map underwent its 
final amendments and improvements and was submitted to the European Commission as its final 
deliverable. The commission requested an abridged version for publication. Once again, 
working on behalf of the collaboration, my two students and I assembled the “short” SHARE 
Road Map which was published as a booklet by the Commission and after further editing and 
peer review by the editorial board, republished as the opening chapter of Cannataro’s Handbook 
of Research on Computational Grid Technologies for Life Sciences, Biomedicine, and 
Healthcare [56]. 








Much of our discussion of “grid computing” readily translates to the language of “cloud 
computing”. However, the two are not synonymous and in view of the pervasive success of 
cloud computing in the world at large, I will briefly explore the clear differences and comment 
on the apparent failure of the SHARE road map to address the economics of highly distributed 
infrastructures in a convincing way. 
The distinction—or, depending on one’s point of view, the similarities—between clouds and 
grids became a contentious issue because the later technology, clouds, appeared to be usurping 
certain features of grids without acknowledgement. Grids had emerged laboriously over many 
years of academic work, culminating in a diversity of systems and protocols. Clouds appeared to 
be the adaptation, perhaps annexation, of grid principles to large distributed infrastructures 
motivated by commercial interests. The term “cloud”, as a descriptor of a distributed 
computational architecture, was certainly in use by the end of the SHARE project and was 
contrasted with “grid” at the gathering of experts to evaluate the SHARE roadmapvii. It soon 
became clear that in parallel with the SHARE project, the EU had also funded a similar study on 
cloud computing, motivated largely by a perceived need to bridge the gap from academia and 
the sciences to industry and “production” systems. 
In his 2008 blog, There’s grid in them thar clouds, Ian Foster identifies many elements of grids 
that have found their way into clouds [57]. In that same year, at the Grid Computing 
Environments Workshop, a highly technical workshop on grid computing, we encounter the 
paper Toward a Unified Ontology of Cloud Computing [58]. One easily forms the impression 
that, at this stage, the grid community is looking to understand and respond to the phenomenon 
that has upstaged it. Viewed from a little further afar, it would appear now that the benefit of 
cloud technologies went beyond the kind of resource sharing that grids adopted and used the 
infrastructure to address a number of requirements, some arising from vendors’ interests and 
some from those of their clients. Chronologically first among the advantages of clouds was, I 
believe, “application service provision”, i.e. the ability to manage software, such as office 
applications, remotely. This benefits the software vendor, since it makes it possible effectively 
to control the licensing of the software to authorized users. The arguable benefit to the client lies 
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in the remote management of services, with a corresponding reduction in application 
administration costs, but at some risk of losing data that is only accessible through an 
application that is no longer under their control. Second, in many successful grid collaborations, 
there was already a background conversation on the cost of services, fair charging models, the 
need to load balance, perhaps through a market mechanism, or through planning and batch 
processing—as though the grid world was inadvertently reinventing the economic system 
arguments of the nineteenth and twentieth centuries. Clouds made elasticity and scalability 
through virtualization their principal claim in the economics of business information systems. 
SHARE identified uses for data grids and computational grids, two prime paradigms that pre-
existed the project. Taking its cue from the UK e-Science programme, it also advanced the 
“collaboration grid” as a third paradigm, with a future envisioned “knowledge grid” as the 
culmination of all these types, though one that could not yet be realized. This typology bears 
only the most superficial resemblance to the cloud distinctions of Infrastructure, Platform or 
Software as a Service (IaaS, PaaS, SaaS or, collectively, XaaS—anything as a service). The 
succinct assertion that “clouds are grids with a business model” provides a useful contrast. 
SHARE had recognized economic constraints, had factored organizational and regulatory 
concerns into its designs, and had asserted the possibility of its electronic network serving as a 
marketplace. It was therefore closer in spirit to cloud computing than any comparable proposal 
from the same domain. Perhaps—to address what I still consider a puzzle—this was the reason 
why we failed to recognize the cloud as a genuinely new paradigm. 
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In closing the chapter on SHARE and the road map, I wish to address certain issues that 
provided a focus of concern at the time of the project and led to some ideas that I have come to 
suggest since then. 
One of the persistent issues in a project in which potentially identifying data will be shared is the 
protection of that data. Regulatory frameworksviii envisage such instruments as legally binding 
Data Sharing and Data Use Agreements, where two parties intend to collaborate, and Business 
Associate Agreements, where one party serves the other under contract. One of the research 
problems I formulated and proposed to my student Hanene Rahmouni was the translation of 
legal rules (expressed in some form of declarative logic) to operational rules in an infrastructure 
(expressed in some form of deontic logic of permissions and obligations). It seems a common 
experience that researchers find regulatory frameworks rather restrictive. Policy makers and 
technologists do not join in a single conversation, and law and policy tend to be handed down to 
technologists without space for negotiation. I was, in a sense, asking, could we, as technologists 
force a dialogue by showing that we could meet the regulatory framework halfway, build some 
significant part of it into our technology? 
Hanene showed that data sharing may be viewed as a transaction of the form  
<preconditions> Conditional Actions <postconditions>. 
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The preconditions may be that valid agreements are in place and that the patient’s consent has 
been given and applies to this transaction. The postconditions relate to what the receiving party 
must undertake to do or not to do. Dr. Rahmouni’s solution to this problem has been published 
in a number of journal papers. My part in this work was advisory in relation to the technical 
content and in extensive co-authorship in terms of interpretation, validation, explanation, and 
dissemination. I presented the problem as a trade-off between creativity and compliance in a 
refereed presentation to the 16th World Congress on Medical Law. 
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I developed this theme a little further in a collaboration with two colleagues from Middlesex 
University, presented to the Second International Conference on Medical Imaging and Medical 
Informatics in Beijing in 2007. The paper was subsequently re-reviewed and invited as a journal 





Following the principle to automate as much as possible in any data sharing interaction, I was 
naturally led to consider the use of agents in settling matters under different jurisdictions. I 
developed this theme at a 2010 keynote address to the PRIMA conference and developed it into 




At this conference I learned of the work of Frank Dignum, Henry Prakken and others of the 
Amsterdam school and began to formulate my ideas in terms of norms and institutions. I took 
norms to be breakable rules (in the spirit of “break the glass”) where the breach had to be 
justified after the fact in some way. Institutions would then be abstracted as the collection of 
norms that apply in their interactions. 
In 2012, I was invited to give a keynote address to the HealthGrid and Life Science Grids 
conference in Amsterdam. I developed an example in the spirit of this theoretical framework, 
based on an exchange of data as might have taken place in MammoGrid: 
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Dr. House in the UK wishes to share a series of mammograms with Dr. Casa in Italy. The 
purpose of this is to get a second opinion. The patient has given consent that allows her 
images to be shared provided the purpose is delivery of care—which, indeed, it is. Dr. 
House lets Dr. Casa know that the only (post)condition he must impose is that the image 
must be destroyed or deleted once it has been used. Dr. Casa points out that her profess-
ional insurance requires her to keep all images on which she gives an opinion for a period 
of at least two years. 
This contradictory situation need not be the end of the collaboration. If the rule in England is 
treated as a norm, an exchange can take place along these lines: 
 
House – So, my only condition is that you must delete the mammograms after you have 
given your opinion. 
Casa – But you know I cannot do that. I will keep the images for at least two years, 
provided no controversy arises. If any does, of course, I will need to keep them even 
longer. 
The exchange of data takes place. 
House – OK, you have “broken the glass”, but in these circumstances (“for good cause”) 
I am empowered to modify the condition. You must undertake to delete these images at the 
earliest time consistent with your situation at the time. Until then, your record [where?] 
will show that you have broken the glass.  
This suggests that a logic of argumentation may be best suited for this type of interaction. I am 
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The Institute of Medicine, as the National Academy of Medicine was known in 2006, had 
instituted a Roundtable on Evidence-Based Medicine whose vision statement began: 
The Institute of Medicine’s Roundtable on Evidence-Based Medicine has been convened to help 
transform the way evidence on clinical effectiveness is generated and used to improve health and 
health care. We seek the development of a learning healthcare system that is designed to generate 
and apply the best evidence for the collaborative healthcare choices of each patient and provider; 
to drive the process of discovery as a natural outgrowth of patient care; and to ensure innovation, 
quality, safety, and value in health care. 
The first report, The Learning Healthcare System: A Workshop Report [59], was published in 
2007 and set in motion a number of different trains of activity, including studies of the necessary 
digital infrastructure, on citizen engagement, on data commons, and on costs—indeed, with a 
redesignation of the meetings to Roundtable on Value & Science-Driven Health Care. 
Dr. Jonathan Silverstein, at that time Associate Director of the University of Chicago / Argonne 
National Laboratory Computation Institute, had been aware of my group’s work on healthgrids 
and had encouraged the formation of HealthGrid.US to promote relevant activities in the United 
States. Through Dr. Silverstein, I received an invitation to speak at the roundtable’s workshop 
on Digital Infrastructure for the Learning Health System [60]. This was an exceptional 
opportunity: whereas in Europe our work had appeared as one of the multitude of threads that 
the EU was spinning through its Framework Programmes, the IOM initiative appeared to 
promise an engagement both with the need for Practice-Based Evidence (else, how would the 
system “learn”?) and the need to secure data re-use in a well-regulated process. In other words, 
the SHARE programme, the work with Hanene Rahmouni on data annotation and automated 
compliance, and the fledgling work with Mark Olive on “PBE for EBP” could all be brought 
together in one movement. The presentation of those aspects of this work that were sufficiently 
mature to withstand scrutiny were presented and are incorporated in the report [61]. 
Dr. Charles Friedman, a major exponent of the Learning Health System (LHS) concept has since 
led this nascent movement through to the incorporation of the Learning Health Community as “a 
grassroots not-for-profit organization”. [62]. Its mission and vision are summed up on its home 
page: 
LHC MISSION 
The Community's Mission is to galvanize a national grassroots movement in which 
multiple and diverse stakeholders work together to transform healthcare and health by 
collaboratively realizing the LHS Vision. 
LHC VISION 
The Learning Health Community (“Community”) aims to mobilize and empower multiple 
and diverse stakeholders to collaboratively realize a national-scale (and ultimately 
global), person centered, continuous and rapid learning health system (LHS). 
The principles and exemplars that flesh out this vision and mission bear a close relationship to 
the work presented here. The fundamental principle is the creation of relevant knowledge:  
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[The LHS] will improve the health of individuals and populations. The LHS will 
accomplish this by generating information and knowledge from data captured and 
updated over time – as an ongoing and natural by-product of contributions by individuals, 
care delivery systems, public health programs, and clinical research – and sharing and 
disseminating what is learned in timely and actionable forms that directly enable 
individuals, clinicians, and public health entities to separately and collaboratively make 
informed health decisions… The proximal goal of the LHS is to efficiently and equitably 
serve the learning needs of all participants, as well as the overall public good. 
This is consistent with, if somewhat broader than, the goals of the Patient Centered Outcomes 
Research Institute. 
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The Patient-Centered Outcomes Research Institute (PCORI) was established under the 
Affordable Care Act with the mission to support research with a focus on the patient, the 
caregiver, the patient advocate, or the citizen in general, as increasing attention is paid to health 
maintenance and self-management. The main case for funding this initiative, however, was the 
prohibitive cost of randomized control clinical trials (RCTs) and the length of time it takes for 
all the prescribed stages to be completed and a new product or protocol be proposed for 
adoption. The argument is that with sufficient numbers, observational data should prove rich 
enough to enable researchers to control for confounders and other possible statistical 
contaminants. Thus, PCORI supports comparative effectiveness research (CER) into clinical 
outcomes that matter to patients and their families. PCORI has funded a number of regional 
collaborations under two headings, Clinical Data Research Networks (CRDN) and Patient-
Powered Research Networks (PPRN). 
The initial goal of all CDRNs was to create an interoperable infrastructure each within their own 
network, and to prove it through a number of initial studies. A national network of networks, 
PCORnet, has been established with the 13 CDRNs and 20 PPRNs as its nodes, again as a 
national infrastructure for CER. One of these nodes, the Chicago-based CDRN, is introduced 
next. 
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CAPriCORN, the Chicago Area Patient Centered Outcomes Research Network, is a remarkable 
alliance of Chicago-land institutions representing a very diverse community—diverse both in 
the type of institutions involved and, importantly, in the populations they serve.  Among certain 
of the institutions in CAPriCORN, there is substantial overlap in populations, sometimes as high 
as 20%. This is largely explained by the economics of healthcare for those with inadequate or no 
insurance. With no primary care physician (PCP) registration, the Emergency Room (ER) 
becomes the place where care is received. 
This phenomenon presents certain challenges in the design of an integrated information system 
in the absence of a unique (national or local) patient identifier. Notwithstanding the adoption of 
a common data model, the architecture of the virtual CAPriCORN repository is essentially a 
federated one. Indeed, it is doubtful whether the term “repository” is justified, even with the 
qualifier “virtual” attached. Except where its centralized IRB has given approval to approach 
patients for consent, all data for sharing within CAPriCORN—and in the wider community at a 
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later stage—are in a HIPAA-compliantix [63], de-identified format, and assembled only on a 
study by study basis. The Informatics Working Group has devised a distributed data 
architecture, a data model with appropriate standards, and a designed data flow engineered to 
ensure that no protected health information (PHI) is released other than under strictly controlled 
conditions, at the same time as maintaining the research value of the data that is released. 
Indeed, even de-identified data is released only for a single study at a time, not as an aggregate 
population. A pseudo-identifier is generated for each patient in such a way that patients’ records 
that are distributed across different providers in the network can be matched and integrated, 
without data being moved outside protected home institution environments. Consent is always 
sought when access to PHI or directly to the patient for patient-reported outcomes is necessary. 




In the first phase of the project, which was intended as a proof of concept, NorthShore 
University HealthSystem, where I work, participated in studies of four conditions: Anaemia in 
in-patients; Obesity and Overweight; Asthma; and Recurrent Clostridium difficile Infection. 
These studies were conducted on de-identified data except for small numbers of patients who 
consented to be interviewed about their outcomes.  
In the second, “live” phase, colleagues and I are participating in a number of national studies, 
including ADAPTABLE, a study of Aspirin dosing for patients with a documented history of 
cardiovascular disease, and two obesity-related studies, one on Bariatric Surgery, comparing 
different types of surgical procedure for their effects on the patient’s subsequent health and 
weight, and another, which I co-lead in our own CDRN, on Short- and Long-Term Effects of 
Antibiotics on Childhood Growth: do antibiotics in the first two years of life affect the child’s 
weight as he or she grows up? [64] Further studies of patients with high healthcare needs and 
costs, of patients with chronic obstructive pulmonary disease (COPD), and others are being 
planned. 
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The development of the technical infrastructure was necessarily phased, both to address the 
heterogeneity of the collaborating institutions, and also to match the evolving ideas (and 
sometimes asserted requirements) of the overarching national network, PCORnet. It was also 
necessary to phase technology and workflow specifications so as to remain in step with the 
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concurrent development of a common IRB, with its associated policies and procedures, and to 
remain respectful of the entirely new Patient and Clinician Advisory Council (PCAC) which 
was poised to become the voice of stakeholders in the system. 
First to be designed and agreed was a basic data model to serve as a common design for a 
CAPriCORN data mart at each institution. It was also axiomatic that there should be a means, 
ideally independent of the data mart, for a “hashing” algorithm to be applied to patient 
identifiers so as to generate an almost certainly unique “de-identifier” (with about 98% 
certainty). This would provide the means of de-duplicating patients who visited and had records 
at more than one institution, and a private “crosswalk” table at each institution to enable a 
researcher with all necessary credentials and permissions to re-identify an anonymized patient 
should it become necessary to contact them – e.g. for consent and follow-up. Next, the means of 
querying the institutional data marts was prescribed by PCORnet; it would be the ad hoc 
distributed query engine, PopMedNet [65], chosen because of its historic links to one of the 
PCORnet coordinating centres. There then followed the most intense debate, in which I played a 
leading part, on the correct workflow and formulation of a so-called “Master Protocol” which is 
to be considered a prefix to any other protocol for submission to the central IRB. 
The import of the somewhat complex processes of de-identification, de-duplication and virtual 
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In this dissertation, I have considered a number of interlinked concepts, propositions and 
relations, and put forward a set of design theses, to support the role of informatics in the overall 
goal of knowledge-based, information-driven, integrated, patient-centred, collaborative 
healthcare and research. This rather ambitious scope may be delimited by exclusion: the work is 
not concerned explicitly with genomics or bioinformatics, but it does encompass certain aspects 
of translational medicine and personalized healthcare, which I take to be subsumed in some 
sense under “knowledge-based” and “information-driven”. Although I do not exclude public 
health informatics, my exposure extends only to surveillance of infectious diseases, patient 
engagement, and the effectiveness of screening programmes. I do take ethical, legal, social and 
economic issues (ELSE) to be included, at least to the extent that I aim at an infrastructure that 
encompasses these issues and aims to incorporate them in technical designs in an effort to meet 
ethicists’, lawyers’, policy makers’, and economists’ concerns halfway. To a first 
approximation, the aim has been to integrate two strands of work over the last decade or more: 
the informatics of medical records on one hand and the distributed computational infra-
structures for healthcare and biomedical research on the other.  
OYF! N):1)'',1):%9)"/+:1'7%%
Two engineering analogies are sometimes made in the discussion of biomedical and healthcare 
informatics: the “airline analogy” (AA) and the “bridge analogy” (BA). 
In AA, the main question concerns patient safety: air travel is notoriously safe, so why can’t we 
learn from practices in that industry to make medical and healthcare systems safer? It is 
asserted that the airline industry is safe because (a) the design, manufacture and implementation 
of its systems (aircraft, air traffic control, etc.) follow strict engineering principles and are fully 
tested before deployment, and (b) in that industry’s operations, there is a “no fault” system for 
reporting human error and near misses. These two elements of safety are evident in the work of 
several national and international medical informatics associations, such as the European 
Federation for Medical Informatics (EFMI), the International Medical Informatics Association 
(IMIA), and the American Medical Informatics Association (AMIA) [66], leading, for example, 
to work on the evaluation of electronic health record systems (EHR) [67] and to analyses of 
otherwise unreported systems failures, e.g. in anaesthesia pumps [68]. Thus, the AA focuses on 
“how”, seeking and providing evidence that a system is safe: 
•! Requirements are established through an iterative process which defines scope, establishes 
validity (self-consistent, unambiguous, capture what is needed) and adequacy ("complete 
enough") 
•! Formal proof is sought that a specification conforms to requirements. 
•! Formal proof is sought that a system does what is has been specified to do. 
In BA, the emphasis shifts from the observation that a bridge can be built on sound civil 
engineering principles and be certain to be “fit for purpose” – a safe construction that can bear 
the weight it was designed to and can last for a long time subject to some regular maintenance – 
to the observation that some unintended and unexpected effects of the bridge may be less than 
desirable – e.g. change in traffic flows that result in a congested city centre. In healthcare 
informatics, the BA is reflected in the way physicians’ workflows are modified when electronic 
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systems are introduced. Even where a system is consciously introduced through a “business 
process re-engineering” programme, changes in workflow may be due to working around a 
sclerotic technology as much as to a deliberate decision to improve process. The BA focuses on 
“what” and “why”, beginning with the question whether a bridge should be built: 
•! Why should a bridge be built? 
•! Where should the bridge be built? 
•! What impact will it have? (rather than merely Will it be safe?) 
•! Must those who opposed it refuse to use it? May they refuse to use it? 
We may distinguish two “pure” paradigms for systems development: in the first, a need is 
identified and a system commissioned, i.e. development begins with “why” and “what” and 
moves to “how”; this is more or less the case in much industrial systems development. In the 
second paradigm, a potential innovation is identified through a technological advance and a 
service or application is envisioned based on it, i.e. “how” leads to “what” and thence to “why”. 
This can be seen, for example, in the development of mobile communication technologies, from 
smartphones to the ubiquitous “apps” that run on them. In other fields, these paradigms may be 
described as “pull” and “push” models. In the majority of cases, of course, the reality of systems 
development exhibits elements of both these paradigms. 
These themes have been explored and illustrated in the work presented here through a number of 
publications arising from specific projects as well as in a few “position” papers. 
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Two distinct approaches have been adopted in my research, one leading from medical or 
healthcare issues to technological innovation and a complementary one that begins with 
technology and moves to healthcare applications. These approaches have been adopted singly 
and together in different projects. Examples include: 
Medicine to Technology The EuroPGD Code project was commissioned by the European 
Agency for Health and Consumers and the European Society for Human Reproduction and 
Embryology to support data collection on preimplantation genetic diagnosis (PGD) in Europe. 
As the principal technical investigator, I worked directly with physicians and researchers to 
understand their research goals and hypotheses, designed a data collection system and guided its 
implementation. PGD is a method of screening for specific conditions in the process of assisted 
reproduction. The project concerned the subsequent developmental health of children born 
following in vitro fertilization (IVF) and PGD. 
Technology to Medicine An internally funded project with Dr Kay Wilkinson at the University 
of the West of England, Bristol, began with the assumption that methods of artificial intelligence 
could be applied in the analysis of histopathology reports of patients with inflammatory bowel 
disease (IBD). This was an early example of anticipated value in the analysis of medical records. 
Using technologies from the design of decision support systems and from natural language 
processing, it was shown that although reported conclusions in the reports were consistent with 
findings, the latter were often not sufficient to warrant the conclusion. Further examination of 
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the reports with the pathologists who had issued them revealed patterns of reporting based on 
what was considered “relevant” or “obvious” and thus worthy of recording or not. 
Technology and Medicine The MammoGrid project was based on the hypothesis that a grid 
computing approach to the sharing of mammography data in two distinct populations would 
enhance diagnostic collaboration between physicians and provide a diverse population base for 
the study of certain physiological hypotheses concerning breast cancer risk. The project 
developed a highly interactive approach and a common language (based on “use cases”) that 
allowed both the expression of medical requirements to the technologists and a clear 
presentation of technical possibilities to the physicians. 
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Healthgrids 
The technological strand of my work has arisen from other research in software engineering, 
notably in the realm of physics and engineering applications. Translating advances made in the 
context of the new physics experiments at CERN, I was closely identified with the development 
of “healthgrids”, the application of grid computing principles in support of medical research and 
healthcare. Developed through a number of highly collaborative projects, this work led to 
several exemplars which eventually informed the study of the principles of this approach in the 
SHARE project. Earliest among the paradigmatic projects was MammoGrid in which the 
effectiveness of a distributed infrastructure to support diagnostic practice and epidemiology was 
demonstrated. This was particularly successful in epidemiological terms in that it provided a 
means to validate known research findings in breast cancer physiology through the study of two 
populations, demonstrating the effectiveness of a distributed learning system as well as the 
applicability of grid principles to healthcare. In the light of this and other successful European 
projects, the European Commission funded the SHARE project to produce a research road map 
for healthgrids. This was undertaken first through a study of existing systems and projects, 
leading to a “state of the art” report; it then followed through with several in-depth domain case 
studies and, in parallel, a thorough mapping of ethical, legal and socio-organizational issues; 
finally, the project developed a road map in two stages with a multifaceted expert review to 
validate the findings and principles between the two stages. The concepts of grid computing 
have since been incorporated with various business models into what has come to be known as 
cloud computing. This is commonly spoken of inaccurately as “the cloud”, a singular reference 
that may ultimately only be justified through an abstract framework provided by the 
infrastructure to support different business models. An analysis of the different paths taken by 
the grid and cloud paradigms, with particular reference to biomedical research (including 
pharmaceutical industries) and to healthcare will also be used as a vehicle to explore the 
dimensions of biomedical and healthcare informatics. 
Large-Scale Systems 
There is a second interesting perspective on the first question above, (a) Should a health system 
maintain a single integrated record for each patient? In pragmatic terms, there is an extensive 
history of failures in healthcare systems across the world attempting to adopt or to construct an 
integrated health record. The present author was a public critic of the Connecting for Health 
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programme in England, whose overreach and poor development process was evident from 
relatively early on [69]. Yet this was what became, after a number of political twists and turns, 
of the visionary “Burns Report” Information for Health [70] whose process had been rejected as 
“too slow”. More recently, it has been reported in the United States that the Veterans 
Administration and the Department of Defense have abandoned an attempt to integrate their 
respective EHR systems after investing several hundred millions of dollars in the attempt. This 
despite the widely acknowledged quality of the VA’s own VistA system which has been so 
successfulx that it has been marketed as a product in its own right. Comparing the critique of 
these two megaprojects by the National Audit Office in the UK and the Government 
Accountability Office in the US, shows a remarkable overlap in problems identified, criticisms 
and reasons for failure. The more recent failure of the launch of HealthCare.gov, the 
“Obamacare” website, is symptomatic of a different kind of complexity in the US health care 
system and will not concern us. However, the complexity that is recognizable in all but the most 
rudimentary healthcare systems forms the backdrop for an essential thread in the work described 
here. 
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The Institute of Medicine of the National Academies in the United States has issued a number of 
reports in its Learning Health System Series based on discussions in its Roundtable on Value 
and Science-Driven Health Care. The report on infrastructure [59] expresses a degree of 
enthusiasm for the “Ultra Large Scale Systems” [71] approach pioneered by Carnegie Mellon 
University computer scientists. There are interesting similarities and differences between ULSS 
and the autonomous “knowledge (health)grid” that was envisaged in the SHARE reports and 
roadmaps. The critical similarity from the point of view of my own research is in the 
requirement that the local systems loosely federated in a greater scheme (a) are autonomous, (b) 
have the capacity to read each other in increasingly sophisticated ways, so that (c) eventually 
they can interoperate with minimal human intervention. This is an important principle behind 
my own work on automation of privacy compliance, in which human intervention has been 
compared with the “red flagging” of early motorcars in the UK because a regulation – intended 
to manage risk to pedestrians in the movement on public roads of motorized agricultural 
machinery – was also applied to them as “motorized vehicles”. Naturally, in due course, this 
inappropriate regulation was replaced by a web of legislation and regulatory requirements, 
including, licensing of cars and drivers, annual checks on vehicle condition, varying speed 
limits, severe sanctions on driving while unfit, and so on. Accidents certainly occur, but on 
nothing like the scale that would suggest that human speed is the only appropriate speed for such 
vehiclesxi. And here I draw a parallel: whatever other problems the motorcar may have brought 
in its wake, it has increased mobility, and mobility of data for the purposes of healthcare and 
healthcare-related research is one of our primary goals.  
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So the argument here rests on what a system can achieve given the right degree of autonomy 
and, therefore, on what the right degree of autonomy is. This belongs to a broader debate on the 
embodiment of policy in technology and the extent to which policy is “technology-savvy”. The 
study of transport systems, broadly conceived, extending from the engineering of small and 
large vehicles to entire systems, their management and social impact, provides a useful 
metaphor in the study of complex information systems. This is highly effectively illustrated in 
the work of Joseph Sussman and his group at MIT [72].  This is in a sense the landing place for 
the bridge from the first strand of work on information-driven healthcare. 
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The work with Hanene Rahmouni was completed in a European context, exploring the varying 
interpretations of the European Data Protection Directive as national legislation in member 
states. I have been able to translate, transplant and adapt the argument to the United States 
context and current research trends there. The adoption of electronic records in the US is 
somewhat patchy, but there are significant national measures to accelerate the process. More 
importantly, the rapid growth in the disciplines of genomic and translational medicine, coupled 
with the prohibitive cost of clinical trials, has led to a number of new approaches to research. 
Two major trends in this respect are comparative effectiveness research (CER) and patient-
centred outcomes research (PCOR). CER is essentially the study of disease development, 
comorbidities and the relative efficacy of treatments in real patients, and is proposed as a means 
of formalizing observational studies to complement clinical trials. PCOR has been promoted and 
heavily favoured in funding mechanisms as a means of involving the patient, at least as 
represented by patient organizations and patient advocates, in the formulation of research 
problems, hypotheses and goals that reflect real patient interests. In support of these trends in 
research, the Institute of Medicine of the National Academies of Science has proposed the 
concept of a “learning health system”, a philosophy and a blueprint for a knowledge-driven 
healthcare system that applies best evidence-based practice and analyses its own effectiveness to 
improve every aspect of its operations, from diagnostic and treatment workflows to its approach 
to population health. My current work in this US context demonstrates the use of integrated 
informatics to support these goals, from concrete developments, such as new ways to record 
patient-physician interactions through structured clinical documentation systems (SCDS) [73] to 
more abstract principles, such as information reciprocity between patients, physicians and 
researchers. The latter proposes and fleshes out a system that adapts technologies from other 
contexts to support the maintenance of informed consent, patient feedback and education, 
improvement of social and organizational aspects of healthcare, and expression of unmet 
research needs as experienced by physicians and patients. 
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The PCORI-funded study on Short- and Long-Term Effects of Antibiotics on Childhood Growth 
has engaged me as a technical advisor to a stakeholder advisory group consisting of parents, 
other carers and primary physicians. The interaction with stakeholders has provided first-hand 
experience of the kind and range of insights that can be brought to bear from a patient 
perspective. The translation of technical documents for lay stakeholders requires a careful 
appraisal of the principles on which a study is based and of the research questions it proposes to 
address. It is sometimes said that the best way to learn something is to teach it; the process of 
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writing, first, a set of explanatory notes on the analytic plan for the study, and then contributing 
to a lay pamphlet to describe and explain the project to parents who have no vested interest in 
the study, unlike the stakeholder group, has underscored both the value of open communication, 
but also the exceptional value of the committed stakeholders. 
The final paper in this collection is a reflection of this experience as well as a summation, in a 
certain sense, of the diverse elements presented here. It is an affirmation of a commitment to 
engage patients’ and carers’, as well as primary physicians’, intimate knowledge of many 
conditions where research has traditionally focused only on medication, on effectiveness by a 
narrow set of clinical measures, and the patient’s wellbeing is at best an afterthought. While I 
believe this to be important in the provision of healthcare, I am now persuaded that it is an 
indispensable element in research also. Moreover, as an intelligent patient, I wish to be informed 
of what is going on in research that may impinge on me for all the good reasons that I may be 
able to impact the research process itself, that the research team may have the benefit of insights 
from a radically different point of view, and that the ultimate success of the proposed 
intervention or innovation may have as much to do with its reception by patients as with the 
statistical results of the study. To repeat the earlier formulation, rather than doing things to 
research subjects, or for philanthropists, we may do research with patient collaborators. The 
main thrust of the paper, however, is not to argue the moral case so much, as to assert that all the 
necessary elements are present and available. 
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Abstract: The past decade has witnessed order of magnitude increases in computing power, 
data storage capacity and network speed, giving birth to applications which may handle large 
data volumes of increased complexity, distributed over the internet.  Medical image analysis is 
one of the areas for which this unique opportunity likely brings revolutionary advances both 
for the scientist’s research study and the clinician’s everyday work.  Grids [1] computing 
promises to resolve many of the difficulties in facilitating medical image analysis to allow 
radiologists to collaborate without having to co-locate. The EU-funded MammoGrid project 
[2] aims to investigate the feasibility of developing a Grid-enabled European database of
mammograms and provide an information infrastructure which federates multiple
mammogram databases.  This will enable clinicians to develop new common, collaborative
and co-operative approaches to the analysis of mammographic data. This paper focuses on one
of the key requirements for large-scale distributed mammogram analysis: resolving queries
across a grid-connected federation of images.
Keywords: distributed database, queries, meta-data, mammography, medical image analysis, 
epidemiological studies 
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1. Introduction
Medical diagnosis and intervention increasingly relies upon images, of which there is a growing 
range available to the clinician: x-ray (increasingly digital, though still overwhelmingly film-based), 
ultrasound, MRI, CT, PET, SPEC etc. This trend will increase as high bandwidth PACS systems are 
installed in large numbers of hospitals (currently, primarily in large teaching hospitals). 
Patient management (diagnosis, treatment, continuing care, post-treatment assessment) is rarely 
straightforward; but there are a number of factors that make patient management based on medical 
images particularly difficult. Often very large quantities of data, with complex structure, are 
involved (3-D images, time sequences, multiple imaging protocols).  In most cases, no single 
imaging modality suffices, since clinically significant signs are subtle and because there are many 
parameters that affect the appearance of an image, like: 
• Patient age, diet, lifestyle, clinical history, …
• Image acquisition parameters
• Anatomical and physiological variations.
Breast cancer as a medical condition, and mammograms as images, are extremely complex with 
many dimensions of variability across the population. Similarly, the way diagnostic systems are 
used and maintained by clinicians varies between imaging centres and breast screening 
programmes, and in consequence so does the appearance of the mammograms generated. It is 
necessary to understand this variability to be able to study the epidemiology of breast cancer and 
enhance the usefulness of mammography breast screening by integrating Computer Aided 
Diagnostic tools [3] and quality control [4], [5] in the process. A geographically distributed 
database that reflects the spread of pathologies across the European population is an essential tool 
for the epidemiologist and the understanding of the variation in image acquisition protocols is 
invaluable to the end-user who runs a screening programme. 
In order to make the most of such a database it is necessary to have the right tools. This requires an 
infrastructure to make the large volume of data available to all the centres in an acceptable time, a 
capable data-mining engine that enables queries based on patient details and text annotations, 
standardization software to enable the comparison of images from different patients and centres, 
image analysis algorithms that provide quantitative information, which is otherwise unavailable 
from visual inspection alone, and detection systems that help in visual diagnosis. 
Usually, related personal and clinical information is important (age, gender, selection criteria, 
disease status).  The number of parameters that affect the appearance of an image is so large that the 
database of images developed at any single site – no matter how large – is unlikely to contain a set 
of exemplars in response to any given query (e.g. “show me all women in their 50s that developed a 
tumor within 5 years of starting HRT”) that is statistically significant. Overcoming this problem 
implies constructing a huge, multi-centre – federated – database, while overcoming statistical biases 
such as lifestyle and diet leads to a database that transcends national boundaries. For any medical 
condition, there are potential gains from a pan-national database – so long as that (federated) 
database is as usable as if it were installed in a single site. 
2. MammoGrid User Requirements
The main output of the MammoGrid project, a Grid-enabled software platform (called the 
MammoGrid Information Infrastructure) which federates multiple mammogram databases, will 
enable clinicians to develop new common, collaborative approaches to the analysis of 
mammograms. This will be achieved through the use of Grid-compliant services for managing 
massively distributed files of mammograms, for handling the distributed execution of mammogram 
analysis software, for the development of Grid-aware algorithms and for the sharing of resources 
between multiple collaborating medical centres. All this is delivered via a novel software and 
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Figure 1: The Mammogram Analyst Use Case diagram 
The MammoGrid project is being driven by the requirements of its user community (represented by 
Udine (Italy) and Cambridge (UK) hospitals along with medical imaging expertise from Oxford) 
that have been elicited and specified in detail [6]. Rational’s Unified Process model (RUP) [7] has 
been used in the requirements specification for MammoGrid and in particular key requirements 
engineering activities. The process has identified major use-case scenarios in the use of a distributed 
database of mammograms deployed across a pan-European Grid and that later can be used to prove 
the MammoGrid prototype. 
The resulting MammoGrid User Requirements Specification (URS) details two essential objectives 
that must be supported and tested in the MammoGrid project: 
• Support of clinical research studies through access to and execution of algorithms on
physically large, geographically distributed and potentially heterogeneous sets of (files of)
mammographic images, just as if these images were locally resident.
• Controlled and assured access for educational/commercial companies to distributed
mammograms for testing novel medical imaging diagnostic technologies in scientifically
acceptable clinical trials that fulfill the criteria of evidence-based medical research.
The choice of a use-case driven approach to requirements gathering seemed most practical as the 
gap between the developers’ background knowledge of the domain and that of the users needed to 
be bridged in order to tackle the problem of architectural and interaction design.  The requirements 
elicitation process was carried out in consultation with the user community at hospitals in Udine, 
Cambridge and Torino.  In these discussions nine core use cases with corresponding actors have 
been identified.  The use case concerned with mammographic analysis describes the tasks that the 
‘Mammogram Analyst’ actor, normally a radiologist or perhaps an epidemiologist, may undertake 
to annotate and/or view mammograms and patient details, to execute radiological queries, including 
use of computer aided detection (CADe) software, and to execute epidemiological queries.  This 
use-case provides the frame for the queries which is the main subject of the further sections of this 
paper.  A brief extract of this use case is shown in figure 1. 
3. Resolving Clinicians’ Queries
In the MammoGrid proof-of-concept demonstrator, real clinician queries will be handled and 
resolved against data resident across a Grids infrastructure. User Requirements have been gathered 
that will enable queries to be executed and data retrieved for the analysis of mammograms. In 
particular the MammoGrid project will test the access to sets of mammogram images for the 
purposes of breast density assessment and for the testing of CADe studies of mammograms. 
Queries can be categorized into simple and complex queries. Simple queries use predicates that 
refer to simple attributes of meta-data saved alongside the mammographic images. One example of 
a simple query might be to ‘find all mammograms for women aged between 50 and 55’ or ‘find all 
mammograms for all women over 50 undergoing HRT treatment’. Provided that age and HRT 
related data is stored for (at least a subset of) patients in the patient meta-data then it is relatively 
simple to select the candidate images from the complete set of images either in one location of 
across multiple locations.  It is also possible to collect data concerning availability of requested 
items so as to inform the design of future protocols, thus engineering a built-in enhancement 
process. 
There are, however, queries which refer to data that has not been stored as simple attributes in the 
meta-data but rather require derived data to be interrogated or an algorithm to be executed. 
Examples of these might be queries that refer to the semi-structured data stored with the images 
through annotation or clinician diagnosis or that is returned by, for example, the execution of the 
CADe image algorithms. 
3.1. Typical Complex MammoGrid Queries 
This section describes three example use-cases illustrating  the nature of complex queries which the 
MammoGrid infrastructure should handle. 
3.1.1. Use Case 1: Patient’s first visit 
Consider a patient on her first visit to the mammography center (following referral by GP, worried 
about a symptom).  The typical workflow of the visit looks like this: 
• Mammograms (2 ´ MLO and 2 ´ CC1) taken
• Radiologist reads them and annotates2 left MLO (LMLO) and left CC (LCC)
• Radiologist requests CADe for LMLO and LCC images.
• Query: Radiologist requests ‘find similar cases’.  Example criteria might include women:
o of same age ± 3
o with same number of children (0), (1-2), (3-4), (5+)
o with same age ranges of children (equivalently, age at first and last pregnancy)
o with images that the algorithm “find one like it” matches well either in MLO or CC
• Radiologist reviews demographics and personal data and determines best four cases to
request images.
• Radiologist reviews comparable images with histories and analyses:
o consider the best match
o take images from first diagnosis to current state
o review growth of lesion (ideally identifies the lesion across images)
3.1.2. Use Case 2: Epidemiology Study 
Consider an epidemiologist who is conducting a study on contralateral breast cancer.  The typical 
queries she is interested in running may include: 
• Find all patients in the distributed database who have developed cancer in the other breast
after successful therapy (specific or otherwise) on the first cancer.
• Consider mammographic features from the time of first diagnosis and any correlation to
occurrence of contralateral cancer.
• Consider measures of asymmetry and their correlation to contralateral cancer.
3.1.3. Use Case 3: Quality Control of Radiology Diagnosis 
Consider the use case of comparative study of radiologists’ annotations.  The typical queries which 
can be used to survey radiologists’ diagnostic processes include the following example queries: 
• For a period of six months, allocate each patient who attends for screening at random to two
out of three radiologists so that all three possible pairs get roughly equal numbers.
• For each patient, ask both radiologists to examine the mammograms and to make any
necessary annotations.
• Submit all annotations for CADe and measure differences between radiologists’
annotations and CADe (could be area if masses, counts if microcalcifications) and between
the two radiologists in each case.
1 MLO – Medio-Lateral Oblique, taken at 45º from shoulder to opposite hip; CC – Cranio-Caudal, taken 
vertically down from above. 
2 Annotation – a region is marked out as suspect or for further analysis. 
• Consider correlation to experience, the length of the viewing session and the serial order of
the given image in that session, and the radiologist’s perception whether this was the first or
second reading.
3.2. The Role of Meta-Data 
During the final phase of implementation and testing, lasting until the completion of the project, the 
meta-data structures required to resolve the clinicians’ queries will be delivered using the meta-
modelling concepts of the CRISTAL project [8]. This will involve customizing a set of structures 
that will describe mammograms, their related medical annotations and the queries that can be issued 
against these data. The meta-data structures will be stored in a database at each node in the 
MammoGrid (e.g. at each hospital or medical centre) and will provide information on the content 
and usage of (sets of) mammograms. 
The query handling tool will locally capture the elements of a clinician’s query and will issue a 
query, using appropriate Grids software, against the meta-data structures held in the distributed 
hospitals. At each location the queries will be resolved against the meta-data and the constituent 
sub-queries will be remotely executed against the mammogram databases. The selected set of 
matching mammograms will then be either analyzed remotely or will be replicated back to the 
centre at which the clinician issued the query for subsequent local analysis, depending on the 
philosophy adopted in the underlying Grids software. All data objects will reside in standard 
commercial databases, which will also hold descriptions of the data items.  
3.3. The Query Handler 
The user will submit queries that are serviced locally and farmed out to available resources when 
data from the network is required.  In resolving queries the system will consult the knowledge it has 
acquired from previous queries. Data will be immediately returned to the user and the knowledge 
base updated.  New data is processed only when necessary.  With this approach the computation 
required by a domain-specific application is analyzed and farmed out to appropriate data sources 
rather than moving or replicating potentially vast amounts of data and processing. 
The querying software largely constitutes: 
Query Manager components 
• Query Translator,
• Query Analyser,
• Local Query Handler,
• Remote Query Handler and
• Result Handler
Data Sources 
• User’s Terms and Mammogrid specific meta-data,
• Local database and
• Stored query database
Figure 2: Query Handling in Mammogrid 
Figure 2 illustrates the query handling and execution in Mammogrid. The sequence of events is as 
follows: 
(1) Clients (e.g. end-users, applications) define their mammogram analysis in terms of queries they
wish to be resolved across the collection of data repositories (either locally- or remotely-held data).
This uses descriptive information (User’s Terms and MG-specific metadata) about the query
domain (both graphical specifications and user-specific terms) to translate the user query into a
‘data request’ using standard terms.
(2) Query Translator takes the user request and translates to a MG-defined formal query
representation.
(3) Queries are executed at the location where the relevant data resides. That is, the sub-queries are
moved to the data, rather than large quantities of data being moved to the clinician, which is
prohibitively expensive given the quantities of data. The Query Analyser  takes a formal query
representation and de-composes into (a) formal query for local processing and (b) formal query for
remote processing. It then forwards these de-composed queries to the Local Query Handler and the
Remote Query Handler for the resolution of the request.
(4) The Local Query Handler generates query language statements (e.g. SQL) in the query language
of the associated Local DB (e.g. MySQL).  The result set is converted to XML and routed to the
Result Handler.
(5) The Remote Query Handler is a portal for propagating a queries and results between sites. This
handler forwards the formal query for remote processing (3b above) to the Query Analyser of the
remote site. The remote query result set is converted to XML and routed to the Result Handler.
(6) The Result Handler is responsible for collecting query results – both local and remote. The
query handlers return XML results, and these are “joined” to create the overall result to be sent back
to the requestor – either the client of the Remote Query Handler.
Figure 3 shows the propagation of queries between sites. 
Figure 3: Propagation of Queries between Sites 
4. Conclusions
The application of computer science in medicine is relatively young.  Proliferation of information 
technology in medical sciences will undoubtedly continue, addressing clinical demands and 
providing increasing functionality.  The MammoGrid project aims to advance deep inside this 
territory and explore the requirements of evidence-based, computation-aided radiology, as specified 
by medical scientists and practicing clinicians.  This paper has emphasized two pillars which are 
likely to prove essential to the success of such a project: the importance of extensive requirements 
analysis and a design which caters for the complexity of the data. 
The very nature of a project like MammoGrid implies that it is inconceivable to define an 
exhaustive list or even complete classification of all possible queries which the radiologists may 
need to run against the distributed database.  Inevitably, when the user community starts using such 
a system, the requirements will undergo adjustments and extension.  This paper  has illustrated the 
kind of complexity of the expected queries, based on initial consultation of radiologists.  It is 
suggested that the design with extensive use of meta-data, as in the by now well-tested CRISTAL 
system, is both capable of handling such complex queries in an efficient way and flexible enough to 
adapt to changing requirements.  A design which handles queries using a reflexive data model has 
been presented as the proposed query model for the MammoGrid infrastructure. 
In its first year, the MammoGrid project has faced interesting challenges originating from the 
interplay between medical and computer sciences and has witnessed the excitement of the user 
community whose expectations from the a new paradigm are understandably high.  As the 
MammoGrid project moves into the implementation and testing phase, further challenges are 
anticipated which will test these ideas to the full.  We hope to return to this subject in future 
publications. 
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Pre-implantation genetic diagnosis (PGD) has
developed considerably in the last 20 years. First 
introduced for sexing embryos in the case of an X-
linked genetic disorder in 1990 [1], this was 
subsequently followed by a live birth after PGD for the 
monogenic disorders cystic fibrosis [2] and Duchenne 
muscular dystrophy [3]. Munné et al [4] then reported 
the first case of using fluorescent in-situ hybridization 
(FISH) for a reciprocal chromosome translocation. 
Internationally, PGD is available for over 200 single 
gene and chromosomal disorders [5] and the 
technology diversified in 1999 to include pre-
implantation genetic screening (PGS). PGS is aimed at 
improving the outcome of in vitro fertilisation (IVF) in 
sub-fertile couples, and also for the selection of human 
leucocyte antigen matched embryos (HLA) as a source 
of therapeutic stem cells for sick siblings [7]. Couples 
undertaking PGD are generally fertile and do not need 
assisted reproductive technologies (ART) to conceive. 
Many care for children with special needs and a some 
have medical problems themselves as a consequence of 
the genetic disorder that affects them and puts their 
offspring at risk. It is important therefore that these 
factors are considered during preparation for PGD. 
PGD (and in particular PGS) remain somewhat 
controversial [6], and while evidence suggests that 
human embryo development in vitro is not affected by 
biopsy, confirmation can only be obtained by long 
term follow up. Another concern is what impact PGD 
might have on the subsequent health and development 
of children born after undergoing it. Long term follow 
up of such children has been recommended since the 
introduction of PGD, but as the number of children 
born remains small, international collaboration and 
standardised data collection is essential. 
The European Society of Human Reproduction and 
Embryology (ESHRE) PGD consortium has completed 
a total of 10 data collection exercises since 1997, 
gathering referral data, biopsy, FISH and other data. 
The analysis of these has in turn lead to a number of 
high quality journal publications, as well as the 
creation of best practice guidelines. The impact of 
PGD/PGS on the success of IVF is understood better 
now than ever before, but many scientific, technical 
and ethico-legal questions remain. Among these is the 
question of the impact of PGD/PGS on the health (or 
morbidity) and development of children born after 
undergoing one of these procedures.  
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This paper describes the outcome of a study of 
children born after embryo blastocyst biopsy, with both 
PGD and PGS cycles included. 
Follow up of babies born by PGD has been 
recommended since the early days of the technology 
[8,9,10,11] and is included in current guidelines. IVF 
and ICSI (intracytoplasmic sperm injections) have 
been available for over 30 years and follow up of 
children born has been long term and case controlled. 
As a result, 3 meta analyses [12,13,14] and a case 
controlled study of 3000 ICSI vs IVF infants [15] 
showed a relative risk of major abnormality of 1.24 in 
ART babies compared with spontaneously conceived 
infants. A major abnormality is considered one that has 
medical or social consequences and occurs in 2-3% of 
live births and 5% of 5 year olds [16]. Longer term 
studies on ICSI/IVF babies showed a relative increased 
risk of abnormality: ICSI (2.77) and IVF (1.8) [17]. 
An increase in imprinting disorders such as 
Beckwith Wiedemann (BWS), Angelmans and 
retinoblastoma has been recognised in ART babies 
[18]. A recent study [19] looking at over 15,000 babies 
born after IVF/ICSI concluded that there was 4.24% 
major abnormality rate with a 5 fold increase in BWS 
(0.04% vs 0.007%) and a 4 fold increase in 
retinoblastoma (0.03% vs 0.006%) over the norm. 
In addition to the technology used in assisted 
reproductive technology (ART), PGD requires 
additional micro-manipulation procedures which may 
have an impact on paediatric outcome. Whilst embryos 
are created using standard ART, testing embryos 
requires embryonic tissue from biopsy at either polar 
body, blastomere or trophectoderm stages [5]. The 
preferred fertilisation method for PGD cases that 
require the use of polymerase chain reaction (PCR) is 
ICSI [5] to avoid the risk of contamination. IVF is 
acceptable for use when FISH analysis is to be used for 
chromosome rearrangements and embryo sex 
determination for X-linked disorders [20]. 
Data available from two studies reviewing 480 PGD 
babies [21] and adding new data to the previous study 
resulting in 576 PGD babies [22] reported a major 
abnormality rate of 1.6 and 1.9% respectively. In the 
latest ESHRE PGD Consortium report [23] which 
amalgamates nine data sets representing outcomes of 
PGD up to 2008, a total of 5047 babies have been 
born, with outcome data available on 4021 (79.7%). 
The total number of babies with minor and major 
malformations in this group was 154/4021 (3.83%); 84 
major and 74 minor abnormalities (with some babies 
having more than 1). The incidence of neonatal 
complications was 10.3% and there was a total of 45 
neonatal deaths (1.1%); 12 singletons, 30 twins and 3 
triplets; further in-depth analysis of this data is now 
being undertaken. The abnormalities that were reported 
varied in severity and ranged from significant cardiac 
abnormalities to mild syndactyly. These outcomes are 
similar to those reported in the IVF/ICSI population 
[15] where neonatal complications occurred in 9% of 
cases, with 1% of cases resulting in neonatal death. 
Liebaers et al. [24] reported the first prospective case 
controlled study comparing 581 PGD birth outcomes 
with 2889 IVF and ICSI babies at 2 months of age. The 
rate of major abnormalities was not statistically 
different at 2.13 and 3.38% respectively, but the rate of 
perinatal death was higher in the PGD multiple 
pregnancies at 11.73 and 2.54% respectively. 
Although limited, a few studies have investigated 
long-term growth and development of children born 
following PGD/PGS. Two studies with 49 and 102 
children [25,26] have compared 2 year old PGD with 
ICSI and normally conceived children. These found 
that, although PGD babies were of lower birth weight, 
their linear growth compared well with normally 
conceived children, and the PGD children had the same 
incidence of congenital abnormality and childhood ill 




>0%$#302"1$02%1. Women who have health-related 
problems associated with their genetic diagnosis 
should be referred to an obstetric or other relevant 
physician to discuss the impact of treatment and 
pregnancy. For example, women who are affected with 
myotonic dystrophy should be assessed before 
anaesthesia as they have an increased risk of 
arrhythmias, prolonged recovery from the anaesthesia 
and a risk of developing malignant hyperpyrexia [27]. 
Their myotonia often deteriorates during pregnancy 
and they are prone to obstetric complications including 
prolonged labour, placenta praevia and postpartum 
haemorrhage. 
>,2%*(2$" (#$6303).. ART is associated with an 
increased risk of multiple births [28]. Attempts to 
increase the chance of pregnancy in PGD cycles by 
replacing more than one embryo have led to a high 
multiple pregnancy rate [5]. Babies born from multiple 
births have a higher risk of prematurity, low birth 
weight, neonatal mortality and neurological disability 
[29]. The issue of the number of embryos for transfer 
needs careful discussion in cases where there is a 
choice. A multiple pregnancy may have both clinical 
and social implications for a couple. Couples 
requesting PGD often also care for children with 
disabilities and special needs as a result of the genetic 
condition within the family, and a multiple pregnancy 
would be a significant additional burden. In addition, 
as part of recommended best practice, confirmatory 
prenatal testing is advised following a successful PGD 
pregnancy [20] and although possible, prenatal testing 
is more complex in a multiple pregnancy. 
The frequency of multiple pregnancies in PGD 
couples has generally reduced, from 25% in 1999-2003 
to 20% in 2003–2004 (although in 2009, ESHRE PGD 
data still reported a multiple birth rate of 27%). Some 
studies in both PGD and ART are now demonstrating 
improvements in live birth outcome using single-
blastocyst transfer [30]. The use of single-embryo 
transfer, especially in women younger than 36 years is 
resulting in fewer multiple pregnancies, without a 
reduction in the overall delivery rate. It has been 
demonstrated that selection of single embryos for 
transfer, with cryopreservation of surplus unaffected 
embryos, maintains a good pregnancy rate while 
reducing multiple births [30]. The implantation rate 
using cryopreserved biopsied PGD blastocysts is 
comparable with that obtained after using non-biopsied 
frozen IVF blastocysts. This is an important step 
towards encouraging couples to opt, where clinically 
indicated, for single-embryo transfer, which may have 
additional benefits for PGD couples. 
?.($"&/"$48#.&"8*&('.. Several biopsy techniques 
are employed with blastomere biopsy used in 90% of 
cases [5]. Polar body biopsy can be used to assess 
maternal genotype or karyotype only. Trophectoderm 
biopsy, which provides a larger tissue sample on day 5, 
is used in only a few centres but there is no evidence 
that this increases treatment success rates [31].  
@,48$#"&/")$22'"8*&('*$-. One or two cells may be 
taken at embryo biopsy. A blastomere may not be 
representative of the embryo as a whole and mosaicism 
is known to occur in up to 50% of cleavage-stage 
embryos, but some embryos, initially mosaic for 
aneuploid cell lines, self correct with increasing cell 
division; the abnormal cell line is selected against and 
the resulting embryo becomes euploid. Centres that 
only use embryos where the two cells biopsied are 
concordant with a normal result will exclude a higher 
proportion of embryos owing to higher rates of false 
positive results. While the reliability of test results is of 
paramount importance, the aim is to identify sufficient 
embryos with transferable results. There is evidence to 
suggest that two-cell biopsy might reduce the number 
of embryos available for transfer even though the 




In 2005 the ESHRE PGD Consortium agreed to 
support a retrospective data collection of the babies 
born following PGD/PGS. 57 centres (members of 
ESHRE) were sent a questionnaire asking about their 
current provision for paediatric follow up and inviting 
them to participate in a retrospective data collection 
study. Ethical approval was obtained through the UK 
National Research Ethics Service1 (NRES) and 6 
centres that met both the NREC requirements and the 
inclusion criteria for the study were included. Written 
parental consent was obtained. Participating centres 
were required to have at least 10 PGD/PGS live births 
before 31/10/07, a patient population that could read 
English or a translated questionnaire (French, Flemish, 
Portuguese, Spanish, Czech or Turkish), and personnel 
to locally administer the questionnaire. 
The questionnaires were comprised of 4 sections. 
Part 1 was completed by the participating centre and 
included technical information about the cycle, embryo 
biopsy, the reason for PGD/PGS and date of embryo 
transfer. Parts 2-4 were completed by the parents of the 
PGD/PGS children and included data relating to the 
pregnancy, birth, health and development of the 
children, and parental demographics. 
The questionnaires were allocated a centre number 
and a case study number to ensure anonymity, and 
were returned to the local study administrator. The 
questionnaires were then translated back into English 
and forwarded to the central study coordinator at Guy’s 
Hospital, London (UK). 
Data was included from 400 questionnaires with 6 
participating centres. 41 questionnaires were excluded, 
mainly because they related to children born outside 
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During the collection of this PGD/PGS data, the 
EuroPGDcode project arose through an initiative from 
the ESHRE Classification of Infertility Taskforce 
(ECIT) for a common nomenclature, and was funded 
by a European Union grant (Executive Agency for 
Health and Consumers, contract A800103 2007-2009).  
The methods of PGD/PGS data collection over the 
past 14 years have varied considerably between 
                                                          
1 See http://nres.npsa.nhs.uk/ 
different laboratories and clinics. While the range of 
data that must be collected has long been established, 
the means of collection has varied from applications 
interfacing hospital systems through spreadsheets, text 
files and proprietary databases, complicating the 
process of combining these into a single, coherent data 
set for analysis. A major part of the EuroPGDcode 
project was the creation of a new system for the 
collection, storage and analysis of PGD/PGS 
questionnaire data (and other anticipated or derived 
data items from concurrent or future data collections), 
based on open source components and made available 
worldwide via a web-based interface. 
An online system was also required due to the 
geographically distributed nature of the work; 
questionnaire data had to be interpreted and entered at 
ART/PGD centres, queries were constructed and 
modified by informaticians at the University of the 
West of England, then executed by PGD specialists at 
Guy’s Hospital. Further local analysis also had to be 
facilitated, with input from medical statisticians. 
Another goal of the project was the creation of a 
prototype XML structure for representing the 
PGD/PGS cycle data, various details relating to the 
babies that were born (such as their health and 






A relational database was constructed, with a web-
based front end for the input, viewing and analysis of 
data. As the data from a questionnaire is entered, a 
graphical, interactive tree is created to visualise the 
record - this also corresponds to the structure of the 
XML document that can be generated. 
Queries can be constructed through an integral 
query editor, or (for expert users) entered directly in 
SQL. These can then be ‘bookmarked’ and stored for 
specific or all users. A variety of complex queries have 
been constructed, and the output of these can be 




































































































In addition to statistical analyses, the full records of 
individuals of interest, which can include cross-
referenced data gathered from multiple questionnaires, 
can be exported as XML documents. These validate 
against a schema, and the XML format defined serves 
as a first step towards the ESHRE goal of creating a 








L.)2$"-$%0*2'. 112 cycles were undertaken for PGD 
(28%), 287 for PGS (71.7%) and one for both. One cell 
biopsy was used in 54 PGD cycles and in 125 PGS 
cycles; two cell biopsy was used in 52 PGD cycles and 
162 PGS cycles and blastocyst biopsy was done in 6 
PGD cycles; the PGD/PGS case was recorded as a one 
cell biopsy. Fresh embryos were used in 107 PGD 
cycles and 284 PGS and 1 cycle that was for both; 
frozen embryos were used in 5 PGD and 3 PGS cycles. 
This compares with the proportion of fresh/frozen 
cycles in the ESHRE Data 10 collection [23]. The date 
of embryo transfer was checked for validity against the 
date of birth by the online system. 11 mothers in this 
cohort had babies born from more than one PGD cycle. 
The number of cycles for any given parent did not 
exceed 2, and the Mean number of cycles was 1.03 for 
mothers and 1.02 for fathers (in 12 cases, no father 
details were recorded). No PGD cycles were 
undertaken for HLA matching or for social sex 
selection. 52 cases were because of a chromosomal 
abnormality, 46 for a monogenic disorder and 14 
cycles were sex selection for X-linked inheritance. The 
parental origin of the monogenic or chromosomal 
disorder was recorded in 106/112 cycles; maternal in 
48 cycles, paternal in 39 cycles and from both in 19 
cycles. The PGD/PGS case was for a monogenic 
disorder and raised maternal age (RMA). Indications 
for PGS included 98 cycles for repeated ART failure, 
58 for miscarriage after ART, 52 for RMA and 
infertility and 5 for RMA only, 7 for recurrent 
miscarriage, 7 for previous aneuploidy, 43 due to male 
factor infertility, 8 with egg donation and 18 did not 
complete. 
F0#$3%02" -$4&6#0(1*)'. The range of birth years 
for mothers was 1958 to 1981 (aged 28 to 51 at the 
time of data collection), with the Mean being 1970 
(age 41). Day and month of birth were not input in 
order to preserve patient anonymity. For fathers, the 
range was 1936 to 1981, with a Mean of 1967. The 
vast majority of mothers and fathers self identified as 
Caucasian at 98.46 and 98.64% respectively; 0.26% of 
mothers were African (0.54% of fathers), and 0.27% of 
fathers were Asian (no mothers). 
F#$6303)."03-"8*#%1. Details of maternal and fetal 
health in pregnancy were collected for 400 deliveries. 
297 (75.25%) women reported no problems. 4 women 
had ovarian hyper-stimulation syndrome, 2 of whom 
had related ovarian torsion, 13 experienced bleeding, 5 
placenta praevia, 15 had symptoms associated with 
onset of premature labour, 11 gestational diabetes, 4 
pre-eclampsia, 4 non related raised blood pressure and 
4 with renal problems. The Mean gestation of delivery 
varied depending on the parity; for singletons, twins 
and triplets the (estimated) Mean gestation was 38.7, 
35.9 and 33 weeks respectively. Mode of delivery 
indicated that 145 (36.34%) births were delivered 
spontaneously, with 38 (9.52%) requiring assisted 
delivery (ventouse or forceps) and 216 (54.13%) by 
caesarian section. The incidence of either planned or 
emergency caesarian section was higher in multiple 
births at 76.4% and 100% in twins and triplets 
respectively compared with 47.4% in singleton 
deliveries. 82.1% of babies were born ≥ 36 weeks 
gestation; 89.5% singletons, 58% twins; 14.5% of 
deliveries were between 30-36 weeks gestation and 
3.2% ≤ 30 weeks.  
D$02%1" &/" 808*$'" 0%" -$2*+$#.. A total of 487/494 
(98.58%) babies were reported by parents as having no 
congenital abnormalities at birth. 7 babies (1.42%) had 
9 congenital abnormalities including tongue tie, talipes, 
clicky hip, undescended testes, cardiac abnormalities 
and hypospadias. Special care was required for 3/7 
babies with abnormalities. Neonatal problems were 
recorded in 129/494 babies (26%) with 113 babies 
(87.6%); 44 singletons (14.3%), 63 twins (44.9%) and 
6 triplets (100%) requiring special care. The Mean 
number of days spent in special care was 18.9 and the 
most common reasons for special care were low birth 
weight, prematurity and respiratory problems. Since 
birth, 378/494 (76.7%) babies had no major illness or 
operations; 115 (23.3%) recorded illnesses, 71 were 
singletons, 43 twins and 1 triplet. The range of 
illnesses can be broadly categorized into respiratory, 
ENT, gastrointestinal, genito-urinary, orthopaedic, 
renal, neurological, ophthalmic, infection, and allergy 
related problems. The incidence of most 
illnesses/problems was confined to 1 or 2 individual 
cases. More frequent respiratory illnesses were asthma 
(9), pneumonia (8), and bronchitis/bronchiolitis (7). 
Surgery was done in 8 cases for adenotonsillectomy 
and 3 children had hearing loss. Six children had 
general allergies with 5 being lactose intolerant. 
Genitourinary problems included 5 children with 
inguinal hernia, 3 with undescended testes and 2 with 
spermatic cysts.  
H$+$2&(4$3%" 0/%$#" 8*#%1. At data collection, the 
Mean age of children was 5, and the range was 1 to 11 
years old. Parents were asked to give the age at which 
their child reached certain motor milestones. For being 
able to sit, entires were made for 441/494 children; 425 
children (99.37%) sat before 10 months with 16 
(3.54%) sitting after 10 months. Parents recorded the 
age of walking unaided in 473/494 cases; 468 babies 
(98.94%) were walking unaided by 20 months whilst 5 
(1.05%) walked after 20 months. 11 children who had 
started school and had begun formal teaching had 
learning difficulties. Of these, 4 were twins, 2 triplets 
and 5 singletons. Birth weights ranged from 0.815 kg 
to 3.26 kg (Mean 2.1916). Three singletons were born 
at > 38 weeks gestation, 2 singleton and 3 twins at > 36 
weeks gestation, 2 triplets at 33-36 weeks gestation and 
1 twin at 25 weeks gestation. 
M: L&3)2,'*&3
Centres from England, Spain, the Czech Republic,
Portugal, Turkey and Belgium returned data on 400 
deliveries; 112 PGD cycles, 288 PGS cycles and one 
cycle with both. These resulted in 494 live babies born 
between December 1999 and October 2007. There 
were 308 (62.3%) singletons, 180 (36.5%) twins and 6 
(1.2%) triplets. Mean birth weights were 3.17, 2.41 and 
1.67 KGs respectively. 77.2% were born at ≥ 36 
weeks, 19.3% between 30-36 weeks and 3.45% ≤ 30 
weeks gestation. Neonatal problems occurred in 129 
babies (26%), 16 of which required no special care. 
113 babies (22.9%) required special care (Mean 18.9 
days). Nine abnormalities were recorded in 7 babies 
(1.42%) including tongue tie, cardiac anomalies, hip 
dysplasia, talipes, hypospadias and undescended testes. 
Since birth 378 (76.7%) babies were recorded as 
having no health problems. The rate of recorded health 
problems for singletons and twins was 23.1% and 
23.9%, Mean ages 15.2 and 16.9 months respectively.  
The analysis of the data collected is ongoing. 
Several cases of special interest have been identified 
(primarily the children with abnormalities); the full 
records of these children and their siblings can be 
exported as XML records for further analysis. 
Complementary data from other sources, such as 
electronic health records (EHRs) and electronic 
integrated care pathways (eICPs), can then be gathered 
in order to build up a full case history; in previous 
papers we have described a method that involves a 
generic ICP ontology, and a method to identify 
portions of an EHR that correspond to periods of 
interest [33, 34].  
Another area being looked at are the differences in 
the health and development of children born after PGD 
when compared with PGS, if any. 
This study has demonstrated that completed 
parental questionnaires can provide valuable 
information about the long term health and 
development of PGD/PGS children. Various methods, 
including an integrated searchable database of OMIM 
(Online Mendelian Inheritance in Man) codes for 
genetic disorders, were employed by the online system 
to standardise responses, and the web-based nature of 
the system can facilitate data capture from a wide 
demographic population. Although retrospective and 
not case controlled the data indicates that the birth 
abnormality rate is low at 1.42%. However, 22.9% of 
PGD infants required special care, and the incidence of 
health problems after birth was 22.3%. 
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#?R$;$*9!+(!+F!2'$&*!(#&(!'&*)$!/?/N'&(+?1MH&F$,!,&(&F$(F!G&1,!&FF?2+&($,!F&P/'$!2?''$2(+?1FK!&*$!1?(!?1'@!+1($*$F(+1)!I?*!
H&F+2!F2+$12$!HN(!&'F?!I?*!(#$!/#&*P&2$N(+2&'!+1,NF(*@U!!!





3N+'(! ?1! /?/N'&(+?1MH&F$,! ,&(&F$(F! F(&(+F(+2&'! F(N,+$F! ?1! (#$! +1I'N$12$! ?I! &''$'+2! /*$,+F/?F+(+?19! H$#&;+?N*&'! &F/$2(F9!
1N(*+(+?1!#&H+(F9!*$)+?1&'!?*!1&(+?1&'!#$&'(#2&*$!P&1&)$P$1(!&1,!P&1@!?(#$*!/&*&P$($*F!R+''!H$!/?FF+H'$U!=!2$1(*&'!(&FS!
I?*!&!O*+,!/*?a$2(!I?*!)$1$(+2!$/+,$P+?'?)@!R?N',!H$!(?!$1&H'$!&1,!(?!/*?P?($!+1($*?/$*&H+'+(@!?I!F(&(+F(+2&'!&1&'@F+F!(??'FU!
A+P+'&*! (?! +1+(+&(+;$F! +1! (#$! I+$',! ?I! F@F($PF! H+?'?)@! &1! $T2#&1)$! F$*;+2$! I?*! F(&(+F(+2&'! P?,$'F! H&F$,! ?1! &! 2?PP?1!
N1,$*F(&1,+1)!&1,!2'&FF+I+2&(+?1!F2#$P$!?I!F(&(+F(+2&'!&//*?&2#$F!R?N',!H$!1$$,$,U!=!/?+1(!(?!F(&*(!R+(#!R?N',!H$!&!](??'!

































































61!(#$!H+?'?)+2&'!&1,!/#&*P&2?'?)+2&'! F+,$9! (#$!,$($*P+1&(+?1!?I!&''$'+2! I*$^N$12+$F!?I!,*N)! (&*)$(!)$1$F! +1!5N*?/$&1!







?I! PN'(+/'$! F2'$*?F+F! /&(+$1(F! (?! (*$&(P$1(! R+(#! D1($*I$*?1FU! =1?(#$*! F2$1&*+?! R?N',! 2?12$*1! (#$! +1F$1F+(+;+(@! ?I! &!
F+)1+I+2&1(!/?*(+?1!?I!(#$!5N*?/$&1!/?/N'&(+?1!(?!(*$&(P$1(!R+(#!)'N2?2?*(+2?+,FU!!!
V*?P!(#$!O*+,!*$F$&*2#!/$*F/$2(+;$9!,*N)!*$'&($,!$/+,$P+?'?)+2&'!F(N,+$F!*$^N+*$!&!(+)#(! +1($)*&(+?1!?I!S1?R'$,)$!
2?P+1)! I*?P! #$($*?)$1$?NF! ,+F2+/'+1$F9! 1&P$'@! /#&*P&2?'?)@! &1,! )$1$(+2FU! LN**$1('@9! S1?R'$,)$! *$/*$F$1(&(+?1F!
G?1(?'?)+$FK!I?*!/#&*P&2?'?)@!&*$!P+FF+1)!H@!&1,!'&*)$v!R$!(#$*$I?*$!$T/$2(!(#&(!&!O*+,!?1!)$1$(+2!$/+,$P+?'?)@!(#&(!
&,,*$FF$F!&F/$2(F!?I!,*N)!&2(+?1!R+''!#&;$!(?!+12'N,$!&1!&2(+;+(@!?1!?1(?'?)@!2?1F(*N2(+?1!I?*!(#$!,?P&+1!?I!/#&*P&2?'?)@U!
=! ]/#&*P&2?'?)@M?1(?'?)@b! R?N',! &'F?! #$'/! (?! I?*P&'+F$! &1,! (?! F(&1,&*,+F$! (#$! ,$F2*+/(+?1! ?I! 2'+1+2&'! /&*&P$($*F!
P$&FN*$,!+1!(#$!2?N*F$!?I!'&*)$!F2&'$!F(N,+$FU!=F!,*N)!&FF$FFP$1(!2?P/*+F$F!&''!&F/$2(F!?I!/#&*P&2?,@1&P+2F9!F/$2+&'!
















































!ANHF(&1(+&'!$II?*(!?1!?/$1!F(&1,&*,F9!2&/(N*+1)!&1,! I?*P&'+F&(+?1!?I!F(&(+F(+2&'!2?1F+,$*&(+?1F! *$'$;&1(! I?*!/&(+$1(!
2?''$2(+;$! F$'$2(+?1!&1,!2?1(*?''$,!;?2&HN'&*+$F! \!?1(?'?)+$F! +F!1$$,$,U!"#$! F2+$1(+I+2!H$1$I+(!?I! FN2#!$II?*(9!#?R$;$*9!
R?N',!H$!/&*&P?N1(p!!















(#&(! (#$! )$1$(+2! #$($*?)$1$+(@! R+(#+1! 5N*?/$! R?N',! ?/$1! 1$R! /$*F/$2(+;$F! (?! ,$I+1$! ]2?1(*?'! )*?N/Fb! +1!
F(&(+F(+2&'!P$(&&1&'@F$FU!!!





(?! H$2?P$! (??! $T/$1F+;$! (?! H$! 2?1(+1N$,! +1! (#$!R&@! (#+F! F2+$12$! #&F! H$$1! ,?1$! +1! (#$! /&F(U! rls! =!O*+,! I?*! )$1$(+2!

































*$^N+*$F! (#$! +1($)*&(+?1! ?I! S1?R'$,)$! I*?P! R?*',F! (*&,+(+?1&''@! &/&*(9! F/$2+&''@! H+?'?)@! &1,! P$,+2+1$U! "?! #&*1$FF!


















2?P$! I*?P! &! ,+F$&F$,! (+FFN$! &''?RF! +1! F?P$! 2&F$F! (#$! +,$1(+I+2&(+?1! ?I! ,+II$*$1(!P?'$2N'&*! F#&/$F! &1,! (#$!
/*?/?F&'! ?I! 1$R! 2'&FF+I+2&(+?1F! I?*! (#$! ,+F$&F$F9! R#+2#! R+''! &''?R! &1! +P/*?;$P$1(! +1! (#$+*! ,+&)1?F$F! &1,!
/*?)1?F$FU!!!
•! .#&*P&2?)$1$(+2F!&1,!.#&*P&2?)$1?P+2Fp!D1!(#$!'&F(!I$R!@$&*F9!FN22$FFIN'!($2#1?'?)+2&'!P$(#?,F!#&;$!H$$1!





(#$! I+$',!?I!/NH'+2!#$&'(#!&1,!$/+,$P+?'?)@9! +(!R+''!H$! +P/?*(&1(! (?!,$;$'?/!$II?*(F! +1!&FF?2+&(+;$!)$1$(+2F9! +1!
)$1?(@/$M/#$1?(@/$!/?/N'&(+?1!F(N,+$F9!&1,! +1!/*?)*&PP$F!(?!,+FF$P+1&($!)$1$(+2! +1I?*P&(+?1!&1,!(?!(*&+1!
#$&'(#!R?*S$*FU!!!
















.*?)*$FF! +1! (#$! N1,$*F(&1,+1)! ?I! (#$! )$1$(+2! 2?,$9! )$1$! /*?,N2(F! &1,! IN12(+?1F9! +F! $'N2+,&(+1)! (#$!P$2#&1+FPF!











































































/&(+$1(! +1;$F(+)&(+?1FU! "#+F! ;+F+?1! *$^N+*$F! (#$!,$F+)1! &1,! +P/'$P$1(&(+?1!?I! 2?P/N($*!P$(#?,F! &1,! (??'F! (?! ,$'+;$*!
$II$2(+;$!/'&(I?*PF!I?*!F$&P'$FF!H+?P$,+2&'!,&(&!&FF?2+&(+?1U!"#$!+1($)*&(+?1!?I!H+?P$,+2&'!S1?R'$,)$!*$F?N*2$F!H*+1)F!
N/!&!1$R!/*?H'$P!,?P&+1!R+(#!F?P$!F/$2+I+2!2#&''$1)$F!(?!H$!&,,*$FF$,p!!
w! "#$*$!&*$!P&1@!,+II$*$1(!F?N*2$F!?I! +1I?*P&(+?1!F/*$&,!?;$*! (#$!R$Hv! (#$!*$'$;&1(! +1I?*P&(+?1!1$$,F! (?!H$!
P?,$''$,9!,+F2?;$*$,9!&22$FF$,!&1,!*$(*+$;$,U!!
w! <&(&! +1($)*&(+?1! +F!,+II+2N'(! F+12$!,&(&H&F$F! 2&1!/*$F$1(!&!R+,$! *&1)$!?I! I?*P&(F!&1,!,+II$*$1(! F$P&1(+2FU! D1!
&,,+(+?19!/NH'+2!+1I?*P&(+?1!*$F?N*2$F!&*$!?I($1!?1'@!&;&+'&H'$!(#*?N)#!R$H!+1($*I&2$F9!1?(!$&F+'@!+1($**?)&($,!
H@!2?P/N($*!&//'+2&(+?1FU!!



















P?'$2N'&*! IN12(+?1! I?N1,! R+(#+1! O$1$! 61(?'?)@! GO6KU! "#$! )$1$! 2?,$F! I?*! &! /*?($+19! &! F$^N$12$! ?I! &P+1?! &2+,F!
GA-DAA.46"KU!"#$!F$^N$12$!,$($*P+1$F!(#$!F(*N2(N*$!?I!(#$!/*?($+1!G.<3KU!"#$!/*?($+1!+F!2'&FF+I+$,!+1(?!/*?($+1!,?P&+1F!
GD1($*M.46K! &1,! #&F! &! IN12(+?1&'! F+($! G.46AD"5KU! .*?($+1F! #&;$! $1_@P&(+2! /*?/$*(+$F! G5T.=AmM57imC5K! +1! P$(&H?'+2!



























w! ,+F2?;$*+1)9! H*?RF+1)!&1,!^N$*@+1)!?I!H+?P$,+2&'! *$F?N*2$F9!?II$*$,!H?(#! (?! #NP&1!NF$*F!&1,! (?! 2?P/N($*!
/*?)*&PF9!,*+;$1!H@!F$P&1(+2!2?12$/(F!?(#$*!(#&1!S$@R?*,Fv!!










'$;$'! F$P&1(+2! F$*;+2$F! &1,! &//'+2&(+?1F9! (#$! '&(($*! 2&1! $1#&12$! /$*I?*P&12$! &1,! $II+2+$12@! ?1! ,+F(*+HN($,! &1,! O*+,!
$1;+*?1P$1(FU!!
ZUeU!!3D6C5<DL=B!O4D<A!V64!%5=B"%!=..BDL="D67A!!!
C&1@! *$F$&*2#! &1,! ,$;$'?/P$1(! &*$&F! ?I! +1I?*P&(+2F! &*$! 1$$,$,! (?! FN//?*(! )$1?P+2! P$,+2+1$9! +12'N,+1)! (#$!
,$;$'?/P$1(!?I!P?,$'F!&1,!,+)+(&'!F+PN'&(+?1F9!P?'$2N'&*!+P&)+1)9!)'?H&'!F2&'$!,&(&!&22$FF!&1,!&FF?2+&(+?19!$(2U!r8esU!O*+,!
($2#1?'?)@!+F!&P?1)!(#$F$!&1,!2&1!2?1(*+HN($!(?!(#$!,$;$'?/P$1(!?I!F?P$!S$@!&*$&F!H@!G8K!FN//'@+1)!#+)#!2?P/N(+1)!




















XU .*?;+,+1)! (??'F! (?! FN//?*(! /#@F+2+&1F`! (*&+1+1)! &1,! (?! +P/*?;$! H+?P$,+2&'! S1?R'$,)$! P&1&)$P$1(U! C?F(
/#@F+2+&1F!#&;$!?1'@!&!*N,+P$1(&*@




























&H+'+(@! (?!,$;$'?/!2?PP?1!*$/*$F$1(&(+?1F! G?1(?'?)+$F9! +1($)*&($,!;?2&HN'&*+$F9!$(2UK! (?!P?,$'!&1,!,$F2*+H$
#$($*?)$1$?NF!+1I?*P&(+?1U!"#$!2#&''$1)$!+F!(?!&,&/(!$T+F(+1)!F@F($PF!?*!(?!,$;$'?/!1$R!?1$F!(#&(!&''?R!(#$
$T2#&1)$!&1,!+1($)*&(+?1!?I!,&(&U!O*+,9!$1#&12$,!R+(#!F$P&1(+2!+1($)*&(+?1!F$*;+2$F9!2&1!#$'/!1?(!?1'@!+1!(#$!









?1(?'?)+$F! (?! ,$F2*+H$! )*+,! *$F?N*2$F9! (?! $1#&12$! &1,! &N(?P&($! F$*;+2$! ,+F2?;$*@! &1,! 1$)?(+&(+?19! &//'+2&(+?1!




















$T/$*+P$1(FU! "#$! P?,$''+1)! F#?N',! 2?P/*+F$! &''! /#&F$F! ?I! $T/$*+P$1(F9! FN2#! &F! F&P/'$! /*$/&*&(+?19! ,&(&!
)$1$*&(+?19! ,&(&! /*$M/*?2$FF+1)! &1,! I+'($*+1)9! +P&)$F! &1&'@F+F9! H+?+1I?*P&(+2F! &1&'@F+F9! H+?MP$,+2&'! &1&'@F+F9!
*$FN'(F!;+FN&'+_&(+?1!r>EsU!!
w! =//'+2&(+?1! 2?P/?F+(+?1! &1,! $1&2(P$1(! '&@$*U! "#+F!R?*SI'?R! 2?P/?F+(+?1! '&@$*!P&S$F! +(! /?FF+H'$! (?! *$&'+_$!
2?P/'$T!H+?+1I?*P&(+2!&1,!H+?P$,+2&'!&//'+2&(+?1F! G$U)U! +1!F+'+2?!$T/$*+P$1(FK!H@!2?P/?F+(+?1!?I!H&F+2! G?/$1!
F?N*2$K!H+?+1I?*P&(+2F!(??'F9!(#&(!R+''!H$!$T$2N($,!?1!(#$!)*+,9!$T/'?+(+1)!(#$!*$F?N*2$F!&1,!,&(&!/*?;+,$,!H@!
*$F$&*2#! 2$1(*$F! I?*P+1)! ,+II$*$1(! 0+*(N&'! 6*)&1+_&(+?1FU! QF$IN'! F?I(R&*$! (??'F! 1$$,! (?! H$! 2'&FF+I+$,! +1! (#$!
P?,$''+1)!'&@$*!?I!(#$!/'&(I?*P9!R+(#!*$F/$2(!(?!($2#1?'?)@!&1,!NF$!&F/$2(FU!:$@!+FFN$F!?I!(#+F!'&@$*!&*$p!,?P&+1!
?1(?'?)+$F! (?! P?,$'! G?/$1! F?N*2$K! H+?+1I?*P&(+2F! F?I(R&*$! 2?P/?1$1(F9! &1,! /NH'+2! &;&+'&H'$! H+?'?)+2&'!
,&(&H&F$Fv! ?1(?'?)@MH&F$,! ^N$*@+1)! &1,! H*?RF+1)! ?1! ,?P&+1! ?1(?'?)+$F! I?*! (#$! ,+F2?;$*@9! F$'$2(+?19! &1,!
'?2&(+?1! ?I! H+?+1I?*P&(+2F! &1,! H+?P$,+2&'! *$F?N*2$F! G,&(&! &1,! F?I(R&*$! 2?P/?1$1(FK9! (?! H$! NF$,! +1! (#$!
2?P/?F+(+?1!?I!&//'+2&(+?1Fv!R?*SI'?RMH&F$,!P?,$''+1)!&1,!F2#$,N'+1)!?I!,+F(*+HN($,!&//'+2&(+?1F!?1!(#$!O*+,v!
$T($1F+;$!NF$!?I!6/$1!A?N*2$!F?I(R&*$!2?P/?1$1(F!&1,!2?P/?1$1(F!/*?;+,$,!H@!(#$!*$F$&*2#!2$1(*$FU!!






























r8[s! VU!C&*(+1MA&12#$_9!0U!C&?a?!&1,!OU!B?/$_ML&P/?F! G>[[>K!]D1($)*&(+1)!O$1?P+2F! +1(?!%$&'(#! D1I?*P&(+?1!A@F($PFb9!C$(#?,F!?I! D1I?*P&(+?1! +1!
C$,+2+1$9!e8p!//U!//U!>hME[U!!






























D1!#$&'(#2&*$9!/&(+$1(F`! F$1F+(+;$!/$*F?1&'!,&(&! +F!*$2?*,$,!&1,!NF$,U!"#+F! +P/'+$F!&!1$$,! I?*!F(*+2(!2?1I+,$1(+&'+(@!&1,!





F$1F+(+;$!,&(&U! D12+,$1(F!?I!&HNF$!#&;$!H$$1!/*$;+?NF'@! *$/?*($,! +1! (#$!/NH'+2!P$,+&! rB[Es9!/*?;+1)! (#&(! (#$! (#*$&(! +F!
)$1N+1$U! L?1F+,$*9! I?*! $T&P/'$9! (#$! +P/&2(! ?1! F?2+$(@! +I! H&1SF9! +1FN*&12$! 2?P/&1+$F! &1,! $P/'?@$*F9! 2?N',! &22$FF!
#$&'(#2&*$! ,&(&! &H?N(! (#$+*! 2NF(?P$*F9! *$;$&'+1)! /&F(9! 2N**$1(9! &1,! /*?H&H'$! IN(N*$! #$&'(#! F(&(NFU! D1,$$,9! &HNF$! ?I!


























=1@! #$&'(#)*+,! +1+(+&(+;$! F#?N',! (#$*$I?*$! H$! &R&*$! ?I! (#$! '&($F(! F$2N*+(@! ,$;$'?/P$1(F! +1! (#$! )*+,! 2?PPN1+(@U!
<$;$'?/P$1(!?I!H&F+2!F$*;+2$F9!FN2#!&F!I?*!$T&P/'$!+1($)*&(+?1!?1!&!'?R$*!P+,,'$R&*$!'$;$'!?I!I+1$!)*&+1$,!&22$FF!2?1(*?'!
G$U)U!/*?;+,$,!H@!L=A!?*!06CA!)*+,!F?'N(+?1FK9!F#?N',!H$!$12?N*&)$,!H@!(#$!H+?P$,+2&'!2?PPN1+(@U!!!


















?I!/*+;&2@! *+FSFU! "#$! G;+*(N&'K! I$,$*&(+?1!?I!&! '&*)$!&P?N1(!?I!/$*F?1&'!P$,+2&'!,&(&! +F!1?(! (#$!?1'@! *+FS!&(!#&1,U!O*+,!
($2#1?'?)@!R+''!N1,?NH($,'@!IN*(#$*!F(+PN'&($!(#$!NF$!?I!)$1?P+2!,&(&!+1!*$F$&*2#U!%?R$;$*9!(#+F!/&*(+2N'&*!(@/$!?I!,&(&!
#&F!&!1NPH$*!?I!F/$2+I+2!2#&*&2($*+F(+2F!*$'&($,!(?!/*+;&2@!R#+2#!&*$!1?(!I?N1,!+1!&1@!?(#$*!(@/$!?I!GP$,+2&'K!+1I?*P&(+?1p!!
w! O$1$(+2!,&(&!1?(!?1'@! 2?12$*1F! +1,+;+,N&'F9!HN(!&'F?! (#$+*! *$'&(+;$FU!=!/$*F?1`F! 2?1F$1(! (?! *$'$&F$!#+F!?*!#$*!
)$1$(+2!+1I?*P&(+?1!2?1F(+(N($F!&!,$!I&2(?!*$'$&F$!?I!+1I?*P&(+?1!&H?N(!?(#$*!+1,+;+,N&'F9!+U$U!#+F!?*!#$*!*$'&(+;$FU!








w! O$1?P+2! ,&(&! +F! $&F+'@! R*?1)'@! +1($*/*$($,! H@! 1?1M/*?I$FF+?1&'Fv! qFNF2$/(+H+'+(@`! (?! ,+F$&F$F! 2&1! $&F+'@! H$!
P+F(&S$1!R+(#!2$*(&+1(@!?I!+''1$FFU!!!




"#$! I+*F(! &//*?&2#! I?2NF$F! ?1! (#$! 2*$&(?*F! &1,!P&+1(&+1$*F! ?I! (#$! +1I?*P&(+?19! /*?#+H+(+1)! (#$P! I*?P!,+F2'?F+1)! (#$!
+1I?*P&(+?1!(?!+1&//*?/*+&($!/&*(+$FU!3&F+2&''@9!(#+F!2?P$F!,?R1!(?!(#$!,$/'?@P$1(!?I!2'&FF+2&'!F$2N*+(@!P$&FN*$F!G&22$FF!








































,?$F!1?(! +P/'@!(#&(!,$;$'?/P$1(! +F!H$@?1,!(#$!F2?/$!?I!&!#$&'(#)*+,! +1+(+&(+;$U!61!(#$!2?1(*&*@9!1$T(!(?!(#$!I&2(!(#&(!
F(*+1)$1(!,&(&!/*?($2(+?1!+F!&!/*$*$^N+F+($!I?*!#$&'(#2&*$!D"9!F(&1,&*,+_&(+?1!?I!.5"!($2#1?'?)@!2&1!H$!$12?N*&)$,!H@!(#$!
,$;$'?/P$1(!?I!F/$2+I+2!)*+,!F$*;+2$F9!FN2#!&F!&!/?'+2@M,*+;$1!/F$N,?1@P+_&(+?1!F$*;+2$!R#+2#!&''?RF!2$1(*$F!&N(?P&(+2&''@!










































+,$1(+I+2&(+?1! *+FS! GH@! +12*$&F+1)! (#$! &1?1@P+(@! F$(KU! V+1&''@! &! *&1)$! ?I! .5"F! R#+2#! &*$! R$''! FN+($,! (?! ,+F(*+HN($,!






























































w! <+*$2(+;$!dl\Zd\5L!?I! (#$!5N*?/$&1!.&*'+&P$1(!&1,!?I! (#$!L?N12+'!?I!>Z!62(?H$*!8ddl!?1! +1!;+(*?!,+&)1?F(+2!
P$,+2&'!,$;+2$FU!!
D(!+F!#$12$!*$^N+*$,!+1!$&2#!/*?a$2(!(?p!!
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Compliance and creativity in grid computing 
Anthony E. Solomonides 





Grid computing ("the grid") is a promising new technology to enhance the services already 
offered by the internet.  This new paradigm offers rapid computation, large scale data storage 
and flexible collaboration by harnessing together the power of a large number of commodity 
computers or clusters of other basic machines.  The grid was devised for use in scientific 
fields, such as particle physics and bioinformatics, in which large volumes of data, or very 
rapid processing, or both, are necessary.  Unsurprisingly, the grid has also been used in a 
number of ambitious medical and healthcare applications.  While these initial exemplars have 
been restricted to the research domain, there is a great deal of interest in real world 
applications.  However, there is some tension between the spirit of the grid paradigm and the 
requirements of medical or healthcare applications.  The grid maximises its flexibility and 
minimises its overheads by requesting computations to be carried out at the most appropriate 
node in the network; it stores data at the most convenient node according to performance 
criteria.  On the other hand, a hospital or other healthcare institution is required to maintain 
control of its confidential patient data and to remain accountable for its use at all times.  
Despite this apparent conflict in requirements, we suggest that certain characteristics of the 
grid provide the means to resolve the problem: in the spirit of this paradigm in which "virtual 
organisations" arise ad hoc, "grid services" may negotiate ethical, legal and regulatory 
compliance according to agreed policy. 
 
Introduction: the computing context 
I will introduce some of the issues that concern us through examples from several recent 
projects in the field of ‘healthgrid’.  I will first motivate the concept of grid computing.  
‘Distributed computer systems’ predate even the internet and the World Wide Web (‘the 
web’).  By means of a network of interconnections, computers are able to share a workload 
that would ordinarily be beyond the capacity of any one of them; they may also distribute data 
to different locations according to need or frequency of use.  On the other hand, since the 
explosion of the web in every conceivable statistic – users, nodes, volume of information – 
we are familiar with its ability to serve information and misinformation in equal measure.  
The grid combines the technical features of distributed systems and the web, but efforts are 
also being made to ensure that it is not beset by the same problems of abuse, misuse and 
contamination as the web has been. 
The ideal grid, envisaged as a servant of a new paradigm of scientific research called ‘e-
science’, would provide transparent processing power, storage capacity and communication 
channels for scientists who may from time to time join the grid, do some work and then leave, 
so that the alliances they form in their scientific endeavours might be described as ‘virtual 
organizations’ or VOs for short.  Different sciences have different needs, and the grid concept 
has become differentiated: particle physics generates enormous amounts of data which must 
be kept, but not necessarily instantly processed; on the other hand, data in bioinformatics is 
not large by comparison – it is, of course, in plain terms, large – but requires intensive 
processing.  In extending the application of grid computing to e-health, another feature 
becomes pre-eminently necessary: that of collaboration. 
An important consequence of the fluidity of collaboration in grid computing has been in 
the choice of ‘architecture’ for grid systems.  ‘Architecture’ is used loosely in computer 
systems to describe the manner in which hardware and software have been assembled 
together to achieve a desired goal.  Favoured also in the commercial application of the web, 
the so-called ‘Service-Oriented Architecture’ has been widely adopted in grid applications.  In 
effect, it means that needed services – software applications – once constructed, are provided 
with a description in an agreed language and made available to be ‘discovered’ by other 
services that need them.  A ‘service economy’ is thus created in which both ad hoc and 
systematic collaborations can take place. 
Compared with data from physics or astronomy, medical data is less voluminous, but 
requires much more careful handling.  Among the services it therefore calls for are ‘fine 
grained’ access control – e.g. through authorization and authentication of users – and privacy 
protection through anonymization or pseudonymization of individual data or ‘outlier’ 
detection and disguise in statistical data.  There are, of course, many more specialist medical 
services, as our examples below reveal.  It is a current requirement in the United States, for 
example, that if head images are communicated outside the team immediately caring for a 
patient, all facial features which might identify the patient must be removed. 
Breast Cancer and MammoGrid 
Breast cancer is arguably the most pressing threat to women’s health.  For example, in the 
UK, more than one in four female cancers occur in the breast and these account for 18% of 
deaths from cancer in women.  Coupled with the statistic that about one in four deaths in 
general are due to cancer, this suggests that nearly 5% of female deaths are due to breast 
cancer.  While risk of breast cancer to age 50 is 1 in 50, risk to age 70 increases to 1 in 15 and 
lifetime risk has been calculated as 1 in 9.  The problem of breast cancer is best illustrated 
through comparison with lung cancer which also accounted for 18% of female cancer deaths 
in 1999.  In recent years, almost three times as many women have been diagnosed with breast 
cancer as with lung cancer.  However, the five year survival rate from breast cancer stands at 
73%, while the lung cancer figure is 5%.  This is testament to the effectiveness of modern 
treatments, provided breast cancer is diagnosed sufficiently early.  These statistics are echoed 
in other countries.  The lifetime risk of breast cancer in the USA has been estimated as 1 in 8.  
Here also incidence has increased but mortality decreased in the past twenty years.  Twenty 
years ago breast cancer was almost unknown in Japan but its incidence now approaches 
Western levels. (For a world-wide picture, see [1].) 
The statistics of breast cancer diagnosis and survival appear to be a powerful argument in 
favour of a universal screening programme.  However, a number of issues of efficacy and cost 
effectiveness limit the scope of most screening programmes.  The method of choice in breast 
cancer screening is mammography (breast X-ray); for precise location of lesions and ‘staging’ 
(establishing how advanced the disease is) ultrasound and MRI may be used.  A significant 
difficulty lies in the typical composition of the female breast, which changes dramatically 
over the lifetime of a woman, with the most drastic change taking place around the 
menopause.  In younger women, the breast consists of around 80% glandular tissue which is 
dense and largely X-ray opaque.  The remaining 20% is mainly fat.  In the years leading up to 
the menopause, this ratio is typically reversed.  Thus in women under 50, signs of malignancy 
are far more difficult to discern in mammograms than they are in post-menopausal women.  
Consequently, most screening programmes, including the UK’s, only apply to women over 
50. 
The increasing use of electronic formats for radiological images, including mammography, 
together with the fast, secure transmission of images and patient data, potentially enables 
many hospitals and imaging centres throughout Europe to be linked together to form a single 
grid-based “virtual organization”.  It is not yet precisely understood what advantages might 
accrue to radiologists working in such virtual organizations, as the technological possibilities 
are co-evolving with an appreciation of potential uses; but one that is generally agreed is the 
creation of huge “federated” databases of mammograms, which appear to the user to be a 
single database but are in fact retained and curated in the centres that generated them.  Each 
image in such a database would have linked to it a large set of relevant information, known as 
metadata, about the woman whose mammogram it is.  Levels of access to the images and 
metadata in the database would vary among authorized users according to their “certificated 
rights”: healthcare professionals might have access to essentially all of it, whereas, e.g., 
administrators, epidemiologists and researchers would have limited access, protecting patient 
privacy and in accordance with European legislation.   
The Fifth Framework EU-funded MammoGrid project (2002-05) [3] aimed to apply the 
grid concept to mammography, including services for the standardization of mammograms, 
computer-aided detection (CADe) of salient features, especially masses and 
‘microcalcifications’, quality control of imaging, and epidemiological research including 
broader aspects of patient data.  In doing so, it attempted to create a paradigm for practical, 
grid-based healthcare-oriented projects, particularly those which rely on imaging, where there 
are large volumes of data with complex structures.  Clinicians rarely analyse single images in 
isolation but rather in a series or in the context of metadata.  Metadata that may be required 
are clinically relevant factors such as patient age, exogenous hormone exposure, family and 
clinical history; for the population, natural anatomical and physiological variations; and for 
the technology, image acquisition parameters, including breast compression and exposure 
data. 
As a research project, MammoGrid encompassed three selected clinical problems: 
i! Quality control: the effect on clinical mammography of image variability due to 
differences in acquisition parameters and processing algorithms; 
ii! Epidemiological studies: the effects of population variability, regional differences such 
as diet or body habitus and the relationship to mammographic density (a potential 
biomarker of breast cancer) which may be affected by such factors; 
iii! Support for radiologists, in the form of tele-collaboration, second opinion, training and 
quality control of images. 
The MammoGrid proof-of-concept prototype enables clinicians to store digitized mammo-
grams along with appropriately anonymized patient metadata; the prototype provides 
controlled access to mammograms both locally and remotely stored. A typical database 
comprising several thousand mammograms has been created for user tests of clinicians’ 
queries. The prototype comprises (a) a high-quality clinician visualization workstation (used 
for data acquisition and inspection); (b) an interface to a set of medical services (annotation, 
security, image analysis, data storage and queries) accessed through a so-called GridBox; and 
(c) secure access to a network of other GridBoxes connected through grid middleware.  The 
GridBoxes may therefore be seen as gateways to the grid. 
The prototype provides a medical information infrastructure delivered in a service-based 
grid framework. It encompasses geographical regions with different clinical protocols and 
diagnostic procedures, as well as lifestyles and dietary patterns.  The system allows, among 
other things, mammogram data mining for knowledge discovery, diverse and complex 
epidemiological studies, statistical analyses and CADe; it also permits the deployment of 
different versions of the image standardization software and other services, for quality control 
and comparative study.   
It was always the intention of MammoGrid to get rapid feedback from a real clinical 
community about the use of such a simple grid platform to inform the next generation of grid 
projects in healthcare.  In fact, a Spanish company has already entered into negotiations to 
commercialize the project and to deliver a real, MammoGrid-based radiology service in the 
region of Extremadura.  Thus, many ideas which came up as questions, issues or obstacles in 
research, must be solved in a real-life system within the next two or three years. 
We may now imaginatively consider what may happen in the course of a consultation and 
diagnosis using the MammoGrid system.  A patient is seen and mammograms are taken.  The 
radiologist is sufficiently concerned about the appearance of one of these that she wishes to 
investigate further.  In the absence of any other method, she may refer the patient for a biopsy, 
an invasive procedure; however, she also knows that in the majority of cases, the initial 
diagnosis turns out to have been a false positive, so the patient has been put through a lot of 
anxiety and physical trauma unnecessarily.  Given the degree of uncertainty, a cautious 
radiologist may seek a second opinion: how can the MammoGrid system support her?  She 
may invoke a CADe service; the best among these can identify features which are not visible 
to the naked eye.  Another possibility is to seek out similar images from the grid database of 
mammograms and examine the history to see what has happened in those other cases.  
However, since each mammogram is taken under different conditions, according to the 
judgement of a radiographer (‘radiologic technician’) it is not possible to compare them as 
they are.  Fortunately, a service exists which standardizes and summarizes the images, 
provided certain parameters are available – the type of X-ray machine and its settings when 
the mammograms were taken.  Perhaps at this particular moment the radiologist’s workstation 
is already working at full capacity because of other imaging tasks, so it is necessary for the 
image to be transmitted to a different node for processing.  Since our grid is distributed across 
Europe, it now matters whether the node which will perform the standardization is in the same 
country or not.  Let us suppose that it is a different country.  A conservative outcome is to 
ensure that, provided the regulatory conditions in the country of origin and in the country 
where the processing will take place are mutually compatible (i.e. logically consistent, 
capable of simultaneous satisfaction) that they are both complied with.  If one set requires 
encryption, say, but the other does not, the data must be encrypted.  If both sets of regulations 
allow the image to be transmitted unencrypted but one country requires all associated data 
transmitted with the image to be pseudonymized, this must be done.  These are human 
decisions, but it is clear that they can be automated.  Where will responsibility lie if 
something goes wrong in this process?  In any case, the story has further ramifications: the 
whole idea of MammoGrid is to build up a rich enough database of images and case histories 
to provide a sound basis both for diagnostic comparison and for epidemiology.  Once 
standardized and returned, is the image now to be stored and made available to others for 
comparative use, or is it to remain outside the system.  This is now a question of informed 
consent.  Will a service, in the sense we have already used the term, be trusted to determine 
whether such informed consent as the patient has given covers this question? 
We now consider the comparison the radiologist wanted to make – the reason for 
standardizing the image to begin with.  The intention is to find images which are sufficiently 
similar and whose associated history gives an indication of the associated risk.  For example, 
if from among the ten most similar instances, seven turn out to be malignant, there would be 
good reason to proceed to the more invasive stage of investigation.  But how is the database to 
be queried so as to suggest valid comparisons?  Clearly, this goes beyond image similarity.  
The risks for a childless woman of 65 are very different from a 50-year old mother of three.  
Image similarity would not be sufficient to warrant a comparison.  Thus we must transmit, as 
part of the database query, data that potentially identify the patient; and the result of the query 
may provide data which potentially identify patients.  On a need-to-know basis, the radio-
logist has to know details of the cases, but not necessarily the names of the patients, although 
it would not be difficult to imagine a case where the name reveals something about ethnic 
background and this turns out to be significant.  In a fully deployed system, there may be 
relevant cases and images from several countries; the system must be capable of ‘policy 
bridging’, as described above, to ensure that all regulatory conditions are met.  Indeed, if the 
impact of including a case from one particular country would be to render the comparison less 
useful overall, perhaps the system should be able to reject that particular case – in other 
words, to apply a criterion which maximizes the information obtained subject to satisfaction 
of applicable laws and regulations – where the ‘applicable set’ is itself a variable. 
Evidence-Based and Individualized Medicine 
Hitherto, I have given a ‘naïve’ account of one system and its approach to diagnosis.  How is 
such a system to fit into the modern conception of evidence-based medicine, i.e. medicine that 
is based on scientific results, rather than on the doctor’s intuition, personal knowledge and 
craft skill?  Evidence-based practice rests on three pillars: medical knowledge, as much as 
possible based on ‘gold standard’ (double-blind, controlled) clinical trials whose results have 
been peer reviewed and then published; knowledge of the patient, as complete as the record 
allows; and knowledge of the resources, procedures and protocols available in the setting 
where the encounter with the patient is taking place. 
There is a very extensive literature on knowledge management and the difficulties and 
opportunities it presents.  Some work currently undertaken in the healthgrid context, such as 
on ontologies and on knowledge representation, is relevant here.  A development which is 
bringing economics into conflict with the traditional approach to the establishment and 
dissemination of knowledge is online publication of research results.  While in medicine at 
present this is restricted to electronic publication of papers that have already been peer 
reviewed and are in the pipeline for printing in a journal, in other fields of science, notably 
physics, immediate online publication of un-peer reviewed results so that they can be viewed 
and critically assessed is now common.  In another field, the journal Nature recently 
conducted a comparative study of errors in Wikipedia and in the Encyclopaedia Britannica; 
the results were equivocal, leading some to argue that an online, user-managed encyclopaedia 
is less error prone, although there have been many hacking attacks on Wikipedia.  In the case 
of medicine, not only malicious postings, but poor research may have serious results.  The 
American Medical Informatics Association is currently promoting the concept of a world 
bank of clinical trials.  Here it may be said that the traditional approach to knowledge has 
failed; negative results are often not published and, as certain legal cases have brought to 
light, even results suggestive of risks are kept under wraps.  Another practice that would 
benefit from being documented is the effective prescription of certain drugs beyond their 
designed purpose or licence, where nevertheless anecdotal clinical evidence has led 
practitioners to believe they are effective. 
However, the MammoGrid application we have described above (and other similar 
projects) takes us a step further in the direction of ‘dynamic’ construction of knowledge.  If 
images and histories are to be used as part of the diagnostic knowledge in new cases, it is 
imperative that they are collected with as much care and rigour as the cases in a controlled 
trial.  Therefore, it is essential to know the ‘provenance’ of the data with precise details of 
how it has been handled (e.g. if standardized and subjected to CADe, which algorithms were 
used, set to what parameters, by whom, and if capture and interpretation were subject to 
appropriate practice standards).  I have labelled this set of issues “the question of practice-
based evidence for evidence-based practice”.  If this were to be accepted as an appropriate 
source of diagnostic information, the underlying grid services which maintain it would have 
to make quality judgements without human intervention. 
A major breakthrough in healthcare is anticipated from the association of genetic data with 
medical knowledge.  In the healthgrid research community we have a map that has become 
almost an article of faith: 
 
Disciplines, levels of being and pathology diagnostics (acknowledgement: F. Martin-Sánchez) 
 
This view of the ‘life’ is in fact shared by many different disciplines, system biology being 
the most obvious among them.  Drug development is increasingly driven by a molecular view 
of the world, using a variety of models to understand both how drugs act and how their action 
may be enhanced, inhibited or frustrated.  This usually means understanding what proteins are 
present and, therefore, which genes code for those proteins.  In the foreseeable future, we may 
anticipate certain drugs to be available in subtypes to account for the specific genetic 
endowment of the patient. 
This would suggest that genetic information would have to be accessed routinely in the 
course of healthcare.  Viewing this as part of the information held on a patient raises a number 
of difficult problems.  Among these are the predictive value and the shared nature of genetic 
information.  Knowing a person’s genome could mean knowing what diseases they may or 
may not be susceptible to.  Knowing one person’s genetic map also reveals that of his or her 
siblings’ in large measure.  This introduces a range of questions, from confidentiality to ‘duty 
of care’ issues.  If physicians will be held liable both for what they do and what they do not 
do, is it necessary for the underlying knowledge technology to ‘be aware’ and to inform them 
of the possibilities? 
The grid could provide the infrastructure for a complete ‘electronic health record’ with 











































the ideal of genomic medicine.  Among many questions being investigated in current projects 
is a set concerning development and illness in childhood, especially conditions in which 
genetic predisposition is at least suspected and in the diagnosis of which imaging is also 
essential.  Physicians want to know how certain genes impact the development of diseases 
and radiologists want to know what the earliest imaging signs are that are indicative of a 
disease.  For example, the Health-e-Child project [5] is investigating paediatric rheumatology, 
cardiac dysmorphology and childhood brain tumours using this approach. Consider its aims: 
i! To gain a comprehensive view of a child's health by vertically integrating 
biomedical data, information, and knowledge, that spans the entire spectrum from 
genetic to clinical to epidemiological; 
ii! To develop a biomedical information platform, supported by sophisticated and 
robust search, optimization, and matching techniques for heterogeneous 
information, empowered by the Grid; 
iii! To build enabling tools and services on top of the Health-e-Child platform, that will 
lead to innovative and better healthcare solutions in Europe: 
-! Integrated disease models exploiting all available information levels;  
-! Database-guided biomedical decision support systems provisioning novel 
clinical practices and personalized healthcare for children;  
-! Large-scale, cross-modality, and longitudinal information fusion and data 
mining for biomedical knowledge discovery. 
With major companies looking to translate research results into products, successful outcomes 
from this and other projects would bring the scenario described above closer to reality. 
Next Steps 
The SHARE project, a so-called ‘specific support action’ within the European Information 
Societies Technology programme, will over the two years 2006-2007 be seeking to define a 
research road map that will allow not only the technology to be developed but the social 
issues also to be addressed, with the goal of establishing a healthgrid as the infrastructure of 
choice for European biomedical activity in the next ten years.  The SHARE collaboration 
includes both computer scientists, experts on social requirements and medical law specialists.  
The project begins with the fundamental assumption that technical and social requirements 
must be addressed concurrently.  It has identified these challenges to the modernization of 
health systems [7]: 
!! creating and populating, connecting and understanding patient records across 
organization boundaries and, in due course, across different national health systems; 
!! increasing the openness and accessibility of systems - e.g. providing patients with 
ownership of their healthcare record - while 
!! ensuring privacy, confidentiality and ethical compliance in the socio-legal plane, and 
!! maintaining data integrity, security and authenticity (e.g. provenance and semantics) in 
the technical plane; 
!! providing appropriate levels of authorization and authentication of users across all the 
services and the citizen; 
!! discovering, grading and certificating trustworthy sources of knowledge and case 
information to guide future action; finally, 
!! winning the trust and commitment of the medical professions at a time of immense 
change and economic pressure. 
At present it seems unlikely that technology will be allowed to determine answers to 
questions of a legal nature, much less so of an ethical nature.  Yet the extent to which we trust 
financial affairs to the internet and the extent to which we have allowed privacy to be invaded 
by online transactions, ‘cookies’ and preference tracking (to say nothing of store loyalty 
schemes) [8] suggests that we may be more flexible in our attitudes that our legal attitudes 
may imply.  Indeed, as far as personal data are concerned, the financial analogy has been 
made before in the concept of a personal data bank.  Would patients be less trusting of a 
‘bank’ with their health record than they are with their money? 
I have argued that ‘healthgrid’, the augmented application of grid computing to health, 
presents an opportunity to review not only information technology for health – a major 
enough task – but also our approach to the complex issues of ethical, legal and regulatory 
compliance as mediated by the technology.  The case in favour of the technology, in terms of 
improved information and knowledge for clinicians, patients, public health officials, 
administrators and governments, is not difficult to make.  The need for ethical and legal 
safeguards cannot be circumvented, but in itself this may prove an insuperable obstacle for 
the deployment of the new technology.  One way forward is to analyse precisely these ‘social’ 
requirements and enhance the technology with the means to apply them automatically with 
minimal human intervention. 
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Abstract 
CAPriCORN, the Chicago Area Patient Centered Outcomes 
Research Network, is one the eleven PCORI-funded Clinical 
Data Research Networks. A collaboration of six academic 
medical centers, a Chicago public hospital, two VA hospitals 
and a network of federally qualified health centers, 
CAPriCORN addresses the needs of a diverse community and 
overlapping populations. In order to capture complete 
medical records without compromising patient privacy and 
confidentiality, the network has devised policies and 
mechanisms for patient consultation, central IRB approval, 
de-identification, de-duplication, and integration of patient 
data by study cohort, randomization and sampling, re-
identification for consent by providers and patients, and 
communication with patients to elicit patient-reported 
outcomes through validated instruments. The paper describes 
these policies and mechanisms and discusses two case studies 
to prove the feasibility and effectiveness of the network. 
Keywords:  
Patient-Centered Outcomes Research; Comparative 
Effectiveness Research; Electronic Health Records; Data 
Collection, —Linkage , —Aggregation, —Sets; 
Deidentification, Re-identification; Consent. 
Introduction 
PCOR, CER and PCORnet 
The Patient-Centered Outcomes Research Institute (PCORI) 
was established following the US Patient Protection and 
Affordable Care Act in 2010. Its mission is to advance and 
support Patient-Centered Outcomes Research (PCOR), which  
[…]  helps people and their caregivers communicate and 
make informed healthcare decisions, allowing their voices to 
be heard in assessing the value of healthcare options. [1] 
In particular, PCOR: 
• Encompasses comparative effectiveness research 
(CER) on interventions to inform decision making. 
• Addresses individuals’ (especially patients’ and care-
givers’) preferences and autonomy. 
• Studies a diversity of settings and populations. 
• Seeks to balance stakeholders’ concerns, including 
burden to individuals and availability of resources. 
One of the principal means by which PCORI has sought to 
achieve these goals is by supporting eleven Clinical Data 
Research Networks (CDRN) and eighteen Patient-Powered 
Research Networks (PPRN). Both kinds of research network 
are seen as infrastructure-building projects, with specific 
structural, process and outcome goals to prove the feasibility 
and usefulness of the networks. CDRNs are focused on major 
academic medical centers; apart from demonstration of viable 
infrastructures, they are expected to demonstrate their value 
by conducting research in a number of specific conditions. 
Each network has had to nominate the conditions on which it 
will work. However, longer term sustainability for the 
infrastructure can only be achieved through manifest success 
in these early studies, by proving to the research community 
that the network represents a valuable resource that is worth 
both exploiting and supporting through further funded studies 
and grant proposals. PPRNs are focused on specific 
conditions, some relatively common and some rare, that are of 
particular concern to patients, carers, and patient advocacy 
organizations. Many have formed around existing formal or 
informal networks of support and advocacy groups. 
Overarching the CDRNs and PPRNs, PCORI has established a 
supra-network, PCORnet, that acts as collaboration venue, 
clearing house, and policy-development body on behalf of all. 
Best conceived of as a network of networks, it ensures that the 
infrastructures created by the different CDRNs and PPRNs 
will remain interoperable and responsive both to researchers’ 
needs and to the expectations of patients, carers and 
advocates. 
CAPriCORN 
One of the CDRNs, CAPriCORN, represents a remarkable 
alliance of Chicago institutions collaborating in recognition of 
the need for pre-competitive comparative effectiveness 
research (CER) in their highly diverse community—diverse 
both in the type of institutions involved and, importantly, in 
the populations they serve. It is not altogether typical of 
CDRNs, although it naturally shares many characteristics. 
Some of its unique features have provided a model for 
collaboration in environments where, for example, patient 
populations at different institutions overlap, as they do within 
a city setting, where nevertheless a full picture of each 
patient’s health record is necessary for meaningful research 
results. 
Data for sharing within CAPriCORN—and in the wider 
community at a later stage—will be in a HIPAA-compliant, 
de-identified format. Two working groups, Informatics WG 
and Ethics and Regulatory WG, have devised a federated data 
architecture, a data model with appropriate standards, and a 
designed data flow engineered to ensure that no protected 
health information (PHI) is released other than under strictly 
controlled conditions, at the same time as maintaining the 
research value of the data that is released. De-identified data 
will be released on a study-by-study basis. A statistically 
benchmarked process is used to generate a pseudonymous 
identity for each patient in such a way that patients’ records 
that are distributed across different providers in the network 
can be matched and integrated, not by being brought together 
into a single central database, but in a virtual repository – by 
allowing distributed queries across the different systems 
through the validated mechanism of PopMedNet [4, 5]. 
Consent will be sought when access to PHI or directly to the 
patient for patient-reported outcomes is necessary. 
Methods 
Population 
CAPriCORN comprises a network of six academic medical 
centers (University of Chicago, University of Illinois, 
Chicago, Loyola University, NorthShore University 
HealthSystem, Northwestern University and Rush University 
Health), the Alliance of Chicago’s Federally Qualified Health 
Centers, a major public hospital, Cook County Hospital, and 
two Veterans Affairs hospitals, VA Edward Hines and VA 
Jesse Brown. Geographically, these serve the greater Chicago 
metropolitan area and are available to a total population of 
approximately 9.5 million. (In addition to these “data-
providing” institutions, 22 other organizations contribute 
research, patient advocacy, and infrastructure services to 
CAPriCORN. Their role is described below.) 
At the time of proposal submission, CAPriCORN institutions 
among them held 2,860,000 covered lives in electronic health 
records. A preliminary analysis of seven of the ten institutions 
indicated 6,923,111 patients, of whom 1,465,285 were 
registered with a primary care provider; however, after de-
duplication, the numbers were 5,741,268 and 1,242,380 
unique patients respectively. Thus some 20.6% of patients are 
associated with more than one institution, and even among the 
primary populations, there are 18% of patients with more than 
one PCP registration. This appears to be symptomatic of 
deprivation in the inner city, where of economic necessity 
individuals move opportunistically from provider to provider.  
The racial breakdown of the primary population is 47.5% 
Caucasian, 27.9% African American and 14.9 Hispanic, with 
just over 9% in other categories. Of this population, 59.3% are 
female, 40.7% male. The mean age is 50 with a standard 
deviation of 17.9. 
De-identification and De-duplication 
While fragmented care may be suboptimal, research on 
comparative effectiveness of treatments requires as accurate 
and as complete a record of each patient’s health status and 
episodes of illness as can be reconstructed, if meaningful and 
valid results are to be achieved. With multiple records for up 
to 20% of patients, de-duplication is strongly indicated. The 
means of achieving this lie in a particular method of de-
identification. 
In the US context, there is currently little prospect of a single 
unique patient identification code. Where health information 
exchanges have been instituted, it has been necessary to 
implement an “enterprise master patient index” (EMPI), but 
even these are rare because of a number of concerns, 
principally privacy and security, and economics and 
sustainability. Nevertheless, prior experience was sufficiently 
encouraging to suggest that a specific design and 
implementation in the Chicago area would be worthwhile. 
This prior knowledge and experience provided a fundamental 
cornerstone for the CAPriCORN network. 
The de-identification algorithm is due to Kho et al [2, 3]. It 
uses a set of strictly personal identifiers, i.e. including nothing 
that may be institution-specific, to generate up to 17 different 
combination strings and uses a statistically selected subset of 
these to construct a “hash-ID”. As its name implies, the 
hashing algorithm is not reversible, but its high specificity 
allows patients who have multiple records to be discovered, 
albeit anonymously. 
Organizational Design 
As a project, CAPriCORN is led by a Principal Investigator at 
the Chicago Community Trust, an organization focused on 
civic leadership and philanthropy. A Steering Committee is 
the decision making body, whose composition has been 
designed around the natural concerns of a network to conduct 
and facilitate patient-centered outcomes and comparative 
effectiveness research across a number of healthcare 
institutions, and also reflects the underlying architectural 
design of the infrastructure and the projected governance and 
regulatory framework of that infrastructure. 
Clinical Data Research Networks are by definition intended to 
be open to external collaboration, are explicitly designed to be 
open to patient concerns, and are subject to all the normal 
ethical and regulatory processes that apply to human subjects 
and social science research. These are, respectively, reflected 
in the network’s External Researcher Committee, Patient and 
Clinician Advisory Committee, and Chicago Area Institutional 
Review Board (CHAIRb). All these figure in the definition of 
processes and workflows for patient and carer consultation, 
for the triage of internal and external research proposals, for 
the handling of data requests, for the release of data, and for 
the consenting process prior to any re-identification of and 
contact with patients. 
Critical to the infrastructural design are two “honest broker” 
roles in the network. Other than in very specific, precisely 
defined circumstances involving only consented patients, 
these organizations hold no protected personal health 
information (PHI) but handle the “de-identifiers”, principally 
the hash-IDs for de-duplication, and subsequent to the 
definition of specific condition cohorts, a second level of 
pseudonymization, the cluster-IDs, which are randomly 
generated “per study, per hash-ID” thus avoiding any 
unintended crosstalk between independent studies. 
The principles, some explicit and some implicit, that have 
guided this design are: 
• All studies, including those that have been submitted 
as “proof of principle” for the network, along with 
new and external proposals, will be subject to triage 
by the Patient and Clinician Advisory and External 
Researcher committees, then subject to review by 
CHAIRb, with the ultimate decision resting with the 
Steering Committee. 
• All PHI will be held at institutions, benefiting from 
all the protections (firewalls, authorizations, etc.) that 
each applies to its own patient data. 
• The data to be collected by an honest broker will be 
strictly non-PHI and will be minimal with respect to 
any cohort identification needs (all that is needed, but 
no more). 
• Identifiers will be hashed into pseudonymous “hash-
IDs” for the purpose of de-duplication. Honest 
Broker 1 (HB1) will provide institutions with a 
unique “hash seed” that each will use to de-identify 
through hashing its own patients.  
• The second honest broker, HB2, will use the hash-
IDs provided by institutions to identify “duplication” 
and determine the set of institutions to which each 
patient corresponds. HB2 then generates a random 
identifier, the cluster-ID, for each unique patient in 
the given cohort. At this point, if considered 
necessary, the institutions themselves may be 
pseudonymized. (No PHI will flow to HB2.) 
• Patients’ records may only be linked through the 
hash-ID. Cohort identification for specific studies 
and specific (non-PHI) data requests from sites for 
the purpose of constructing aggregate records may be 
conducted only by means of a distributed query 
mechanism (currently, PopMedNet [4, 5]) which 
allows queries to be inspected and vetted prior to 
execution and results from queries to be examined 
prior to release. 
• All studies that require access to PHI must identify a 
co-investigator at each site. 
• Provider consent to approach patients to consent for 
particular studies will be requested, and subsequent 
patient consent will be sought, according to 
institutional rules and norms. 
• Randomization of patients for consent will be done 
anonymously both in respect to patients and 
institutions. 
As noted above, these principles are visible in the 
organizational structure of the network, but they are also 
evident in the architectural design of the infrastructure. 
Network Architecture 
The architecture of the network is depicted in Fig. 1 below. 
The processes represented by the various flows in this diagram 
are detailed below. 
 
 
Figure 1 – A schematic diagram of the network displaying  
the two “honest broker” roles, the institutional repositories 
and the central “data hub” which hosts the matching and 
distributed query services. 
 
CAPriCORN has developed a data model and data standards, 
together with “extract-transform-load” processes for its 
institutional data marts. The data model is effectively based on 
a star schema with the concept Encounter at its center, so that 
data can be understood at a transactional level. A data 
dictionary has been adopted showing domains and variables 
within them (apart from patient demographics, radiating out 
from encounters are diagnoses, medications, procedures, vital 
signs, laboratory results, and some additional local variables). 
Standards and terminologies are indicated for values in each 
category. The degree of privacy restriction for each variable 
(within-institution, within-CAPriCORN, within-PCORnet) is 
also indicated. 
Each institution has established a data mart (or other local 
database) which, notwithstanding the differences in platforms, 
precisely matches the CAPriCORN data model. Thus, 
although local adaptations of SQL queries will be necessary, 
the essential logic of queries submitted to the “data hub”, i.e. 
the distributed query service, will remain unaltered, as 
required by PCORnet for its greater vision of seamless 
patient-centered, comparative effectiveness research. 
A Communication Center is also being established to facilitate 
the process of re-identification of patients for provider consent 
to approach patients and for patient consent to participate in 
survey research (patient-reported outcomes, or PROs) and 
intervention studies. Each institution’s processes are 
respected, and no pre-consent PHI flows through the center. 
Process Description 
1. HB1 hosts a stand-alone, generic hashing-seed generator 
application; it generates a SEED and passes it auto-
matically to all participating institutions. 
2. Each INSTITUTION uses the SEED and a set identifiers 
to generate a set of multiple hashes for each patient on 
record: 
[SSN, FirstName, LastName, DoB, Gender ] ! SEED  
" { hashes } 
from which a unique hash-ID is generated and cross-
linked to the patient’s MRN for internal identification. 
This is per patient; […] signifies a vector of personal data. 
Hash-IDs can be used within each INSTITUTION locally, if 
desired. 
3. For each STUDY, every INSTITUTION runs the 
appropriate phenotyping algorithm to select its 
subpopulation of all unique patients who satisfy the 
cohort criteria. The hash-IDs along with all the hashes 
are returned to HB2. 
4. For each study, HB2 collects all hashed data and de-
duplicates, storing the result in a vector as follows: 
{ (institutionID=1) : hash-ID1 } 
    #hash-ID … #hash-ID  
      { (institutionID=10) : hash-ID10 } 
   " hash-ID : institutionVector 
where #hash-ID represent the join on hash-ID. The patient’s 
hash-ID and institutionVector now appear thus: 
 
 Institutions 
Disease D AL CC UC UI LU NS NU RU VH VJ 
 
hash-ID           
xyz123 0 0 0 1 0 0 0 1 0 0 
 
This represents the following “facts”: The patient whose hash-
ID is “xyz123” has been identified as having disease D and 
having partial records at UI and RU. We note that 
(i) the hash-ID is in reality a more complex object (cf. [2]); 
(ii) this may not be the complete record for this patient. 
5. The five collections { hash-ID }, one for each study, are 
returned to all the institutions for cohort verification.  
This is necessary, because, for example, a patient with an 
anemia record at one hospital (RU) may turn out to have a 
record at another hospital (UI) that does not mention anemia. 
Nevertheless, a complete record for that patient must include 
the partial records from both institutions. 
6. Each institution checks the lists against its reference 
hash-ID list and so completes each patient’s record if 
necessary. 
For the sake of illustration, suppose now that we have found 
the patient above has also been seen at yet another hospital 
(CC) for an unrelated condition. The vector now becomes: 
 
Disease D AL CC UC UI LU NS NU RU VH VJ 
 
hash-ID           
xyz123 0 1 0 1 0 0 0 1 0 0 
 
We can now confidently compile a complete record of the 
patient. 
7. At this point, HB2, as an honest broker, must do two 
more de-identification steps:  
a. first, to disguise the institutions, and  
b. second, to replace hash-IDs with non-derived ids for 
the patients; these are the cluster-IDs. 
For the first step, HB2 randomly assigns pseudonyms to the 
institutions, say: 
 AL CC UC UI LU NS NU RU VH VJ 
 ff dd aa jj bb ii cc ee hh gg 
and these are then indexed as: 
 aa bb cc dd ee ff gg hh ii jj 
 UC LU NU CC RU AL VJ VH NS UI 
 
The example patient now appears as: 
 
Disease D aa bb cc dd ee ff gg hh ii jj 
 
hash-ID           
xyz123 0 0 0 1 1 0 0 0 0 1 
 
c. The hash-IDs for each study cohort can now be 
replaced with unique cluster-IDs. 
 
Our example patient now appears as: 
 
Disease D aa bb cc dd ee ff gg hh ii jj 
 
cluster-ID           
D-900093 0 0 0 1 1 0 0 0 0 1 
 
Now, only possession of the table converting hash-IDs to 
cluster-IDs can enable anyone to re-identify the patient. 
Distributed Queries 
With cohort cluster-IDs collected, HB2 can route data requests 
through the distributed query service to the institutional data 
marts (IDMs). Locally, each institution will have the 
opportunity to determine if the proposed query against its 
IDM is acceptable, allow it to execute, and even then 
scrutinize the results before releasing them. Both in sending 
the requests and as results are received, HB2 can match 
cluster-IDs to hash-IDs, so that even a clinician researcher 
working on a project in their own specialty may be able to 
view expanded records of their own patients without 
recognizing them as their own. This provides a very high 
standard of de-identification. 
Re-identification 
Once particular studies based on entire cohorts are launched, it 
is likely that re-identification of subsets of patients may prove 
necessary. Having received approval both from the Steering 
Committee (with advice from PCAC and ERC) and 
permission to proceed from CHAIRb, a researcher may 
request the Communication Center to randomly select a 
possibly weighted sample from across institutional or other 
populations for re-identification. The researcher will also be 
able to submit, through HB2, a data request for controls. It is 
possible, subject to CHAIRb’s approval, for institutional 
processes to be employed to gain provider consent and from 
there patient consent to participate in a study. Given the 
cluster-IDs of the patients in the study group, the 
Communication Center can alert institutions to the hash-IDs of 
patients to be approached for re-identification. In some cases, 
the Communication Center will also provide institutions with 
the means to collect patient-reported outcomes. 
In the case of patients attending multiple institutions, which 
institution (or more precisely, which provider) should consent 
the patient for an identified study may be complex. A variety 
of algorithmic approaches is possible, including some that 
may work well but are computationally expensive. This may 
take the form of querying the system for the number of 
encounters at each institution in the last year (complex, but 
likely to reflect the patient’s expectation) or it may suffice to 
look where the patient is registered for primary care 
(inexpensive, but may be irrelevant). The present ruling of 
CHAIRb only constrains the approach to be through a 
provider who is actually involved in the patient’s care. 
Results 
At this, approximately halfway point in the project, 
achievements across a number of fronts include: 
• Establishment of a sound governance structure, 
including a common central IRB, with data use and 
business associate agreements in place. 
• Establishment and launch of a Patient and Clinician 
Advisory Committee with a clear role in the review, 
triage and approval of new research proposals and a 
comprehensive manual for its operations. 
• Agreed design for the technological infrastructure, 
including a data model designed for ease of 
distributed query as well as with model evolution in 
mind. 
• Agreed processes and workflows now increasingly 
described and approved in protocols. 
• Preliminary tests of the de-identification process and 
the distributed query machinery. 
• Preliminary phenotyping in all five study cohorts 
proposed at project submission (see below). 
Preparatory phenotyping for a number of other 
studies, including incidental findings in osteoporosis, 
the national aspirin trial, bariatric surgery, antibiotics 
and childhood weight, bisphosphonates, and others. 
• The de-identification and de-duplication processes in 
CAPriCORN are increasingly being looked at as a 
model to be replicated across other CDRNs. 
The internal organization of the network lends itself well to 
establishing CAPriCORN as a corporate entity; this would no 
doubt present new challenges, but is under consideration. 
Discussion 
The data model has been deployed at institutions to construct a 
data mart. Based on model variables, five phenotyping 
algorithms have been devised and tested at multiple sites to 
identify overweight and obese patients (as required of all 
CDRNs); ambulatory patients suffering from asthma and in-
patients with anemia (the two common disease cohorts); and 
patients with recurrent Clostridium difficile infection (RCDI) 
and sickle-cell disease sufferers (the two rare conditions). 
In preparation for all these studies (and other anticipated 
future studies, including the PCORnet-inspired Aspirin trial 
and various collaborations with other CDRNs and PPRNs) the 
central IRB, CHAIRb, has already reviewed a Master Protocol 
which serves as a prefix to all specific study protocols. 
Extract-Transform-Load (ETL) processes have been under-
taken against a number of different proprietory EHR systems. 
Some of these have been shared publicly (e.g. through an EHR 
vendor’s community sharing portal, thus conforming with 
requirements of commercial confidentiality). ETL logic has 
been shared among all data-contributing sites to ensure 
compatibility. 
The CAPriCORN data model is a superset of the PCORnet 
common data model against which external requests will be 
formulated. This makes for a straightforward mapping of data 
and requests from PCORnet to CAPriCORN. Additional data 
models that are influencing the central PCORnet design, such 
as (Mini-)Sentinel, OMOP, i2b2 and others have also been 
studied with a view to establishing correspondences should the 
opportunity of collaboration make a translation between 
CAPriCORN and another data model desirable. 
Among the proposed cohort studies, the case of RCDI 
provides a convenient example of a hard test-case for the 
infrastructure. The study has not yet been completed, but 
based on data stored according to the data model and 
addressing queries to pre-existing institutional data 
warehouses rather than the institutional data marts, accurate 
cohort counts have been achieved. 
Index cases of CDiff infection have been identified, either by 
the presence of a diagnosis code or by laboratory test results. 
The first difficulty arises in recognizing resolved CDiff 
infection: how to differentiate between refractory and 
recurrent infection. If there is no encounter with CDiff code, 
laboratory test or relevant medication within eighteen days of 
date of diagnosis or of positive test result, the infection is 
assumed to have cleared. Any further infection in 18 to 56 
days post index date is recorded as recurrence. Infections later 
than 56 days are considered new rather than recurrent. 
One of the key challenges to CAPriCORN’s distributed 
architecture will be in the identification of recurrence across 
institutions. This has not yet been attempted, but will be 
among the first studies that the system will address. The 
cohort is anticipated to be relatively small and the cases of 
patients moving from one institution to another while at risk of 
recurrence of CDiff should be fewer still, so that discovery of 
such cases will represent success with truly rare events. 
Conclusion 
Along with ten other CDRNs, CAPriCORN is at about the 
halfway point of its “Phase I” life span and is ready to test its 
systems with real use cases. The infrastructure has been 
designed to allow for evolution in the data model and 
increasing complexity of queries in future. Five submitted 
cohort studies are currently being processed through stages of 
the CAPriCORN workflow, and a number of new study 
proposals are being prepared. 
The processes of de-identification, matching and de-
duplication, cohort identification, record linkage and 
aggregation, and the distributed query mechanism have been 
described. It is possible to randomize and re-identify securely, 
and to extract matched controls through records in the IDMs. 
Sustainability of the architecture will be demonstrated through 
a number of additional research studies that had not been 
considered at the proposal stage. These are also providing a 
valuable challenge to CAPriCORN’s proposal triage, patient-
centeredness, and external researcher engagement workflows. 
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Recent experience has shown that stakeholders can be 
powerful allies when they are authentically integrated into the 
research process. Patients, advocates and caregivers bring a 
wealth of views and viewpoints to bear on research questions. 
While reimbursement models often inhibit research 
engagement by physicians, we argue that patients can be a 
valuable resource. That we often forget this seems all the 
more paradoxical in view of our oft-asserted “patient-
centered”-ness. We consistently neglect the patient, and more 
broadly the stakeholder, as a resource in research. Is there 
another way to look at this? We suggest “imagineering” in its 
pre-Disney sense: we can imagine a world in which patients 
play a much bigger role in the management of their health 
records—bypassing the fraught issues of ownership and 
custody—and a world in which patients have a means of 
subscribing to research as part of the management of their 
record. This would mean having options to receive bulletins 
about projects and results, information about upcoming 
studies, with the opportunity to choose studies in which to 
participate, perhaps subject to screening by a physician. 
Beyond this, for some it may mean engagement in the research 
process – formulation of research questions and goals, or 
participation in analysis in the spirit of “citizen science”. 
Keywords:  
Patient participation, patient-centered outcomes research, 
informed consent.  
Introduction: The Patient in the Learning 
Health System 
This vision paper aims to bring together a number of parallel 
currents of thought in healthcare, biomedical research, 
informatics, and recent trends in consenting and institutional 
review. Its convergent vision is to relate these strands: the 
Learning Health System community [1]; the Patient-Centered 
Outcomes Research paradigm [2]; the Health Data Bank 
concept [3]; the move towards reform of the consent (or e-
consent) and institutional review board processes [4, 5]; and 
patient engagement strategies through education to play a part 
in their own and others’ care, and by extension, in research. 
[6, 7] The principal goal of this paper is to demonstrate that 
the necessary elements are available and that integration is 
necessary to make the vision a reality. 
Values 
The Learning Health System (LHS) originated in the work of 
Charles Friedman, and matured into a fully fledged idea his 
time as Chief Technology Officer at the Office of the National 
Coordinator for Health IT. His joint paper with Adam K. 
Wong and David Blumenthal [8] in Science Translational 
Medicine provided exemplars rather than a succinct definition 
of the Learning Health System and made heavy use of the 
“Meaningful Use” paradigm that really aimed at the 
conceptually simpler level of Health IT dissemination and 
adoption. Nevertheless, the LHS movement has since 
expanded to encompass many aspects of biomedical research 
activity.  
Among its ten “core values” [9] are three that are particularly 
pertinent to the vision presented here. These are listed here 
retaining the original numbering of core values: The LHS will 
be 
1. Person-Focused: … informing [individuals of] choices 
about health and healthcare. … through strategies that 
engage individuals, families, groups, communities, and the 
general population, …   
The LHS will be characterized by: 
3. Inclusiveness: Every individual and organization 
committed to improving the health of individuals, 
communities, and diverse populations, who abides by the 
governance of the LHS, is invited and encouraged to 
participate.  
and by 
8. Cooperative and Participatory Leadership: … 
[through] a multi-stakeholder collaboration across the 
public and private sectors including patients, consumers, 
caregivers, and families, in addition to other stakeholders. … 
Bold leadership and strong user participation are essential 
keys to unlocking the potential of the LHS. 
Our proposal espouses all the core values of the LHS; these 
three are highlighted here simply because of their particular 
relevance. In arguing for stakeholders—patients, caregivers, 
advocates—to be involved in both healthcare and research 
processes, we acknowledge that this can only happen if there 
is a commitment to inclusiveness and to participatory direction 
of activities. There is already experience, not least from 
PCORI-funded work through PCORnet [10], that stakeholders 
can make a significant contribution to the generation of 
relevant research questions. 
Learning 
Learning in the context of self-management has considerable 
history and literature, both promoting the concept and 
skeptical of it. It is sometimes said that “we used to do things 
to patients, then we did things for patients, and finally we 
want to do things with patients”. This is not to be read as some 
sort of naive history of progress in healthcare; but it does 
reflect the way in which rapid progress in the medical 
sciences, the rising share of gross domestic product dedicated 
to health care, and the “consumer revolution” have shaped the 
current landscape.  
It is as well to remember how each form of care was 
conceived and justified: in the first place, the more objectified 
the patient, the less personal the engagement, the more 
collected and unbiased the physician would be—so we 
thought. Engagement would mean the physician was over-
invested and would lose “his” (more often than not) 
objectivity. 
The consumer revolution resulted in patients looking upon 
healthcare and the maintenance of their wellbeing as a 
consumer good. I pay for my healthcare in much the same way 
as I pay for many other things, so I expect to be provided with 
a good service. And by the way, my health records are mine 
and I can take my business elsewhere whenever I choose. And 
this resulted in many taking an arms-length stance towards 
their own health – there will always be medications to keep 
any condition, from indigestion and reflux to diabetes and 
hypertension, under control, as direct-to-consumer advertising 
still suggests. 
As the cost to patients and health systems rises, there is a clear 
need to engage patients in their own healthcare. We want 
patients to be more engaged and more invested in their own 
health. There is a sense in which patients are more invested 
than ever, but there is also some evidence that positive rather 
than negative motivation is likely to be the more effective. We 
do expect patients to take responsibility for themselves, even 
in the face of poorly understood non-compliant behaviour (e.g. 
we deal with asthma sufferers who smoke and are not 
persuaded to stop by enumerating the dangers or even the self-
evident discomfort they endure). We assert a new imperative, 
that of partnership with the patient, because learning provides 
the only way forward. This paper asserts the need to extend 
this relationship to support for research. 
Beyond “Seventeen Years”: From evidence to 
practice 
It is sometimes asserted that “17 years elapse before a new 
element of validated clinical knowledge finds its way into 
routine clinical practice in the United States”  [8, 11]. 
Although this is now widely seen as an oversimplification, it 
is still the case that new drugs typically require in excess of 
ten years before reaching the patient, while some medical 
devices may only require seven or fewer years to come 
through. These are still surprisingly large numbers, when one 
considers the focused effort that goes into the development 
and testing of a drug or device. [12] 
Conversely, there have been several successful programs of 
data gathering from practice, including monitoring of drugs 
post-marketing, demonstrating a value in pragmatic studies of 
outcomes and of comparative effectiveness. For example, the 
FDA’s Sentinel Initiative page asserts [13] 
Sentinel enhances the FDA’s ability to proactively monitor 
the safety of medical products after they have reached the 
market and complements the Agency’s existing Adverse 
Event Reporting System. Through Sentinel, the FDA can 
rapidly and securely access information from large 
amounts of electronic healthcare data, such as electronic 
health records (EHR), insurance claims data and 
registries, from a diverse group of data partners. Sentinel 
uses a distributed data approach which allows the FDA to 
monitor the safety of regulated medical products, while 
securing and safeguarding patient privacy. 
The PCORnet approach has demonstrated a further value in a 
similar approach: involving stakeholders in creating a vision 
for a study, participation in expressing research questions and 
setting goals, in the collection of data, in reviewing technical 
analyses, in considering how findings may be translated into 
practice, in evaluating how effective an intervention is proving 
to be – for patients, caregivers and providers – and in 
maintaining a bond between a community and a health system. 
This approach to participation also provides a transparent 
means to address gender and racial/ethnic diversity, to 
acknowledge patients and other stakeholders in discourse, and 
to reflect the value of a “skilled PCOR community”. [10] 
The PCORI community has already demonstrated the value of 
its participatory approach, both through its large-scale infra-
structure projects (e.g. the thirteen Clinical Data Research 
Networks), the demonstrator projects undertaken over this 
infrastructure (e.g. studying the effects of antibiotics in 
infancy on subsequent growth patterns), and individual grants 
to specific, locally devised projects, such as a study of women 
with depression in obstetrics and gynecology practices [14] 
and the CHICAGO study of racial disparities in asthma-
related visits to the ED, where reportedly there is a five- to 
seven-fold higher rate of visits to the ED for uncontrolled 
asthma in communities with a high proportion of African–
American and Latino children compared with other 
communities. [15] In both these last cases, engagement of 
stakeholders in the design process proved crucial to success. 
A parallel activity has taken place in oncology, apparently 
arising out of the needs of that community and with little 
correspondence with the PCORI world. There we find a head-
to-head comparison of Phase I-III trials with comparative 
effectiveness studies. [16] 
Health Record Banking 
Fuller engagement of patients both in their own healthcare and 
in research requires reasonable access to the medical record. 
We have learned from the PCORnet experience, if we did not 
already know, that stakeholders can be powerful allies when 
they are authentically integrated into the research process. 
Patients, advocates and caregivers bring a wealth of views and 
viewpoints to bear on the issues. While reimbursement models 
inhibit rather than support research engagement and 
physicians are too pressed to go the extra mile to support 
research, it is odd that we may forget patients as a resource. 
This is all the more paradoxical in view of our oft-asserted 
“patient-centered”-ness. We consistently neglect the patient, 
and more broadly the stakeholder, as a resource in research. (It 
has been observed that this may replicate itself even in 
PCORnet, where recently presented sustainability plans 
appear significantly more focused on the CDRNs than the 
PPRNs.) 
Is there another way to look at this? Perhaps “imagineering” is 
what is needed here (in the sense it had before Disney 
trademarked it): What we can imagine, we can attempt to 
engineer.  What we can imagine is a world in which patients 
play a much bigger part in the management of their health 
records, setting aside the issues of ownership and custody. 
Through “management” we capture the two senses of 
maintenance and control of distribution beyond immediate 
healthcare needs. This much we can at least imagine. 
We may begin with the current of thought—not yet a move-
ment—to have patients maintain their records. There has 
always been an argument, with good cause on both sides, for 
and against patients’ “ownership” of their records.  While the 
rhetoric has always been that the patient owns his or her 
medical record, the custodian of the record has always had to 
be a provider, whether an individual practice or a large 
institution. The idea of health record banking has its roots at 
least as far back as the 1990’s when the idea sprang up both in 
the US and in the UK, and has more recently been the subject 
of several papers and a focal point in both Dr. Patricia 
Brennan’s and more particularly Dr. Amnon Shabo’s keynote 
lectures at MedInfo 2015. 
We may not be quite there yet, but as patients and citizens in 
general collect increasing amounts of data about their health 
(“quantified self”, wearables, fitness devices, etc.) the uptake 
of personal health banking is likely to increase. This presents 
an opportunity for researchers, but it will require a different 
attitude to consenting than the current standard. We need a 
consenting policy that allows patients and researchers to 
maintain a relationship to a degree independent of that with 
their health care provider, but without excluding the provider.  
It should be said here parenthetically that Dr. Bill Dodds [17], 
the Scottish GP who first proposed a “Health Information 
Bank”—an  institution made up of two non-profit and one for-
profit corporations—foresaw many of the issues that would 
have to be addressed and devised a clever structure to address 
most, if not all of them. Of particular note are the primary data 
bank whose job it is to hold the data and manage it on a kind 
of mutual banking basis for the benefit of all clients; an 
academy which would bear the burden of ethical management 
and regulatory compliance, and be the vehicle for research. 
The for-profit corporation would deal, within the constraints 
of the other two, with the commercial exploitation of the data. 
The questions we wish to pose are: 
• Can the data bank concept be extended to become a 
consent management system? 
! the patient gets to choose what studies may be of 
interest to him or her; 
! the patient also has the choice of how deeply to 
engage in a study; e.g. may provide specialist support 
if the patient happens to have the necessary skills, say 
statistics, or may work on the dissemination plan. 
• Can the benefits gained from banking be less focused on 
the financial and more on the additional information that 
can accrue to the interested patient? E.g. 
! links to relevant articles at the level of the patient’s 
choice (from links to the day’s newspaper to PubMed 
references); 
! health messages and alerts – links to m-Health. 
Patient Data as Commodity 
Thus we can also anticipate a world in which patients have a 
means of subscribing to research—in general—as part of the 
management of their record. What would this mean? It would 
mean having options to receive bulletins about projects and 
results, information about upcoming studies, with the 
opportunity to choose studies in which to participate, perhaps 
subject to screening by a physician. 
But there is dystopian vision also. Much of the discussion of 
“commodification” of patient, and more generally, personal 
data revolves around the use that those who gather data on a 
large scale make of this wealth of information, or more 
precisely, about the ways they turn data, often of uneven 
quality but in large volumes, into information with intrinsic 
value. The popular examples, such as the off-the-Wal-Mart 
“beer and diapers” story or the uncanny accuracy of Target’s 
pregnancy predictor, emphasize the value these corporations 
respectively extracted from the data by using analytics to turn 
it into worthwhile information. It has, of course, been said that 
some of these stories have been overhyped, and more recent 
examples, such as Google’s apparent ability to recognize 
influenza epidemics on the basis of search terms entered by 
users have also been questioned. Nevertheless, the terms “big 
data”, sometimes capitalized or depicted as a massive 
monolith, and “analytics” are ubiquitous in the popular 
technical literature; one suspects that this degree of excitement 
and volume of investment must be a reflection of excellent 
results. 
In healthcare, analytics has been applied to service 
improvement in hospitals and other provider organizations. 
The large-scale distributed research data repositories currently 
envisioned by such projects as the PCORI Clinical Data 
Research Networks, are expected to bring value to healthcare 
delivery through comparative effectiveness research (CER) 
and patient-reported outcomes. In due course, it is anticipated 
that industry, including pharma, will be able to mine these to 
identify optimal care pathways, to accelerate drug develop-
ment, to rationalize services and to manage public health.  
A more intimate example lies in the concept of Microsoft’s 
HealthVault, which, at least at one time, had ambitions to join 
up all the commonly collected health-related information 
about a person (under the individual’s control, so it was said) 
from the content of their shopping basket (courtesy of their 
supermarket loyalty card), to their daily exercise levels 
(through wearables or gym machines), to their relationship 
with their healthcare provider (numbers and kinds of visits, 
prescriptions, etc.). From here, it is easy to imagine one’s 
mobile phone might soon be delivering messages about the 
inadvisability of chocolate, given one’s BMI, just as one was 
reaching into the shelf in the store. But there are more benign 
examples: HealthHeritage has been established to help anyone 
construct and link up their health family tree, a social network 
focused on conditions that may have a genetic component and 
whose prevalence in one’s family is worth knowing about. 
A variant of the personal health record idea took the form of a 
scheme to support the global poor in countries where, in any 
case, pharmaceutical companies are already conducting lightly 
regulated clinical trials. The increasing adoption of EHRs in 
developing countries opens up an opportunity to conduct 
research based on data at the same time as supporting “the 
global poor” with payment for use of their data. The 
unpublished paper by Dzenowagis and Eyal [17] discusses the 
ethical, social and economic issues that arise: as well as the 
immediate issues of consent, confidentiality and privacy 
protection, the paper explores the form and distribution of 
benefits, who may be counted among “the global poor” and 
should be allowed to pay to access their data, whether such 
payments may constitute “undue inducement” and even an 
incentive to corruption. The authors acknowledge the issues to 
be addressed, but are favorably inclined none the less. 
In the context of such wide-ranging uses and possible abuses 
of personal data, electronic informed consent and the 
conditions for regulatory compliance themselves become 
rather obscure.  
Informed and Active Consent 
There is a need for vigilance in what one allows one’s data to 
be used for: this much has been clear in the quotidian world of 
internet and mobile apps, social media, cloud storage, 
unencrypted email, and much else. Informed choices in health-
care are certainly advocated by all organizations, but are often 
observed peremptorily, as when the task is delegated to 
reception staff rather than a physician or other clinician who 
can address questions. 
Defining an “adequate consent process”, the Federal Drug 
Administration’s Information Sheet – A Guide to Informed 
Consent [21] asserts: 
Thus, rather than an endpoint, the consent document 
should be the basis for a meaningful exchange between the 
investigator and the subject. 
This expresses the true requirement as clearly and succinctly 
as it can be put. Informatics offers a genuine opportunity to 
create an informative, up to date, intelligent consent process 
that allows patients to choose, e.g., whether they wish to 
participate in any given study, and how, how they would wish 
their data to be used, and in what form (fully de-identified, or 
in limited data set form?), what information to receive back, 
whether lay or technical communications or both, and whether 
to offer a greater degree of involvement, such as undertaking a 
task in a project or co-presenting to other patients in the 
context of a self-management program. 
Current discussion around e-Consent is relevant here, since 
the quality of information that can be provided through an 
electronic consent process is itself under scrutiny. An online 
presentation by Quorum Review IRB [5] highlights certain 
advantages of e-Consent: information and possible choices 
can be presented in a variety of ways, so that the user can 
choose one that chimes with their personal cognitive style: one 
may prefer to see a video, or a presentation with voiceover, an 
animation, text and tabulation, or a graphical explanation. 
While direct interaction with another person has many 
advantages, the explainer’s performance will almost certainly 
vary as they get tired or bored, faced with a keen listener or 
someone who is also tired or bored. There is also the potential 
to refer to other places for further explanation, to materials 
presented by other patients, by other research teams with a 
different point of view, and so on. However, among the issues 
that would need to be addressed in such an ecumenical 
approach to knowledge sharing is the poor quality of much of 
the information available on the internet. [19] A research team 
could be the best guide to what to view. Universal standards, 
such as those put forward by the Health on the Net 
Foundation, [20] have gained limited traction, so perhaps a 
“think global, act local” attitude is most effective—where 
local means in one’s area of expertise, in one’s specialty, or 
even in one’s community. We note in passing that the recent 
OHRP/FDA “guidance”, meaning non-binding advice on good 
practice, asserts: 
Although both OHRP and FDA affirm that the informed 
consent process begins with subject recruitment,4 
recommendations on using electronic media and processes 
for subject recruitment are outside the scope of this 
guidance.   
This acknowledges a difficulty that would be faced by anyone 
seeking to provide a broad spectrum of commentary and yet 
avoid a free for all leading to confusion and misinformation. 
Education, Citizen Science and Quantified Self 
Meaningful stakeholder engagement with the research process 
requires, on one hand, an understanding of what research 
involves, how it achieves results, how the significance of such 
results may be assessed, and on the other, an appreciation of 
the professional, social and economic issues that constrain 
decisions on what research to pursue. Knowledge of these 
forces enables stakeholders to intervene at an appropriate 
point and on an appropriate scale, whether to influence the 
direction of a research program or to nudge a small project to 
include some aspect of particular interest. The Colorado Boot 
Camp Translation project offers many possibilities. [6] The 
value of the  “boot camp” has certainly been demonstrated in 
many specific conditions, some of which have resulted in 
publication. [21]  
Also in the realm of patient self-care, the remarkable work 
begun by Kate Lorig at Stanford, which has now spread inter-
nationally has led to a book of essays centering mainly on its 
British incarnation. [7] The essays in the book are drawn from 
different points of view, but focus on the notion of an “expert 
patient” and home in particularly on self-management 
education in the UK and especially on the NHS Expert Patient 
Programme. 
Education of patients, now specifically with the goal of 
enabling them to become co-investigators, can derive many 
lessons from the Citizen Science movement [22] and its open 
door philosophy. The virtual organization Zooniverse [23] 
showcases many projects and lists an extraordinary number of 
publications, especially in Astronomy and Space Science, 
where data analysis is a prominent activity, but remarkably 
includes no fewer than 22 publications in the field of “Meta 
Studies” exploring, e.g., Science Learning via Participation in 
Online Citizen Science, Playing with Science: Aspects of 
Gamification Found on the Online Citizen Science Project - 
Zooniverse, and Exploring the Motivations of Citizen Science 
Volunteers (the full list at [22]). Indeed, all this is in addition 
to all the contributions of patients and other stakeholders who 
happen to have, from their own professional life, a set of 
necessary skills that a project may exploit—project 
management, statistics, education, and others. 
The Quantified Self movement [23] represents a different 
aspect of Citizen Science. There are numerous remarkable 
examples of individuals putting their own “numbers” under 
scrutiny, as in Erica Forzani’s exploration of her own 
pregnancy, unusual pattern of resting metabolic rate, apparent 
gestational diabetes and weight gain. [24]. While many 
women may monitor their pregnancy closely, there is a 
particularly scientific spirit of quantification in this and other 
exemplars of ‘quantified self”.  
Conclusions 
We have discussed, in turn, the values and the “learning” 
aspect of the Learning Health System. We have explored the 
perceived need for Comparative Effectiveness and Outcomes 
Research to accelerate the translational process from scientific 
evidence to practice. We have proposed forms of Health 
Record Banking that would be supportive of research. We 
have touched on the “commodification” of patient data and the 
possibility of patients taking control. We considered informed 
consent and electronic consent (e-Consent) policies and their 
potential to keep an open line between patient, stakeholder-
researcher, provider, and research team. Finally we touched on 
self-education and research for potential stakeholder-scientists 
through such approaches as expert patient programs, boot 
camps, and the Quantified Self movement. 
We have demonstrated that the elements are at least available, 
either because they already exist and can be used, or can be 
implemented if the right regulatory framework were in place. 
Integration of these would be sufficient to realize the vision of 
stakeholder scientists, participating in the formulation of 
research questions, being subjects in studies, providing and 
sharing their own data, and providing unique insights into 
chronic conditions for researchers and fellow patients alike. 
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